Conditioned Reinforcing Effects of a Remifentanil-Paired Stimulus in the Rat. by Bertz, Jeremiah W.





Jeremiah W. Bertz 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Psychology) 



















Professor James H. Woods, Chair 
Assistant Professor Brandon J. Aragona 
Professor Terry E. Robinson 
Professor John R. Traynor 








Thanks first of all to my mentor, James Woods, for giving me the opportunity to learn the 
principles and practices of behavioral pharmacology.  The breadth of your interests and depth of 
your experience, as well as your enthusiasm for new information, are truly inspirational.  I 
always appreciated how you were willing to pause whatever else you were doing when I would 
knock on your office door to ask a question or talk about an experiment in progress.  Thanks to 
Gail Winger for asking incisive questions and giving constructive criticism of both my oral 
presentations and written work.  It always helped to have you ask, “Why are you doing this 
again?”  Thanks to Brandon Aragona, Terry Robinson, and John Traynor for serving on my 
dissertation committee.  Your questions and comments definitely helped me to think more 
critically about these data and about my career path.  It was an honor to have worked with you 
all. 
A number of current and former members of the Woods laboratory provided significant 
help and support during the course of my studies:  Remy Brim, Gregory Collins, Emily 
Jutkiewicz, Adam Kirry, Mikhail Koffarnus, Jessica Priebe, and Nhu Truong.  Special thanks to 
those of you who were around during my first year in the lab when I was especially lost and 
clueless, and to Nhu Truong for being a good neighbor and sympathetic officemate.   
Thanks to Davina Barron, Emily Brooks, Alyssa Cunningham, Adam Kynaston, and 
Yong-Gong Shi for your excellent technical assistance, as well as all of the animal husbandry 
staff for helping house and care for all of my rats.  Thanks to Joseph Crossno for helping me with 
administrative issues of all sorts and for sharing an office with me for a year.  Thanks to 
	  iv	  
Shaomeng Wang and the members of his laboratory for preparing the SB-277011A used in these 
studies. 
I have had the opportunity to work with a number of talented undergraduate research 
assistants.  Thanks to the students who worked on the experiments reported presently or issues 
related to them:  Spencer Bonadeo, Amy Branam, Tomas Davaloz, Lisa Drayer, Andrea Gunn, 
Sydney Johnson, Jennifer Lin, Laurel Mulder, Melissa Oddo, and Amanda Prentice.  Special 
thanks to Tomas Davaloz for staying on term after term and always doing excellent work. 
Thanks to all of the other biopsychology graduate students for being such excellent peers 
and friends.  I thank especially the other members of my cohort:  Caitlin Orsini, Benjamin 
Saunders, Jocelyn Richard, and Eila Roberts.  Thanks to all of my other friends outside of 
Michigan who put up with me seeming to drop off the face of the earth while I ran experiments 
and wrote. 
 Finally, thanks to my family:  my grandparents, Dolores and Howard; my father, Steven; 
and my brother and sister-in-law, Ben and Lauren.  You have all been such incredible advocates 


















I. General Introduction ...............................................................................................1 
II. Acquisition of a New Response with a Remifentanil-Paired Conditioned 
Reinforcer .............................................................................................................37 
III. Effects of Pramipexole on Responding Maintained by Remifentanil-Paired 
Stimuli:  Resistance to Extinction of Self-Administration and New-Response 
Acquisition ............................................................................................................64 
IV. Effects of Pramipexole on New-Response Acquisition with Remifentanil-
Conditioned Reinforcement:  Involvement of Dopamine D3 vs. D2         
Receptors .............................................................................................................122 
V. General Discussion .............................................................................................160 
	  vi	  




2.1  Acquisition of a novel nose-poke response that produced a stimulus previously paired with  
response-independent IV remifentanil injection ...................................................................60 
2.2  Persistence of nose-poke responding across acquisition sessions conducted under either  
fixed ratio 1 or random ratio 2 schedules of reinforcement ..................................................61 
2.3  Lack of acquisition of nose-poke responding when the number of remifentanil-stimulus  
pairings is reduced .................................................................................................................63 
3.1  Progressive ratio performance of rats when self-administering remifentanil or pretreated  
with pramipexole in extinction ............................................................................................111 
3.2  Intrasession allocation of active responding in extinction under the progressive ratio  
schedule ...............................................................................................................................113 
3.3  Effects of pramipexole when active responding did or did not produce the stimuli previously  
paired with remifentanil availability and/or remifentanil injection .....................................114 
3.4  Effects of pramipexole pretreatment on the acquisition of a novel nose-poke response that  
produced a stimulus previously paired with response-independent IV remifentanil       
injection ...............................................................................................................................115 
3.5  Nose-poke responses made by rats treated with pramipexole after random Pavlovian  
conditioning, when the remifentanil and stimulus were paired only by chance .................117 
3.6  Intrasession allocation of active responding by animals treated with either 0.0 mg/kg  
(vehicle) or 0.32 mg/kg pramipexole ..................................................................................118 
	  vii	  
3.7  Effects of different pramipexole pretreatment intervals (10 min vs. 190 min) on the  
acquisition of nose-poking with the remifentanil-paired stimulus ......................................120 
4.1  Effects of the D3-preferring antagonist, SB-277011A, or the D2-preferring antagonist,       
 L-741,626, on pramipexole-induced increases in responding with the remifentanil-paired    
 stimulus ................................................................................................................................155 
4.2  Effects of SB-277011A or L-741,626 on the latency to the first active response in the    
session .................................................................................................................................157 



















 When environmental stimuli are paired with a primary reinforcer (e.g., food, certain 
drugs), these stimuli may become conditioned reinforcers capable of maintaining behavior in the 
absence of the primary reinforcer.  Drug-associated conditioned reinforcers are thought to 
contribute significantly to human drug abuse and dependence; however, few studies have 
characterized specifically the conditioned reinforcing effects of drug-paired stimuli, controlling 
for other, confounding associative and nonassociative processes that can change behavior.  The 
present experiments, therefore, assessed the conditioned reinforcing effects of a stimulus paired 
with the potent, short-acting mu-opioid agonist, remifentanil, using a behaviorally stringent new-
response acquisition procedure.  First, in Pavlovian conditioning (PAV) sessions, rats received 
response-independent IV injections of remifentanil and presentations of a light-noise stimulus.  
In paired PAV groups, injections and stimulus presentations always co-occurred.  In random 
PAV control groups, injections and stimulus presentations occurred independently of each other.  
Next, in instrumental acquisition (ACQ) test sessions, rats could respond in an active nose-poke 
that produced the stimulus alone or an inactive nose-poke that had no scheduled consequences.  
Rats acquired nose-poking (i.e., active > inactive) after paired PAV, but not random PAV.  These 
results show responding was (1) not due to association of the nose-poke with remifentail, (2) 
sensitive to the Pavlovian contingency between the stimulus and remifentanil, and (3) sensitive 
to the instrumental contingency between a nose-poke and the stimulus.  After, thus, validating 
the behavioral procedure, the effects of the dopamine D3 receptor-preferring agonist, 
pramipexole, on responding with the remifentanil-paired stimulus was assessed.  Dopamine D2-
like receptor agonists can enhance new-response acquisition with food-paired conditioned 
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reinforcers, but this effect has not, to my knowledge, been previously demonstrated with drug-
paired stimuli.  When pretreatments of saline or pramipexole were given before ACQ sessions, 
pramipexole dose-dependently increased active responding without changing inactive 
responding.  Control animals given pramixpole after random PAV did not acquire nose-poking.  
The response-enhancing effects of pramipexole were attenuated by the D2 receptor-preferring 
antagonist, L-741,626, but not the D3 receptor-preferring antagonist, SB-277011A.  D2 activity 
may, therefore, be particularly important for responding with conditioned reinforcement.  
Together, these experiments demonstrate that new-response acquisition can provide a valid, 






Primary and conditioned reinforcement 
 
Many instances of human and non-human animal behavior are separated significantly 
from the delivery of a primary reinforcer such as food, water, or certain drugs.  These separations 
can involve temporal delays and physical distance to the delivery of the primary reinforcer, as 
well as the interpositioning of other behaviors of various kinds between a target response and the 
primary reinforcer (e.g., in multi-operant sequences or chains, Thompson and Pickens 1969, 
Figure 9).  It is difficult, therefore, for primary reinforcement contingencies alone to account for 
many instances of learning and much of the behavioral repertoire.  Rather, the environmental 
stimuli that have been associated with a primary reinforcer may play a significant role in 
structuring behavior until that primary reinforcer is ultimately obtained (Fantino 2008; Goldberg 
1975; Goldberg and Gardner 1981; Hull 1943; Keller and Schoenfeld 1950; Pierce and Cheney 
2004; Skinner 1953; BA Williams 1994).  One important way in which these environmental 
stimuli may influence behavior is by serving as conditioned reinforcers.  Whereas both primary 
and conditioned reinforcers increase the frequency of the responses that produce them, 
conditioned reinforcers may be distinguished from primary reinforcers in that conditioned 
reinforcers are effective only after certain histories (e.g., Kelleher and Gollub 1962, p 545).  
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Without these histories, stimulus presentation will not be an effective instrumental reinforcer and 
will not strengthen the behaviors upon which it is contingent.  Primary reinforcers do not have 
the same dependency on previous experience.  This is not to say that no learning is needed before 
a primary reinforcer will be effective (Balleine 2005) or that different histories cannot affect 
performance with primary reinforcement (Campbell and Carroll 2000; Robinson and Berridge 
2001; Young et al. 1981), but that the types of histories or particular operations that make for 
effective primary and conditioned reinforcers are different. 
Although alternatives have been proposed (e.g., Fantino 2008), the operations that 
establish conditioned reinforcers have most often been described as “pairing” the stimulus with a 
primary reinforcer or having the stimulus “accompany” the primary reinforcer (e.g., Hull 1943, 
Chapter 7; Hendry 1969; Hyde 1976; Keller and Schoenfeld 1950, Chapter 8; O’Brien and 
Gardner 2005; Schindler et al. 2002; Shahan 2010; Wike 1966, § 1; BA Williams 1994).  It is 
important to recognize, however, that a number of different behavioral processes, other than 
conditioned reinforcement, can influence the rate of responding when an animal makes a 
response that produces a stimulus after that stimulus has been paired with a primary reinforcer.  
These processes may be associative or nonassociative, and they may be related to exposure to the 
stimulus itself, exposure to the primary reinforcer itself, or to some other effect or aspect of the 
stimulus-reinforcer pairing (Cunningham 1993).  For example, depending on the particular 
situation, responding may be altered by the primary reinforcing effects of the stimulus (i.e., 
sensory reinforcement), discriminative effects of the stimulus, unconditioned effects of primary 
reinforcer or stimulus exposure (e.g., neurotoxic effects of certain drugs), nonassociative 
learning (e.g., habituation to the sensory aspects of the stimulus), and other influences.  The need 
for more specific characterizations of the necessary and sufficient conditions for a stimulus to be 
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an effective conditioned reinforcer has been long recognized (e.g., Wike 1966, § 3.3.1).  
Mackintosh (1974, p 234) proposed three criteria for a sufficient demonstration of conditioned 
reinforcement:  the rate of the response that produces the stimulus must (1) not depend on a 
current or historical association between the response and a primary reinforcer; rather, the rate 
must (2) depend on the Pavlovian association between the stimulus and a primary reinforcer and 
(3) depend on the instrumental association between the response and the stimulus.  In brief, the 
first two criteria ensure that the putative conditioned reinforcer is, in fact, conditioned, whereas 
the third ensures that it is a reinforcer.  These criteria will be used presently in evaluating the 
validity of the laboratory procedures that have been developed to study conditioned 
reinforcement. 
 
Laboratory procedures used to study conditioned reinforcement 
 
Since the initial studies of Grindley (1929) on chickens and KA Williams (1929) on rats 
running an alleyway or maze toward food-associated stimuli without receiving the food itself, 
several different types of procedures have been designed to study conditioned reinforcement in 
laboratory animals (reviewed by Fantino 1977; Kelleher and Gollub 1962; Mackintosh 1974; 
Wike 1966, § 1.4; BA Williams 1994).  Because runway or maze procedures may demonstrate 
the ability of a stimulus to elicit Pavlovian conditioned approach, as well as or instead of 
instrumental reinforcement (Dickinson and Balleine 1994), the present review will focus on 
procedures involving free-operant responding (e.g., lever-pressing, nose-poking).  Broadly, these 
procedures may be divided into two categories (cf., Wike 1966; BA Williams 1994):  (1) 
methods in which both the primary reinforcer and (putative) conditioned reinforcer are 
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programmed concurrently on a response so that both types of reinforcer are delivered as a result 
of responding in the same experimental sessions (e.g., second-order schedules, chain schedules) 
and (2) methods in which responding produces the (putative) conditioned reinforcer in the 
absence of the primary reinforcer (e.g., resistance to extinction of an established response, new-
response acquisition).  In these two types of procedures, the primary reinforcement contingency 
and conditioned reinforcement contingency are positively and negatively correlated, respectively 
(BA Williams 1994). 
Procedures in which a given response produces both the primary reinforcer and the 
stimulus under investigation (i.e., the putative conditioned reinforcer) have been favored by a 
number of authors who emphasize their practical utility (e.g., Hendry 1969):  it is possible for 
stimulus presentation to generate high rates of responding and for these high rates to persist over 
time, providing stable baselines upon which the effects of different manipulations can be 
assessed within-subjects and with less concern for floor effects.  However, the ongoing pairing of 
the response with the primary reinforcer makes it difficult to determine whether or not the 
stimuli have any reinforcing effects of their own (Mackintosh 1974).  Presentation of the 
stimulus may result in high rates, but it is not necessarily acting as a conditioned reinforcer in 
doing so.  Rather than having reinforcing effects, the stimulus may be acting strictly as 
discriminative stimulus for the primary reinforcement contingency (Schindler et al. 2002; BA 
Williams 1994).  This discriminative stimulus function is sufficient to explain the differences 
observed when responding with a reinforcer-paired stimulus is compared to responding either 
without stimulus presentation or with control stimuli that have not been paired with the primary 
reinforcer (BA Williams 1994).  Each of these control conditions includes differences in both the 
potential reinforcing effects and discriminative effects of the control stimulus compared to the 
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reinforcer-paired stimulus, and so they cannot resolve the mechanism(s) influencing responding.  
Separate analyses of different portions of the session (e.g., Di Ciano et al. 2003; Pilla et al. 1999) 
may help to account for changes in responding that result from the unconditioned effects of 
primary reinforcer presentation (e.g., drug-induced changes in locomotor behavior, Schindler et 
al. 2002), but they also cannot fully resolve the contributions of the conditioned and primary 
reinforcement contingencies.  When delivery of the primary reinforcer is restricted to the end of 
the session or the end of an interval of analysis (e.g., a pre-drug interval and post-drug interval in 
the study of drug self-administration), the first portion of the session necessarily consists of 
presentation of the putative conditioned reinforcer alone.  Reinforcer type is confounded with the 
passage of time, and other learning processes may control responding before vs. after primary 
reinforcer delivery (e.g., habituation and dishabituation to stimulus presentation, McSweeney et 
al. 2005).  There are a number of compelling reasons to investigate the combined effects that 
primary reinforcers and their associated stimuli together have on behavior, or to determine how 
stimuli can influence a behavior that ultimately leads to a primary reinforcer (e.g., Goldberg and 
Gardner 1981; see also the two kinds of models of craving discussed by Markou et al. 1993).  
However, the present studies are concerned with establishing the ability of conditioned 
reinforcers to sustain behavior on their own and so will focus on situations in which responding 
produces the (putative) conditioned reinforcer in the absence of the primary reinforcer. 
Among procedures with a negative correlation between the primary and conditioned 
reinforcement contingencies, a number of similar interpretational difficulties arise when 
assessing the effects of stimulus presentation on the extinction of an established response 
(Mackintosh 1974; Wike 1966; BA Williams 1994).  As in the positive correlation procedures 
reviewed above, the response that produces the (putative) conditioned reinforcer is also 
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associated with the primary reinforcer.  First, during the response-training phase of these 
experiments, responding produces both the primary reinforcer and the stimulus of interest.  Then, 
during extinction, the primary reinforcer is withheld, and the stimulus alone is presented as a 
consequence of responding.  In this case, the association of the response with the primary 
reinforcer is historical, rather than ongoing, but it may control behavior in similar ways.  It is 
possible that, during response training, the stimulus is established as a discriminative stimulus 
for the primary reinforcer instead of or in addition to a conditioned reinforcer.  Presentation of 
exteroceptive stimuli that were intentionally programmed as discriminative stimuli during 
response training can subsequently produce significant increases in extinction responding (e.g., 
Weiss et al. 2001).  Stimuli “inadvertently” established as discriminative stimuli when 
attempting to generate conditioned reinforcers may also increase responding.  Extinction 
responding may also be influenced by generalization decrements between the training and testing 
phases of the experiment:  any manipulation that makes the extinction test sessions more similar 
to the response-training sessions could increase rates of responding as animals fail to 
discriminate between the two types of session (Kelleher and Gollub 1962; Mackintosh 1974; 
Wike 1966, § 1.4; BA Williams 1994).  This similarity may depend on the elements of the 
experimental situation playing the same associative roles during training or testing or on the 
mere overlap of sensory elements.  Therefore, control conditions or groups cannot resolve the 
particular importance of conditioned reinforcement, as these discriminative mechanisms could 
account for the differences when responding with the reinforcer-paired stimulus is compared to 
responding without stimulus presentation or with control stimuli.  As above, there are a number 
of compelling reasons to study the effects of stimulus presentation on extinction responding.  
With drug self-administration, in particular, changes in extinction responding after drug self-
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adminsitration training may provide useful models of human drug abusers’ tendency to relapse 
after a period of abstinence (Epstein et al. 2006; Katz and Higgins 2003; Shaham et al. 2003).  
However, in considering conditioned reinforcement specifically, these procedures cannot provide 
statisfactory measures of the conditioned reinforcing effects of the stimuli (Mackintosh 1974). 
New-response acquisition procedures can provide valid measures of conditioned 
reinforcement, in that they can produce responding that clearly meets Mackintosh’s (1974) three 
criteria (e.g., Cador et al. 1991; Hyde 1976; Sosa et al. 2011; Taylor and Robbins 1984).  
Classical new-response acquisition procedures are divided into two phases:  (1) an initial phase 
of Pavlovian conditioning, in which animals receive response-independent presentations of a 
primary reinforcer and an exteroceptive stimulus, and (2) a subsequent phase of instrumental 
acquisition, in which the stimulus alone is programmed as the consequence of a previously 
untrained response.  Physically withholding the response manipulandum during the Pavlovian 
conditioning phase and the primary reinforcer during the instrumental acquisition phase prevents 
direct association of the response with the primary reinforcer.  Appropriate control conditions 
can establish that responding during instrumental acquisition depends on both the Pavlovian 
contingency between the stimulus and the primary reinforcer and the instrumental contingency 
between the response and the stimulus.  These controls do or do not program the stimulus as a 
consequence of responding after the stimulus has had different associative relationships with the 
primary reinforcer.  For example, in a particularly extensive investigation of food-associated 
stimuli, Hyde (1976) compared rats that received pairings of an auditory stimulus and food 
delivery (CS+ condition) to control rats that received pairings of the stimulus and the absence of 
food delivery (CS– condition), random food and stimulus delivery (CSØ condition), or food 
delivery without stimulus presentation (US only condition).  After establishing these different 
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associative histories, the rats were given access to a lever, and lever-pressing either did or did not 
produce the auditory stimulus.  Rates of responding were higher when lever-pressing produced 
the food-paired stimulus than in all other conditions.  The manipulations of the associative 
relationships during the first phase of the study established that responding was sensitive to the 
Pavlovian contingency between the stimulus and the food, and the comparison of the groups in 
which responding did vs. did not produce the stimulus established that responding was sensitive 
to the instrumental contingency between the response and the stimulus.  These procedures, thus, 
provide a sufficient demonstration of the conditioned reinforcing effects of the stimulus 
(Mackintosh 1974). 
Whereas the conceptual or interpretive advantages of new-response acquisition 
procedures have been long recognized, it has also been thought that negative correlation 
procedures produce “weak” responding (i.e., low rates) that is ultimately too unstable or 
transitory to be useful practically in studying conditioned reinforcement (e.g., Gollub 1977; 
Hendry 1969; Schindler et al. 2002; Shahan 2002; BA Williams 1994).  The conditioned 
reinforcing effects of the stimulus are necessarily assessed after the pairing of the primary 
reinforcer and stimulus has stopped; therefore, in programming the stimulus alone as the 
consequence of responding, instrumental acquisition by design coincides with Pavlovian 
extinction.  This Pavovian extinction may cause the stimulus to lose rapidly its conditioned 
reinforcing effects, limiting the number and/or length of the acquisition sessions that can be 
conducted before behavior is no longer maintained by stimulus presentation.  As Mackintosh 
(1974, p 237) summarizes:  “The very procedure used to provide an uncontaminated measure of 
conditioned reinforcement guarantees the effect will be evanescent.”  For instance, in the first 
operant new-response acquisition experiment reported, Skinner (1938, Figure 13) measured 
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lever-pressing in a single acquisition test session and found that responding slowed progressively 
over the course of the session.  Several influential early reviews citing this experiment 
emphasized the apparent degradation of responding in the absence of the primary reinforcer 
(Hull 1943; Keller and Schoenfeld 1950; Miller 1951).  Skinner (1938) himself characterized the 
pattern of performance obtained as a flattened extinction curve, emphasizing the ultimate 
decrease in behavior, but he also noted that “considerable conditioning can be effected before a 
state of more or less complete extinction is reached” (p. 82).  Several more recent new-response 
acquisition studies have found persistent differences between the experimental and control 
groups over the course of multiple (up to 13) acquisition sessions (e.g., Hyde 1976; Di Ciano and 
Everitt 2004; Di Ciano et al. 2008).  These more recent results suggest that at least some 
resiliency of responding is possible with new-response acquisition; however, more work is 
needed to determine when new-response acquisition procedures do or do not produce sustainable 
behavior (Pierce and Cheney 2004, Chapter 10).  Whereas different authors may have different 
criteria for judging the durability of a conditioned reinforcer (Wike 1966, § 3.3.1), the present 
concern is that the conditioned reinforcing effects of the stimulus are detectable over the periods 
necessary for the evaluation of relevant environmental or pharmacological interventions.  For 
example, when testing the effects of a drug on new-response acquisition, the conditioned 
reinforcing effects of the stimulus should be apparent in a vehicle control condition over the 
interval of testing required to establish the drug effect (see e.g., Beninger et al. 1981; Samaha et 
al. 2011; Slawecki et al. 1997). 
 
Acquisition of responding with drug-associated conditioned reinforcement 
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Drug-associated conditioned reinforcers have long featured in theoretical accounts of 
human drug addiction (Berridge et al. 2009; Di Chiara 1999; Everitt and Robbins 2005; Everitt et 
al. 2008; Koob and Le Moal 2001, 2008; Milton and Everitt 2010; Robinson and Berridge 2008; 
Stewart et al. 1984; Wikler 1973; Wikler at al. 1971).  Different authors may interpret the 
conditioned reinforcing effects of drug-paired stimuli differently or attribute particular 
importance to conditioned reinforcement in maintaining different phases or aspects of the 
addiction syndrome; however, refined techniques for measuring the conditioned reinforcing 
effects of drug-paired stimuli, as distinguished from other stimulus functions, should be useful to 
researchers with a wide variety of theoretical orientations. 
Despite this potential usefulness, new-response acquisition studies with drug-paired 
stimuli have not been widely pursued in drug abuse research.  Early work by Davis, SG Smith, 
and colleagues (reviewed by Davis and SG Smith 1976, 1987; see also Goddard and Leri 2006; 
Marcus et al. 1976) showed that rats would increase their responding on a lever that produced a 
buzzer noise after the noise was paired with response-independent IV injections of morphine or 
amphetamine, compared to a pre-conditioning baseline period when lever-presses produced the 
noise and IV saline injection.  These results are consistent with the noise becoming a conditioned 
reinforcer by Pavlovian association with the drug, but several alternative explanations for these 
changes are equally viable, as these studies did not include a second, inactive lever or other 
control for nonspecific changes in behavior and/or a pharmacological control to account for 
potential effects of drug exposure regardless of the programmed drug-stimulus association.  
More recently, a variation on classical new-response acquisition procedures has been developed 
in which drug self-administration is trained using one type of manipulandum (e.g., a nose-poke), 
with each IV drug injection accompanied by a particular stimulus, and then responding on a 
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second type of manipulandum (e.g., a lever) is trained with the stimulus alone.  These procedures 
have been used most commonly to study responding with cocaine-paired stimuli (Di Ciano 2008; 
Di Ciano and Everitt 2004; Di Ciano et al. 2007, 2008; Hutcheson et al. 2011; Panlilio et al. 
2007; Samaha et al. 2011) or nicotine-paired stimuli (Palmatier et al. 2007, 2008).  Crucially, 
among these studies, work with both cocaine (Di Ciano and Everitt 2004; Panlilio et al. 2007) 
and nicotine (Palmatier et al. 2007, 2008) has included both a control manipulandum and a 
pharmacological/associative control condition to assess the sensitivity of responding to the 
Pavlovian contingency between the stimulus and drug.  In addition to studying cocaine-paired 
stimuli, Di Ciano and Everitt (2004) did measure rats’ acquisition of responding with heroin-
paired stimuli.  However, whereas an unpaired stimulus control condition was included for the 
cocaine-trained animals, no control was included for the heroin-paired stimulus in the heroin-
trained animals.  Therefore, no study has yet, to my knowledge, established the conditioned 
reinforcing effects of opioid-paired stimuli under conditions that clearly meet Mackintosh’s 
(1974) criteria for a sufficient demonstration of conditioned reinforcement. 
 
Dopamine and conditioned reinforcement 
  
If valid measures of the conditioned reinforcing effects of opioid-paired stimuli can be 
obtained, the ability of various environmental and neurobiological manipulations to alter these 
effects specifically can then be assessed.  Dopaminergic agonism and antagonism are of 
particular interest because these manipulations have consistently been found to alter rats’ 
performance with food- and water-conditioned reinforcers in new-response acquisition 
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procedures.  It is important to determine if these effects depend on the class of primary reinforcer 
(i.e., non-drug vs. drug) with which the stimulus was paired. 
Based on their effects on responding reinforced by electrical brain stimulation, Stein 
(1964, p 91) made an early suggestion that amphetamine and related drugs act on “a brain 
mechanism for reward” that includes the processing of reward-related and/or response-related 
environmental stimuli.  Noting that these compounds can significantly increase or decrease 
behavior maintained by primary reinforcers depending on the schedule of reinforcement and 
other environmental variables, Hill (1970, p 783) proposed more specifically that amphetamine-
like drugs increase the “effectiveness” of conditioned reinforcers.  The first experiments 
addressing this hypothesis assessed the effects of pipradrol on the extinction of food- or water-
trained responding.  Systemic pipradrol administration dose-dependently increased lever-
pressing that produced a sound and/or light that had been paired with food or water delivery 
during response training, whereas pipradrol did not increase responding when lever-pressing had 
no scheduled consequences or produced a stimulus that had not been previously paired with the 
primary reinforcer (Hill 1970; Robbins 1975).  Pipradrol is structurally related to amphetamine 
and, like amphetamine, blocks reuptake and causes release of dopamine and norepinephrine 
(Coppola and Mondola 2012; Robbins et al. 1983).  The response-enhancing effects of pipradrol 
appeared quite robust, as Hill (1970, Figure 2) noted that pipradrol could be repeatedly 
administered and withheld, with corresponding decreases and increases, respectively, in 
responding, and pipradrol administration could increase lever-pressing even after extensive 
extinction training (~20,000 responses made in ~100 sessions without food delivery). 
Shortly thereafter, the response-enhancing effects of pipradrol were established in new-
response acquisition procedures with food- or water-paired stimuli (Beninger et al. 1980; 
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Robbins 1976, 1978; see also Chu and Kelley 1992), and the effectiveness of several other 
indirect dopaminergic agonists was established.  Methylphenidate produced numerical increases 
that resembled those produced by pipradrol, although the effects were highly variable across 
animals (Robbins 1978).  Amphetamine, administered systemically (Beninger and Ranaldi 1992; 
de Borchgrave et al. 2002; Mazurski and Beninger 1986; Ranaldi and Beninger 1993; JK Smith 
et al. 1997; but see Robbins 1978; Beninger et al. 1981) or directly into the nucleus accumbens 
(NAcc) (Cador et al. 1991; Fletcher 1995; Kelley and Delfs 1991; Parkinson et al. 1999; Taylor 
and Robbins 1984; Wolterink et al. 1993) produced significant, dose-dependent increases in 
responding.  It is important to note that, among these studies, the effects of amphetamine have 
been assessed under stringent conditions.  Under the same circumstances where enhanced 
responding with a reinforcer-paired stimulus was observed, amphetamine (1) did not increase 
responding on a control manipulandum that did not produce the stimulus and (2) did not increase 
the response that produced the stimulus when the stimulus had not been consistently paired with 
the primary reinforcer (Cador et al. 1991; Taylor and Robbins 1984).  In contrast to its effects in 
the NAcc, amphetamine did not increase responding when injected into the thalamus (Taylor and 
Robbins 1984) or into several other striatal regions (Kelley and Delfs 1991), but increases caused 
by injection into the caudate-putamen broadly (Taylor and Robbins 1984) or anterior dorsal 
striatum more specifically (Kelley and Delfs 1991) have been reported.  Administered 
systemically, cocaine itself failed to increase responding (Beninger et al. 1981; Robbins et al. 
1983), but the cocaine analogues WIN 35,428 and WIN 35,065-2 were effective (Robbins et al. 
1983).  Cocaine administered directly into the NAcc was shown to dose-dependently increase 
lever-pressing that produced a food-paired stimulus (Chu and Kelley 1992), but these results are 
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more difficult to interpret because neither a control response (i.e., an inactive lever) or 
associative control group (e.g., an unpaired-stimulus group) was included in this particular study. 
Given that these indirect agonists can affect other neurotransmitter systems (e.g., 
norepinephrine), evidence for the involvement of dopamine, specifically, in the enhancement of 
respsonding with food- or water-conditioned reinforcers was provided initially by lesion studies, 
followed by studies with dopaminergic antagonists.  Robbins and Everitt (1982, Figure 9) first 
reported that 6-hydroxydopamine (6-OHDA) lesions located preferentially in either the caudate-
putamen or NAcc reduced the responding of animals treated systemically with pipradrol, 
compared to animals that received pipradrol after sham lesions or no surgery.  Subsequently, it 
was shown that 6-OHDA lesions of the NAcc attenuated the effects of intra-NAcc amphetamine 
injection (Taylor and Robbins 1986), whereas lesions of the dorsal noradrenergic ascending 
bundle did not alter the effects of intra-NAcc amphetamine administration (Cador et al. 1991).  
In this latter study (Cador et al. 1991), acquisition of responding with a water-paired stimulus 
was also enhanced when dopamine itself, but not norepinephrine, was injected into the NAcc, 
and the effects of intra-NAcc dopamine administration were blocked by systemic administration 
of the nonselective dopamine receptor antagonist, α-flupenthixol.  In a subsequent study of 
selective D1-like (D1, D5) or D2-like (D2, D3, D4) receptor antagonism, systemic 
administration of the D1-like antagonist, SCH 23390, or the D2-like antagonist, pimozide, 
produced complex patterns of increases or decreases in responding that, overall, suggested the 
amphetamine dose-effect function was shifted rightward (Ranaldi and Beninger 1993), although 
the descending limb was not clearly determined under the influence of the antagonists.  Systemic 
administration of SCH 23390, or the D2-like antagonist, raclopride, reduced the responding of 
animals injected with pipradrol directly into the nucleus accumbens (Chu and Kelley 1992), and 
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intra-NAcc SCH 23390 or raclopride attenuated the response-enhancing effects of intra-NAcc 
amphetamine (Wolterink et al. 1993).  When the effects of several antagonists were assessed on 
their own, however, systemic administration of the D2-like antagonists, haloperidol, pimozide, 
raclopride, and sulpiride, all produced significant increases in responding with a food-paired 
stimulus, whereas increases were not observed with SCH 23390 (JK Smith et al. 1997).  These 
increases were interepreted as a result of the D2-like antagonists blocking autoreceptors, thus 
serving as indirect dopaminergic agonists (but see Wolterink et al. 1993). 
The first studies with direct dopamine receptor agonists were conducted with the 
nonselective D1-like/D2-like agonist, apomorphine.  Apomorphine did not enhance response 
acquisition with food- or water-conditioned reinforcers (Beninger and Ranaldi 1992; Mazurski 
and Beninger 1986; Robbins et al. 1983), producing instead changes in the rate of both the 
response that produced the stimulus and an inactive control response (Beninger and Ranaldi 
1992; Robbins et al. 1983) or, over a smaller dose range, no significant change in either response 
(Mazurski and Beninger 1986).  Subsequent studies with selective D1-like or D2-like agonists 
have shown that systemic administration of D2-like, but not D1-like, agonists can enhance 
response acquisition with food-paired stimuli.  Systemtic administration of several D2-like 
agonists has been shown to increase responding with food-paired stimuli:  bromocriptine 
(Beninger and Ranaldi 1992; Sutton et al. 2001), quinpirole (Beninger and Ranaldi 1992), or 7-
OH-DPAT (Sutton et al. 2001).  In contrast, systemic administration of a range of doses of a 
variety of D1-like agonists—SKF 38393, SKF 77434, SKF 81297, SKF 82958, and CY 208-
243—either failed to increase or suppressed responding (Beninger and Ranaldi 1992; Beninger 
and Rolfe 1995).  Different patterns of effects, however, have been reported with central agonist 
administration.  Chu and Kelley (1992) reported that neither quinpirole (0.0-20.0 µg) nor CY 
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208-243 (0.0-10.0 µg) increased responding with a food-paired stimulus when injected into the 
NAcc, whereas Wolterink and colleagues (1993) reported that injection of either quinpirole (0.1-
1.0 µg) or SKF 38393 (0.1-10.0 µg) into the NAcc increased responding. 
Compared with these studies of food- or water-paired stimuli, the evidence that 
dopaminergic manipulations can alter new-response acquisition with drug-paired stimuli is 
limited.  Several studies have examined the effects of amphetamine on new-response acquisition 
after drug self-administration training.  Slawecki and colleagues (1997) assessed the effects of 
intra-NAcc amphetamine injection on responding with ethanol-paired stimuli; however, the 
increases in responding found are difficult to interpret in terms of drug-based conditioned 
reinforcement because the stimuli were also paired with sucrose during the course of ethanol 
self-administration training.  Importantly, it was recently shown that systemic amphetamine can 
increase responding with cocaine-paired stimuli when rats acquired a response with the stimuli 
alone after IV cocaine self-administration training (Di Ciano 2008; Samaha et al. 2011).  These 
results suggest that indirect dopaminergic agonism can increase responding with drug-paired 
stimuli, as it does with food- or water-paired stimuli.  However, the behavioral selectivity of 
amphetamine’s effects are unknown, as the previous studies did not examine the effects of 
amphetamine on responding with stimuli that were not consistently paired with cocaine (Di 
Ciano 2008; Samaha et al. 2011).  Furthermore, no study has, to my knowledge, used new-
response acquisition to characterize the effects of selective direct dopaminergic agonists or 
antagonsists on stimuli paired with IV drug.  Characterizing the specific dopamine receptor 
subtypes involved in responding with drug-based conditioned reinforcement may be useful 
generally for understanding the neurobiological mechanisms of reinforcement and, more 
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specifically, for the development of medications designed to reduce the influence exerted by 
drug-paired stimuli over human drug abusers (e.g., Heidbreder and Newman 2010). 
 
Dopamine D2-like agonists in clinical use 
 
Among dopaminergic manipulations, the present study is concerned with the effects of 
systemic administration of the D2-like agonist, pramipexole.  Pramipexole is of particular 
interest because of its widespread clinical use.  Approved for human use internationally, 
pramipexole has become the most widely prescribed direct dopamine agonist treatment for 
Parkinson’s disease (Antonini et al. 2010).  Pramipexole has also been approved by regulators in 
both the United States and Europe to treat restless legs syndrome (Brindani et al. 2009), and 
pramipxole is commonly used “off label” to treat fibromyalgia (Roskell et al. 2011).  Therefore, 
it may be important to characterize the behavioral effects of pramipexole and other, similar D2-
like agonists that are presently approved for human use (e.g., ropinerole) using the routes of 
administration used clinically in dopamine agonist therapy:  peroral, subcutaneous injection, and 
transdermal patch application (Perez-Lloret and Rascol 2010).  Understanding possible changes 
in associative learning and/or motivational processes caused by systemic pramipexole 






Aim 1:  The first set of experiments was designed to validate a new-response acquisition 
procedure for characterizing the conditioned reinforcing effects of a stimulus paired with the 
potent, short-acting µ-opioid agonist, remifentanil, in the rat.  Pavlovian conditioning procedures 
alone were used to pair IV remifentanil injection with a light-noise compound stimulus, and 
animals had no operant training history before the start of the response acquisition test sessions, 
when the stimulus alone was programmed as the consequence of a novel nose-poke response.  To 
verify that acquisition depended on the Pavlovian contingency between the stimulus and 
remifentanil, the responding of animals exposed to stimulus-remifentanil pairings was compared 
to the responding of control animals given remifentanil injections and stimulus presentations 
without consistent pairing (i.e., in a “truly random” arrangement, Rescorla 1967).  Likewise, to 
verify that acquisition depended on the instrumental contingency between a particular response 
and the stimulus, responding in an active nose-poke, which produced the stimulus, was compared 
to responding in an inactive nose-poke, which had no scheduled consequences.  Acquisition was, 
thus, assessed in terms of the effects of two types of associative history (paired vs. random) on 
two instrumental responses (active vs. inactive).  Several parameters of the Pavlovian 
conditioning sessions and/or acquisition test sessions were also manipulated to determine their 
effects on responding with the remifentanil-paired sitmulus:  the ability of responding to persist 
across multiple acquisition test sessions under different schedules of reinforcement was 
evaluated, and the influence of the number of remifentanil-stimulus pairings on response 
acquisition was assessed. 
 
Aim 2:  The second set of experiments was designed to characterize the effects of the dopamine 
D2-like receptor agonist, pramipexole, on responding with remifentanil-associated stimuli in two 
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different behavioral assays:  the new-response acquisition procedure developed in Aim 1 and a 
resisistance-to-extinction procedure designed to study the response-maintaining effects of stimuli 
that had been paired with self-administered remifentanil.  The resistance-to-extinction task was 
modeled on procedures recently used to assess the effects of pramipexole on responding with 
cocaine-associated stimuli (Collins et al. 2012); therefore, this procedure was used first in a 
preliminary study to guide the selection of behaviorally active doses of pramipexole.  In the 
resistance-to-extinction experiment, after a pramipexole dose-effect function was determined, the 
role of different stimulus types (contextual stimuli, discriminative stimuli, discrete conditioned 
stimuli) in the effects of pramipexole was assessed.  Next, a pramipexole dose-effect function 
was determined using the new-response acquisition procedure.  The behavioral selectivity of 
pramipexole was established by giving the same course of pramipexole treatment to a “truly 
random” control group, as was used in Aim 1.  Following the discovery that, in both behavioral 
assays, pramipexole increased rates of responding, but did so only in the final 40-50% of the 
session, a second new-response acquisition experiment was designed to separate the effects of 
the duration of exposure to pramipexole itself from the duration of exposure to the task while 
under the influence of pramipexole. 
 
Aim 3:  The final set of experiments was designed to clarify the receptor mechanisms involved 
in the response-enhancing effects of pramipexole observed in Aim 2.  Whereas previous studies 
have indicated that pramipexole is D3-preferring in vitro and in vivo, pramipexole also has 
significant activity at D2 receptors (e.g., Collins et al. 2007).  Therefore, pretreatments of the D3 
-preferring antagonist, SB-277011A, or the D2-preferring antagonist, L-741,626, were given 
attempting to block the effects of pramipexole.  After finding that SB-277011A did not 
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significantly modify the effects of pramipexole on new-response acquisition, an experiment was 
performed to demonstrate that SB-277011A could attenuate the yawning behavior and penile 
erection elicited by pramipexole.  While not necessarily related to conditioned reinforcement, 
alterations in yawning and penile erection would verify that SB-277011A can modify responses 
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Exposure to drug-associated environmental stimuli can significantly enhance drug self-
administration behaviors in both humans and laboratory animals (Everitt and Robbins 2000; 
Olive and Kalivas 2011; Le Foll and Goldberg 2005; See 2005).  Many of these effects are 
consistent with the drug-associated stimuli functioning as conditioned reinforcers to increase the 
frequency of drug-taking and/or drug-seeking responses; however, it can be difficult 
experimentally to distinguish conditioned reinforcement from the other associative and 
nonassociative effects of drug exposure and stimulus presentation (Cunningham 1993; Kelleher 
and Gollub 1962; Mackintosh 1974; Williams 1994).  Treatments for drug abuse and dependence 
are increasingly focused on techniques to reduce human drug takers’ reactions to drug-associated 
stimuli (e.g., Milton and Everitt 2010; Myers and Carlezon 2010; Taylor et al. 2009).  To 
decrease drug-taking and related maladaptive behaviors while minimizing the risk of disruptions 
to other, more adaptive behaviors, these treatments should target precisely the specific learning 
mechanisms responsible for drug-stimulus associations and stimulus-maintained behaviors (cf., 
Hogarth and Duka 2006).  To help address the specific contributions that conditioned 
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reinforcement can make to drug abuse and dependence (as distinguished, even, from other 
Pavlovian conditioned effects; Milton and Everitt 2010), thorough behavioral assessments are 
needed to characterize the conditioned reinforcing effects of drug-associated stimuli and to 
determine the necessary and sufficient conditions for such stimuli to act as conditioned 
reinforcers. 
Three criteria must be satisfied to establish that a stimulus is, indeed, acting as a 
conditioned reinforcer (Mackintosh 1974, p 234).  Changes in the rate of the response that 
produces the stimulus must (1) not depend on a current or historical association between the 
response and a primary reinforcer; rather, rates must depend (2) on the Pavlovian association 
between a primary reinforcer and the stimulus and (3) on the instrumental association between 
the response and the stimulus.  Among the experimental procedures developed to study 
conditioned reinforcement (reviewed by Williams 1994), new-response acquisition is considered 
particularly rigorous because it can generate behavior that clearly satisfies all three of these 
criteria (e.g., Hyde 1976; Sosa et al. 2011).  In classical new-response acquisition procedures, 
animals are first given response-independent pairings of a primary reinforcer and exteroceptive 
stimulus.  Subsequently, the stimulus alone is programmed as the consequence of a previously 
untrained instrumental response, and the ability of animals to learn to make that response is 
assessed.  In this case, the animals do not have the opportunity to associate directly the 
instrumental response with the primary reinforcer, as the response that produces the stimulus 
does not and did not produce the primary reinforcer, and if adequate controls are included, the 
effects of the specified Pavlovian and instrumental associations can also be established. 
New-response acquisition procedures have been used widely to study the conditioned 
reinforcing effects of food- or water-paired stimuli, and the basic behavioral procedures have 
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been adapted for more complex studies of the associative and neurobiological determinants of 
performance with conditioned reinforcement (e.g., Beninger and Ranaldi 1994; Beninger and 
Rolfe 1995; Burke et al. 2007; de Borchgrave et al. 2002; Olausson et al. 2004; Parkinson et al. 
1999, 2005; Snycerski et al. 2005).  Despite these advances with non-drug reinforcers, new-
response acquisition has not been extensively used to study stimuli paired with drugs of abuse.  
Early work by Davis, Smith and colleagues (reviewed by Davis and Smith 1987; see also 
Goddard and Leri 2006; Marcus et al. 1976) showed that rats would increase their responding on 
a lever that produced a buzzer noise after the noise was paired with response-independent IV 
injections of morphine or amphetamine, compared to a pre-conditioning baseline period when 
lever-presses produced the noise and IV saline injection.  These results are consistent with the 
noise becoming a conditioned reinforcer by Pavlovian association with the drug.  However, 
several alternative explanations for these increases are equally viable, as these studies did not 
include a second, inactive lever or other control for nonspecific changes in behavior and/or a 
pharmacological/associative control to account for potential effects of drug exposure regardless 
of the programmed drug-stimulus association (see Cunningham 1993 for more on interpreting 
such pre- vs. post-conditioning designs). 
More recently, new-response acquisition procedures have been developed in which self-
administration of a drug is trained using one type of manipulandum (e.g., a nose-poke), with 
each IV drug injection accompanied by a particular stimulus, and then responding on a second 
type of manipulandum (e.g., a lever) is trained with the stimulus alone (e.g., Di Ciano and Everitt 
2004; Palmatier et al. 2007; Panlilio et al. 2007).  Importantly, the use of self-administered drug 
gives these procedures at least face validity with human drug abuse; however, the fact that the 
drug-stimulus pairing takes place in the context of operant reinforcement can make it more 
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difficult to resolve the associative structures controlling performance.  Compared to explicitly 
Pavlovian procedures, experimenters have less control over the precise specification of the 
pairings, and the animals’ operant training history could significantly influence subsequent 
response acquisition, as generalization occurs between response types (i.e., as the distributions of 
the form, force, duration, location, etc., of an animal’s movements are or are not modified to 
differentiate a new response from a previously trained response). 
The present experiments, therefore, characterized rats’ acquisition of a novel instrumental 
response (nose-poking) that produced a light-noise stimulus that had been paired with the potent, 
short-acting µ-opioid agonist, remifentanil.  Pavlovian conditioning procedures alone were used 
to establish the drug-stimulus pairing, and animals had no operant training history before the 
start of nose-poke acquisition.  To establish that acquisition depended on, or was sensitive to, the 
Pavlovian contingency between the stimulus and remifentanil, animals exposed to stimulus-
remifentanil pairings were compared to animals given remifentanil injections and stimulus 
presentations without consistent pairing (a “truly random” control, Rescorla 1967).  Likewise, to 
establish that acquisition depended on the instrumental contingency between a particular 
response and the stimulus, animals were allowed to choose between an active nose-poke 
manipulandum, which produced the stimulus, and an inactive nose-poke manipulandum, which 
had no scheduled consequences.  Three experiments were conducted.  Experiment 1 
characterized rats’ responding in 2 instrumental acquisition sessions after 5 Pavlovian 
conditioning sessions.  In Experiment 2, animals were tested in 7 instrumental acquisition 
sessions after 5 Pavlovian conditioning sessions.  These additional acquisition sessions were 
conducted to assess the persistence of responding with the stimulus.  Experiment 3 assessed the 
influence of the number of drug-stimulus pairings, giving animals 7 acquisition sessions after 
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only 1 Pavlovian conditioning session.  Finally, to investigate the influence of the schedule of 
reinforcement on new-response acquisition, the active response produced the stimulus under 




Subjects:  Male Sprague-Dawley rats weighing at least 250 g were obtained from Harlan 
(Indianapolis, IN) to serve as subjects in all experiments.  Experimental groups contained 8-12 
rats.  Animals were housed individually in a temperature (21-23 °C) and humidity controlled 
facility on a 12 h light/dark cycle (lights on at 7:00 am).  Experimental sessions were conducted 
6-7 days/week during the light phase of the cycle.  All animals had unrestricted access to tap 
water and standard pellet chow in the home cage for the duration of their experiment.  All studies 
were performed in accordance with the Guide for the Care and Use of Laboratory Animals 
(Institute of Laboratory Animal Research 1996), as adopted and promulgated by the National 
Institutes of Health, and all experimental procedures were approved by the University of 
Michigan Committee on the Use and Care of Animals. 
 
Surgery:  After at least 7 days of acclimation to the facility, each rat was implanted with a 
chronic indwelling femoral vein catheter to allow for IV drug administration.  Catheterization 
surgery was performed under ketamine/xylazine (90:10 mg/kg, IP) anesthesia.  Catheters, custom 
made from polyurethane tubing (MRE 040, Braintree Scientific, Braintree, MA) and Tygon 
tubing (S-54-HL, Norton Performance Plastics, Akron, OH), were inserted into the left femoral 
vein and routed subcutaneously to the area between the scapulae for externalization.  At the 
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scapulae, the catheter was attached to 22 ga stainless steel tubing that was passed through and 
secured to a Dacron mesh back-plate (DC95BS, Instech Laboratories, Plymouth Meeting, PA).  
Rats were allowed at least 5 days to recover from surgery before starting experimental sessions.  
Catheters were flushed with 0.25 ml of saline with heparin (50 U/ml) each day during recovery, 
as well as before and after experimental sessions to ensure patency. 
 
Apparatus:  Experimental sessions were conducted in two experimental chambers (ENV-008, 
Med Associates, St. Albans, VT) contained inside light- and sound-attenuating cubicles.  Each 
experimental chamber was located in a separate room of the laboratory.  The right wall of each 
experimental chamber contained a white incandescent houselight (ENV-215M, Med Associates) 
and a sound generator and speaker (ENV-230 and ENV-224AM, Med Associates).  Two nose-
poke manipulanda with built-in LED stimulus lights (ENV-114BM, Med Associates) could also 
be inserted into the right wall.  When present, the nose-pokes were located 2.5 cm above the grid 
floor.  The right nose-poke was located 4 cm from the front wall of the experimental chamber, 
whereas the left nose-poke was located 4 cm from the rear wall.  The houselight was centered 
horizontally between the nose-pokes and located 9 cm above the grid floor.  The speaker was 
located above the right nose-poke, 7.5 cm above the grid floor.  Blank aluminum panels were 
inserted when the nose-pokes were removed, but all other elements of the experimental chamber 
remained in place. 
IV drug injections were delivered by motorized syringe drivers (PHM-107, Med 
Associates) through Tygon tubing (S-54-HL, Norton Performance Plastics) connected to a fluid 
swivel (375/22PS, Instech Laboratories or QCS-D, Strategic Applications Inc., Lake Villa, IL) 
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and spring tether, which were mounted to a counterbalanced arm.  The syringe drivers were 
located outside of the light- and sound-attenuating cubicles. 
 
Pavlovian conditioning:  After recovery from catheterization surgery, rats received either 
“paired” or “random” Pavlovian conditioning (PAV) sessions.  During all PAV sessions, the 
nose-pokes were removed from the experimental chambers, and all animals received response-
independent IV injections of remifentanil (3.2 µg/kg/injection delivered in a volume of 100 
µl/kg) and response-independent deliveries of a light-noise compound stimulus.  The dose of 
remifentanil was chosen based on previous work in the laboratory on remifentanil self-
administration (Cooper et al. 2008).  The light-noise stimulus consisted of houselight 
illumination and white noise (80±5 db as measured at the center of the chamber).  Injections and 
stimuli lasted 2.0±0.5 s, depending on the weight of the individual animal.  In the paired PAV 
groups, a single variable time (VT) 3 min schedule controlled both remifentanil injection and 
stimulus delivery, and injections and stimuli always co-occurred.  In the random PAV control 
groups, remifentanil injection and stimulus delivery were each controlled by independent VT3 
min schedules.  Injections and stimuli were not explicitly unpaired.  For both paired PAV and 
random PAV, inter-injection/inter-stimulus intervals ranged from 0.0 to 6.0 min.  The 3 min 
average inter-injection interval was chosen based on the half-life of remifentanil (Crespo et al. 
2005) to allow for extensive drug metabolism between injections.  PAV sessions lasted until 20 
injections and 20 stimulus deliveries occurred, approximately 60 min.  In Experiments 1 and 2, 
separate groups of animals received paired PAV or random PAV for 5 consecutive sessions (100 
total injections/stimulus deliveries).  In Experiment 3, all groups of animals received 1 session of 
paired PAV (20 total injections/stimulus deliveries). 
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Instrumental acquisition:  Instrumental acquisition (ACQ) test sessions began the day after the 
conclusion of PAV.  ACQ sessions were conducted the same way following paired PAV and 
random PAV.  During ACQ sessions, the two nose-pokes were present in the experimental 
chambers.  The start of each ACQ session was indicated by the illumination of the stimulus 
lights inside both nose-pokes, and both nose-pokes remained illuminated for the duration of the 
session.  In each group, the right nose-poke was active for one half of the animals, whereas the 
left nose-poke was active for the other half of the animals.  Responses in the active nose-poke 
produced the light-noise stimulus alone.  No remifentanil injections were given:  animals were 
attached to the tether, but saline replaced remifentanil on the syringe driver, and the syringe 
driver did not operate at any point.  In Experiment 1, responses in the active nose-poke produced 
the stimulus under a modified RR2 schedule.  Under the RR2 schedule, the first response in the 
active nose-poke in each session produced the stimulus with a probability of 1.0, whereas each 
subsequent response in the session produced the stimulus with a probability of 0.5.  In 
Experiments 2 and 3, in separate paired PAV and random PAV groups, responses in the active 
nose-poke produced the stimulus under the RR2 schedule or under a FR1 schedule.  In all 
groups, responses in the inactive nose-poke were recorded but had no scheduled consequences.  
Active and inactive responses made during stimulus presentation itself were not recorded.  All 
ACQ sessions lasted for 60 min.  In Experiment 1, ACQ was conducted for 2 consecutive 
sessions for all animals.  In Experiments 2 and 3, ACQ was conducted for 7 consecutive sessions 
for all animals. 
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Data analysis:  Based on the acquisition criteria of Cunningham (1993, p 375), two hypotheses 
were tested:  (1) a remifentanil-associated conditioned reinforcer will produce differential 
responding, i.e., animals will make more active responses than inactive responses after paired 
PAV but not after random PAV, and (2) a remifentanil-associated conditioned reinforcer will 
increase responding compared to the control animals, i.e., animals will make more active 
responses after paired PAV than after random PAV.  In Experiments 1 and 2, for each schedule 
of reinforcement, the mean active and inactive nose-pokes made in each ACQ session were 
analyzed using three-way ANOVA with the within-subjects factors of manipulandum (active vs. 
inactive) and session (ACQ1-2 in Experiment 1, ACQ1-7 in Experiment 2) and the between-
subjects factor of PAV history (paired vs. random).  Paired t-tests were then used to compare the 
active and inactive responses of each group in each ACQ session.  Following a significant PAV 
history X manipulandum interaction and nonsignificant interactions involving PAV history and 
session, responding was averaged across sessions, and unpaired t-tests were used to compare the 
mean active responses of the paired PAV vs. random PAV groups and the mean inactive 
responses of the paired PAV vs. random PAV groups.  The Holm-Bonferroni method was used 
to correct for multiple pairwise comparisons.  In Experiment 3, for each schedule of 
reinforcement, the mean active and inactive nose-pokes made in each ACQ session were 
analyzed using two-way ANOVA with the within-subjects factors of manipulandum and session.  
Because no main effects or interactions were significant in these ANOVAs, no pairwise tests 
were performed.  Analyses were performed using Prism 5.0 (GraphPad Software, La Jolla, CA) 




Drugs:  Remifentanil was obtained from the hospital pharmacy of the University of Michigan 
Health System (Ultiva brand, GlaxoSmithKline, Uxbridge, Middlesex, UK) and dissolved in 




Experiment 1:  Responding in 2 ACQ sessions after 5 PAV sessions 
 
Figure 2.1 presents the nose-poke responses of rats in 2 ACQ sessions after 5 sessions of 
either paired PAV (Figure 2.1a) or random PAV (Figure 2.1b).  Animals responded differently in 
the active vs. inactive nose-poke [main effect of manipulandum;  F(1,18) = 6.04, p = .024; 
session X manipulandum:  F(1,18) = 4.45, p = .049].   By pairwise comparison, animals that 
received paired PAV made significantly more active responses than inactive responses in ACQ2 
[t(9) = 3.55, p = .012], whereas the active and inactive responses of animals that received 
random PAV were not different in either ACQ session [0.12 < t(9) <  1.61, all p’s > .10].  
Between groups, however, the effects of PAV history were not significant [main effect and all 
interactions:  0.24 < F(1,18) < 2.82, all p’s > .10]. 
 
Experiment 2:  Responding in 7 ACQ sessions after 5 PAV sessions 
 
Figure 2.2 presents the nose-poke responses of rats in 7 ACQ sessions after 5 sessions of 
either paired or random PAV.  Animals responded under either the RR2 (Figures 2.2a-2.2c) or 
FR1 (Figures 2.2d-2.2f) schedule of reinforcement.   
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Under the RR2 schedule, animals responded differently in the active vs. inactive nose-
poke [main effect of manipulandum:  F(1,20) = 16.48, p < .001; session X manipulandum:  
F(6,120) = 2.47, p = .027].  By pairwise comparison, animals that received paired PAV made 
significantly more active responses than inactive responses in each session from ACQ2-7 [Figure 
2.2a; 3.20 < t(11) < 4.64, all p’s < .05].  After random PAV, animals’ active and inactive 
responses were not different in any ACQ session [Figure 2.2b; 0.20 < t(9) < 1.99, all p’s > .10].  
Between groups, animals responded differently after paired PAV vs. random PAV [main effect 
of PAV history:  F(1,20) = 6.69, p = .018], and the effects of PAV history differed for active vs. 
inactive responding [PAV history X manipulandum:  F(1,20) = 9.63, p = .006].  Responding 
changed across ACQ sessions [main effect of session:  F(6,120) = 3.48, p = .003], but the effects 
of PAV history did not depend on the session [session X PAV history:  F(6,120) = 1.08, p = .37; 
session X PAV history X manipulandum:  F(6,120) = 1.56, p = .16].  Collapsing across sessions 
to characterize the PAV history X manipulandum interaction (Figure 2.2c), animals made more 
active responses after paired PAV than after random PAV [t(20) = 2.91, p = .017), whereas 
inactive responding was not different after paired PAV vs. random PAV [t(20) = 1.40, p = .17]. 
Under the FR1 schedule, numerically, animals made more active responses than inactive 
responses after paired PAV and more inactive responses than active responses after random 
PAV.  The main effect of manipulandum was not significant [F(1,18) = 2.97, p = .10], but 
responding differed significantly within the paired PAV group.  By pairwise comparison, 
animals that received paired PAV made significantly more active responses than inactive 
responses in ACQ2 and from ACQ4-7 [Figure 2.2d; 3.41 < t(11) < 4.75, all p’s < .05].  After 
random PAV, animals’ active and inactive responses were not different in any ACQ session 
[Figure 2.2e; 0.0 < t(7) < 2.93, all p’s > .10].  Animals’ responding under the FR1 schedule was 
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affected by their PAV history as it was under the RR2 schedule:  under the FR1 schedule, as 
well, animals responded differently after paired PAV vs. random PAV [main effect of PAV 
history:  F(1,18) = 7.17, p = .015], and the effects of PAV history differed for active vs. inactive 
responding [PAV history X manipulandum:  F(1,18) = 15.48, p < .001].  Responding changed 
across ACQ sessions [main effect of session: F(6,108) = 16.23, p < .001], but the effects of PAV 
history did not depend on the session [session X PAV history:  F(6,108) = 1.03, p = .40; session 
X PAV history X manipulandum:  F(6,108) = 1.22, p = .30].  Collapsing across sessions to 
characterize the PAV history X manipulandum interaction (Figure 2.2f), animals made more 
active responses after paired PAV than after random PAV [t(18) = 3.60, p = .004], whereas 
inactive responding did not differ by PAV history [t(18) = 0.37, p = .71]  
 
Experiment 3:  Responding in 7 ACQ sessions after 1 PAV sessions 
 
Figure 2.3 presents the active and inactive responses of rats in 7 ACQ sessions after 1 
session of paired PAV.  Rats responded under either the RR2 (Figure 2.3a) or FR1 (Figure 2.3b) 
schedule of reinforcement.  Under the RR2 schedule, responding did not differ by nose-poke 
[main effect of manipulandum:  F(1,7) = 2.07, p = .19] or across sessions [main effect of session:  
F(6,42) = 1.74, p = .13; session X manipulandum:  F(6,42) = 1.14, p = .35].  Under the FR1 
schedule, likewise, responding did not differ by nose-poke [main effect of manipulandum:  
F(1,9) = 3.96, p = .078] or across sessions [main effect of session:  F(6,54) = 0.90,  p = .49; 
session X manipulandum:  F(6,54) = 0.99, p = .43].  The trend toward a difference between the 
nose-pokes under the FR1 schedule was caused by a slight, but persistent, preference for the 
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inactive response over the active response.  Because paired PAV did not produce any significant 




Various behavioral processes can change rates of responding when animals are exposed 
to a drug-paired environmental stimulus.  These processes may be related to exposure to the drug 
itself, exposure to the stimulus itself, and/or the drug-stimulus pairing.  In addition to the 
conditioned reinforcing effects of the stimulus, responding may be altered by the primary 
reinforcing effects of the drug, primary reinforcing effects of the stimulus (i.e., sensory 
reinforcement), discriminative effects of the stimulus, unconditioned effects of drug exposure, 
nonassociative learning (e.g., habituation to the sensory aspects of the stimulus), and other 
influences.  These alternatives can confound a number of experimental preparations intended to 
measure conditioned reinforcement (Cunningham 1993; Kelleher and Gollub 1962; Mackintosh 
1974; Shahan 2010; Williams 1994).  The present study, therefore, used a behaviorally stringent 
new-response acquisition procedure to characterize the conditioned reinforcing effects of a light-
noise stimulus that was paired with the µ-opioid agonist, remifentanil. 
After 5 sessions of paired PAV, rats acquired a novel nose-poke response that produced 
the light-noise stimulus alone.  Under either the RR2 or FR1 schedule of reinforcement, 
significant preferences for the active response developed rapidly (by ACQ2, Experiments 1 and 
2) and persisted across multiple testing sessions (active > inactive even in ACQ7, Experiment 2).  
Control rats did not acquire nose-poking when the stimulus and remifentail were not consistently 
paired:  after 5 sessions of random PAV, no significant preference for the active response was 
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observed in any ACQ session.  With the 7 ACQ sessions in Experiment 2, furthermore, rats 
made more active responses after paired PAV than after random PAV.  Pairing the stimulus with 
remifentanil selectively affected active responding, as inactive responding did not differ by PAV 
history under either schedule.  Thus, the remifentanil-paired stimulus maintained both 
differential responding (active > inactive within-subjects) and increased responding (active > 
active between-subjects).  Different criteria may be used to determine when a response has been 
successfully acquired with either conditioned or primary reinforcement; however, in 
experimental designs that include two manipulanda, testing for both within-group and between-
group differences in active responding may provide a more comprehensive account of the 
response strength obtained, even if it is not always used as the minimum requirement for an 
adequate demonstration of reinforcement (Cunningham 1993; Snycerski et al. 2005).  In contrast 
to the effects of 5 sessions of paired PAV, rats did not acquire responding under either schedule 
of reinforcement after 1 session of paired PAV.  These results are consistent with earlier studies 
of the effects of pairing number on the conditioned reinforcing effects of food-associated stimuli, 
as well as more general notions of “associative strength” or the degree of association underlying 
other behaviors that depend on Pavlovian learning (reviewed by Kelleher and Gollub 1962; 
Mackintosh 1974). 
Responding with the remifentanil-paired stimulus, therefore, satisfies the three criteria for 
conditioned reinforcement reviewed above (Mackintosh 1974, p 234).  First, the absence of the 
nose-poke manipulanda during PAV and the absence of remifentanil during ACQ prevented 
direct association of the nose-poke response with remifentanil as a primary reinforcer.  Rather, 
the differences between the paired PAV and random PAV groups show that acquisition 
depended on the Pavlovian pairing of the stimulus with remifentanil.  Prior exposure to 
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remifentanil and stimulus presentation without consistent pairing did not produce differential 
responding during ACQ or as much active responding as paired PAV.  Finally, the differences 
between active and inactive nose-poke responding during ACQ indicate that acquisition 
depended on the instrumental association between the active response and the stimulus.  The side 
of the active nose-poke (left vs. right) was counterbalanced across animals in each group, and the 
houselight and speaker were not consistently located above the active nose-poke.  It is, therefore, 
unlikely that either a spatial bias or Pavlovian conditioned approach to the remifentanil-paired 
stimuli was the sole basis for differential responding.  Likewise, both nose-pokes simply 
remained illuminated for the duration of the session, and so the differences in responding are 
unlikely to have emerged from a difference in the sensory aspects of the active vs. inactive 
manipulanda themselves.  The patterns of performance observed appear to depend on the 
different consequences of the active and inactive nose-poke responses. 
This is not to say that independently programmed or randomized presentations of drugs 
and environmental stimuli have no effect on behavior, or that the random control groups learned 
nothing during their PAV sessions.  Even with the significant differences between the paired 
PAV and random PAV groups reviewed above, animals in the random PAV groups still made 
~5-10 active and inactive responses per session during ACQ.  This responding may be due to 
associative processes (e.g., from pairing the operant chamber context generally with 
remifentanil) and/or nonassociative processes (e.g., reactions to the nose-poke manipulanda as 
novel objects inside the operant chamber).  Some of these same processes may have also 
influenced the responding of the paired PAV groups, in addition to the effects of the 
remifentanil-stimulus pairing.  It is beyond the scope of the present discussion to consider fully 
the different contingency-dependent and contingency-independent theories of Pavlovian 
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conditioning that have been proposed (see, e.g., Kirkpatrick and Church 2004; Miller and Matzel 
1989; Papini and Bitterman 1990), but it is important to recognize that there continues to be 
debate about the procedures that comprise adequate controls in Pavlovian conditioning 
experiments.  A random control procedure was chosen for the present study to ensure that the 
experimental and control groups were matched for their exposure to the individual experimental 
elements—both total remifentanil exposure and exposure to the light-noise stimulus—during 
PAV (Cunningham 1993).  The present study cannot address the details of the learning of the 
animals in the random PAV groups, except to note that this learning (whatever it was) did not 
produce the same effect on nose-poke responding that paired PAV did, and so the differences 
between the groups in this target behavior are still relevant to understanding how a specific drug-
paired stimulus can control a specific behavioral response. 
In human drug abuse and dependence generally, Pavlovian drug-associated stimuli are 
thought to play a number of distinct, but interacting, roles in maintaining drug self-
administration behaviors and provoking relapse (reviewed by Milton and Everitt 2010).  As 
conditioned reinforcers, specifically, drug-paired stimuli may help to sustain (1) prolonged 
sequences or chains of behavior that ultimately lead to drug consumption and (2) drug-seeking 
responses in extinction, when the drug itself is unavailable (Milton and Everitt 2010).  Human 
drug abusers are often required to engage in long, complex sequences of behavior to obtain and 
prepare drugs prior to consuming them, and laboratory animals can also be trained to produce 
extended multioperant chains with self-administered drug (e.g., Thompson and Pickens 1969, 
Figure 9).  Reducing the conditioned reinforcing of drug-paired stimuli may disrupt the 
performance of such chains, reducing access to and drug-taking in their terminal links.  Next, by 
maintaining existing responses and training new responses in the absence of the drug itself, 
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conditioned reinforcers may both complicate the detoxification process, as individuals attempt to 
break ongoing patterns of drug self-administration, and contribute to relapse after extended 
abstinence.  The sustained preferences for the active response observed in the present study are 
noteworthy in this regard.  Historically, researchers have questioned whether new-response 
acquisition behavior is too transient to be of practical use in studying conditioned reinforcement:  
because responses during instrumental acquisition necessarily present the stimulus in the absence 
of the primary reinforcer, Pavlovian extinction may rapidly reduce or eliminate the conditioned 
reinforcing effects of the stimulus (Mackintosh 1974; Williams 1994; Sosa et al. 2011).  Many of 
the details of the interactions between Pavlovian and instrumental learning remain to be 
elucidated (e.g., Palmatier et al. 2008), but it is becoming increasingly clear that sustained 
response-acquisition performance can be obtained with drug-based conditioned reinforcement 
(see also Di Ciano and Everitt 2004).  Altogether, therefore, interventions aimed at reducing the 
conditioned reinforcing effects of drug-paired stimuli may help make drug-seeking and drug-
taking behaviors less flexible and less sustainable.  New-response acquisition procedures may 
provide useful models for studying the enduring control drug-paired stimuli can exert over 
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Figure 2.1.  Acquisition of a novel nose-poke response when responses in the active nose-poke 
produced a stimulus that was previously paired with response-independent IV remifentanil 
injection 
 
Figure 2.1.  Acquisition of a novel nose-poke response when responses in the active nose-poke 
produce a stimulus that was previously paired with response-independent IV remifentanil 
injection.  a:  Active and inactive nose-poke responses made by rats (n = 10) after 5 sessions of 
paired PAV.  b:  Active and inactive nose-poke responses made by control rats (n = 10) after 5 
sessions of random PAV.  * p < .05.  Significant difference between active and inactive 
responding in the given ACQ session as assessed by paired t-test.  All data are presented as the 
mean±SEM. 
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Figure 2.2.  Persistence of responding across ACQ sessions with the remifentanil-paired 






Figure 2.2.  Persistence of responding across ACQ sessions with the remifentanil-paired 
stimulus under both the RR2 and FR1 schedules of reinforcement.  a:  Active and inactive nose-
poke responses made by rats (n = 12) under the RR2 schedule after 5 sessions of paired PAV.  b:  
Active and inactive nose-poke responses made by control rats (n = 10) under the RR2 schedule 
after 5 sessions of random PAV.  c:  Mean active and inactive responses made from ACQ1-7 
under the RR2 schedule after paired or random PAV.  d:  Active and inactive nose-poke 
responses made by rats (n = 12) under the FR1 schedule after 5 sessions of paired PAV.  e:  
Active and inactive nose-poke responses made by control rats (n = 8) under the FR1 schedule 
after 5 sessions of random PAV.  f:  Mean active and inactive responses made from ACQ1-7 
under the FR1 schedule after paired or random PAV.  * p < .05; ** p < .01.  Significant 
difference between active and inactive responding in the given ACQ session as assessed by 
paired t-test.  # p < .05; ## p < .01.  Significant difference between paired and random PAV as 
assessed by unpaired t-test.  All data are presented as the mean±SEM. 
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Figure 2.3.  Lack of acquisition of nose-poke responding when the number of remifentanil-
stimulus pairings is reduced 
 
Figure 2.3.  After 1 session of PAV, rats do not acquire nose-poke responding with the 
remifentanil-paired stimulus.  a:  Active and inactive nose-poke responses made by rats (n = 8) 
under the RR2 schedule after 1 session of paired PAV.  b:  Active and inactive nose-poke 
responses made by rats (n = 10) under the FR1 schedule after 1 session of paired PAV.  All data 














Effects of Pramipexole on Responding Maintained by Remifentanil-Paired Stimuli:  




Among the dopamine D1-like (D1, D5) and D2-like (D2, D3, D4) receptors, the D3 
receptor shows a particularly constrained neuroanatomical distribution, with expression focused 
in limbic brain regions (Beaulieu and Gainetdinov 2011).  In both rodents and primates, 
moderate-to-high densities of D3 receptor protein and/or mRNA are found in brain structures 
and systems associated with the reinforcing effects of drugs of abuse and responding with drug-
associated stimuli, including the mesolimbic dopaminergic system, extended amygdala, and 
corticostriatal loops (reviewed by Heidbreder and Newman 2010; Le Foll et al. 2005; Shafer and 
Levant 1998; Sokoloff et al. 2006).  Accordingly, D3 receptor activity is thought to be important 
for drug self-administration behaviors, and D3-preferring or D3/D2 ligands have received 
considerable attention as potential therapeutics for human drug abuse and dependence (Garcia-
Ladona and Cox 2003; Heidbreder 2013; Heidbreder and Newman 2010; Le Foll et al. 2005; 
Newman et al. 2012; Sokoloff et al. 2006; Shafer and Levant 1998). 
In both laboratory rodents and nonhuman primates, treatment with D3-preferring or 
D3/D2 agonists and antagonists has been shown to modify significantly both drug self-
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administration responding and responding with drug-associated stimuli (reviewed by Self 2010).  
In rats, much of this work has focused on the ability of these compounds to alter responding with 
cocaine-associated stimuli in extinction after cocaine self-administration training (e.g., in 
reinstatement procedures) or with ongoing self-administration under second-order schedules of 
stimulus and cocaine availability.  Tested in extinction after self-administration training, 
systemic pretreatments of a variety of D3-preferring or D3/D2 agonists can increase (Cervo et al. 
2003; Collins and Woods 2009; Collins et al. 2012; De Vries et al. 1999, 2002; Dias et al. 2004; 
Edwards et al. 2007; Fuchs et al. 2002; Koeltzow and Vezina 2005; Self et al. 1996; Wise et al. 
1990), and D3-preferring or D3/D2 antagonists can decrease (Cervo et al. 2003, 2007; Crombag 
et al. 2002; Gál and Gyertyán 2006; Gilbert et al. 2005; Weiss et al. 2001), cocaine-appropriate 
responding.  In these studies, rats responded in the presence of cocaine-associated contextual and 
discriminative stimuli, and/or responding on the cocaine-associated manipulandum produced 
stimuli (e.g., cue lights, tones) previously paired with cocaine injection, but not cocaine itself.  
D3-preferring agonists also can enhance (Fuchs et al. 2002; Self et al. 1996), and D3-preferring 
or D3/D2 antagonists can attenuate (Peng et al. 2009; Vorel et al. 2002; Xi et al. 2006; see also 
Weissenborn et al. 1996), the ability of cocaine pretreatment to increase extinction responding 
under these circumstances.  Likewise, pretreatments of either a D2-preferring or a D3-preferring 
antagonist can attenuate the ability of a D3-preferring agonist to increase cocaine-trained 
responding (Collins et al. 2012).  Under second-order schedules of cocaine self-administration, 
D3-preferring antagonist administration has been shown to reduce rats’ behavior before any 
cocaine has actually been delivered, i.e., in an initial phase of the session when responding has 
only produced the cocaine-associated stimuli (Di Ciano et al. 2003; see also Pilla et al. 1999). 
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Compared to this body of work with cocaine, fewer studies have examined the effects of 
D3-preferring or D3/D2 ligands on responding with stimuli associated with other drugs of abuse, 
particularly opioid-associated stimuli (Heidbreder 2013; Heidbreder and Newman 2010; Self 
2010).  Wise and colleagues (1990) first reported that response-independent IV injection of the 
D3/D2 agonist, bromocriptine, increased rats’ extinction responding after either cocaine or 
heroin self-administration.  Subsequently, De Vries and colleagues (2002) reported that SC 
injection of the D3-preferring agonist, quinpirole, increased extinction responding after heroin 
self-administration training, and this effect depended on the number of extinction sessions 
conducted before the quinpirole challenge sessions (see also De Vries et al. 1999).  Among 
antagonists, the D3/D2 antagonist, raclopride, was shown (numerically) to attenuate the increase 
in extinction responding caused by experimenter-administered heroin pretreatment after heroin 
self-administration training (Shaham and Stewart 1996).  These results demonstrate the 
importance of D3/D2 activity in opioid-related behaviors, but the role(s) played by particular 
opioid-associated stimuli remain unclear.  For example, when testing the effects of 
bromocriptine, Wise and colleagues (1990) continued to present response-contingently the cue 
light that was paired with heroin injection, whereas De Vries and colleagues (2002) sought 
specifically to limit the effects of drug-paired cues in their quinpirole test sessions and withheld 
the stimuli that had previously accompanied heroin injection.  There were a number of other 
procedural differences between these studies, and so the relative importance of delivering vs. 
withholding the drug-paired stimuli during agonist testing is unclear.  Therefore, additional work 
is needed to characterize (1) the effects of D3-preferring ligands on opioid-trained responding 
and (2) the behavioral mechanisms by which these compounds act when they change responding. 
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In particular, several authors have suggested that D2-like receptor ligands can alter the 
conditioned reinforcing effects of drug-paired stimuli (Cervo et al. 2003, 2007; Collins and 
Woods 2009; Collins et al. 2012; Di Ciano et al. 2003; Gál and Gyertyán 2006; Le Foll et al. 
2005; Pilla et al. 1999).  The exteroceptive stimuli that accompany drug injections may, because 
of this pairing, become conditioned reinforcers.  If so, increases or decreases in responding when 
these stimuli are presented in the absence of the drug could be due to increases or decreases, 
respectively, in the effectiveness of these conditioned reinforcers.  However, the behavioral 
procedures so far used cannot isolate the conditioned reinforcing effects of the stimuli:  changes 
in the extinction of a previously trained response or in responding under second-order schedules 
of reinforcement can be caused by a number of behavioral mechanisms other than conditioned 
reinforcement, including the primary reinforcing effects of the training drug and the 
discriminative stimulus functions of the training drug, the testing drug, and the stimuli (Collins et 
al. 2012; Kelleher and Gollub 1962; Mackintosh 1974; Wike 1966; Williams 1994).  Measuring 
the ability of animals to acquire a new response that produces a drug-paired stimulus (i.e., a 
response that does not or did not also produce the drug itself) can provide a more valid 
assessment of the conditioned reinforcing effects of that stimulus (Mackintosh 1974; Williams 
1994).  Consistent with a role for D2-like receptor activity in conditioned reinforcement, 
specifically, systemic administration of D2-like, but not D1-like, receptor agonists has been 
shown to enhance new-response acquisition with food-paired stimuli (Beninger and Ranaldi 
1992; Beninger and Rolfe 1995; Sutton et al. 2001).  However, there have not been 
corresponding studies reported, to my knowledge, of the effects of D2-like agonists on new-
response acquisition with drug-paired conditioned reinforcers. 
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To clarify the potential importance of changes in conditioned reinforcement to the effects 
of D2-like agonists on opioid-related behaviors, the present study characterized the effects of the 
D3-preferring agonist, pramipexole (PRAM), on responding with opioid-associated stimuli in 
two different behavioral tasks:  (1) resistance-to-extinction/reinstatement of remifentanil self-
administration and (2) new-response acquisition after Pavlovian remifentanil-stimulus pairing.  
Three experiments were conducted.  Experiment 1 tested a series of doses of PRAM in extinction 
after rats were trained to self-administer remifentanil under a progressive ratio (PR) schedule.  
Finding that PRAM significantly increased responding, and that these increases depended on the 
presentation of the stimuli that had been paired with remifentanil injection, the effects of PRAM 
on new-response acquisition were evaluated in Experiment 2.  Finally, Experiment 3 addressed 




General methods for Experiments 1-3 
 
Animals:  Male Sprague-Dawley rats weighing at least 250 g were obtained from Harlan 
(Indianapolis, IN) to serve as subjects in all experiments.  Experimental groups contained 8 rats 
except where noted in Experiment 3.  Animals were housed in a climate controlled facility under 
a 12 h light-dark cycle (lights on at 7:00 am).  All animals were allowed to acclimate to the 
facility for at least 7 days before the start of any experimental procedures.  Experimental sessions 
were conducted 5-7 days/week during the light phase of the cycle.  All animals had unrestricted 
access to standard pellet chow and tap water in the home cage for the duration of their 
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experiment.  All studies were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Research 1996), as adopted and 
promulgated by the National Institutes of Health, and all experimental procedures were approved 
by the University of Michigan Committee on the Use and Care of Animals. 
 
Surgery:  After acclimating to the facility, each animal received a chronic, indwelling venous 
catheter to allow for IV drug administration.  Catheters were custom made from polyurethane 
tubing (MRE 040, Braintree Scientific, Braintree, MA) and Tygon tubing (S-54-HL, Norton 
Performance Plastics, Akron, OH).  Catheterization surgery was performed under 
ketamine/xylazine (90:10 mg/kg, IP) anesthesia.  The catheter was inserted into the left femoral 
vein and routed subcutaneously to the area between the scapulae for externalization.  At the 
scapulae, the catheter was attached to 22 ga stainless steel tubing which was passed through and 
secured to a Dacron mesh back-plate (DC95BS, Instech Laboratories, Plymouth Meeting, PA).  
Rats were allowed at least 5 days to recover from surgery before starting experimental sessions.  
Catheters were flushed with 0.25 ml of heparinized saline (50 U/ml) each day during recovery, 
as well as before and after experimental sessions to ensure patency.  In Experiment 1, animals 
continued to be tested if catheter patency was lost after the conclusion of self-administration.  In 
Experiments 2 and 3, animals had patent catheters throughout the experiment. 
 
Drugs:  Remifentanil was obtained from the hospital pharmacy of the University of Michigan 
Health System (Ultiva brand, GlaxoSmithKline, Uxbridge, Middlesex, UK).  Pramipexole was 




Experiment 1:  Resistance to extinction of remifentanil self-administration responding 
 
The methods of Experiment 1 were adapted from those used by Collins and colleagues 
(2012) to study the effects of PRAM in cocaine-trained rats. 
 
Apparatus:  Experimental sessions were conducted in four experimental chambers (ENV-008, 
Med Associates Inc., St. Albans, VT) located inside light- and sound-attenuating cubicles.  The 
right wall of each experimental chamber contained a nose-poke manipulandum (ENV-114BM, 
Med Associates), located 5 cm above the grid floor and 4 cm from the front wall, and a lever 
manipulandum (H21-03R, Coulbourn Instruments, Whitehall, PA), located 5 cm above the grid 
floor and 4 cm from the rear wall.  The nose-poke aperture contained a yellow LED stimulus 
light, and a set of green, yellow, and red LED stimulus lights (ENV-222M, Med Associates) was 
located directly above the nose-poke.  A white incandescent houselight (ENV-215M, Med 
Associates) was located in the left wall of each experimental chamber, centered horizontally 9 
cm above the grid floor. 
Drug solutions were delivered by a motorized syringe driver (PHM-107, Med Associates) 
through Tygon tubing (S-54-HL, Norton Performance Plastics) connected to a fluid swivel 
(375/22, Instech Laboratories) and spring tether that were mounted to a counterbalanced arm.  
The syringe drivers were located outside of the light- and sound-attenuating cubicles. 
 
Remifentanil self-administration training:  Following recovery from surgery, animals were 
trained to self-administer 3.2 µg/kg/injection remifentanil (delivered in a volume of 100 µl/kg) in 
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90 min sessions.  Responding was initially trained under a fixed ratio (FR) 1 schedule of 
reinforcement.  The ratio requirement was gradually increased to FR5 before training under the 
PR schedule began.  Under the PR schedule, ratio requirements increased within the session (1, 
2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95, 118, 145, 178, 219, 268, 328, 402, 492, 603, 737, 
901, 1,102, etc.) according to the equation of Richardson and Roberts (1996):  ratio value = 
[5e(reinforcer number * 0.2)]−5.  PR sessions lasted for 240 min or until a ratio requirement was not 
completed in 45 min, whichever occurred first.  The value of the final ratio completed before the 
end of the session was recorded as the animal’s break point. 
 Under both the FR and PR schedules, the start of the session was signaled by the 
illumination of the nose-poke aperture light.  Upon completion of a ratio requirement in the nose-
poke, a remifentanil injection was delivered accompanied by the illumination of the three LED 
stimulus lights above the nose-poke aperture for the duration of the injection (2.0±0.5 s, 
depending on the weight of individual animal).  A 5 s time out (TO) followed the conclusion of 
each injection.  During the TO, the nose-poke aperture light was extinguished, and the houselight 
was illuminated.  The houselight was extinguished, and the nose-poke aperture light was re-
illuminated at the conclusion of the TO.  Responses on the lever were recorded but had no 
scheduled consequences. 
 
Extinction testing I, PRAM dose-effect determination:  Testing began when remifentanil self-
administration under the PR schedule stabilized (at least 3 sessions with less than 20% difference 
and no increasing or decreasing trend in the number of ratios completed across sessions).  
Animals were tested in extinction under the PR schedule.  Sessions began with the illumination 
of the nose-poke aperture light, and nose-poke responses produced the LED stimulus light 
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illumination and TO but no injection.  Animals were attached to the tether, but saline replaced 
remifentanil on the syringe driver, and the syringe driver did not operate at any point.  Lever 
responses were counted but had no scheduled consequences.  Pretreatment injections were 
administered SC immediately before the start of each test session.  All animals received all 
PRAM doses:  vehicle (0.0 mg/kg), 0.032-1.0 mg/kg.  PRAM doses were administered in either 
ascending or descending order, counterbalanced across animals, and each dose was administered 
for three consecutive sessions. 
 
Extinction testing II, stimulus manipulation:  After the determination of the dose-effect 
function, the effects of 0.0 mg/kg and 0.32 mg/kg PRAM were reassessed within-subjects when 
different remifentanil-associated stimuli were presented/withheld in the session.  Stimulus 
manipulation sessions began directly after completion of the PRAM dose-effect determination:  
no additional remifentanil self-administration training or exposure to remifentanil was given.  
Under all stimulus manipulation conditions, the PR schedule was in effect, and responses were 
counted as they were in the previous phases of the study.  Responding was measured in four 
stimulus conditions, differentiated by whether or not the remifentail-associated discriminiative 
stimulus (DS, nose-poke aperture illumination) and/or the remifentanil-paired conditioned 
stimuli (CS, LED and houselight illumination) were presented.  (1) In the context condition, the 
nose-poke aperture light was not illuminated, and responses in the nose-poke did not produce 
LED or houselight illumination.  (2) In the DS only condition, the nose-poke aperture light was 
illuminated for the duration of the session, and responses in the nose-poke did not produce LED 
or houselight illumination.  (3) In the CS only condition, the nose-poke aperture light was not 
illuminated at any point, but responses in the nose-poke produced the ~2 s LED and 5 s 
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houselight illumination.  (4) In the DS+CS condition, the nose-poke aperture light was 
illuminated for the duration of the session (except during TO), and responses in the nose-poke 
produced the ~2 s LED and 5 s house-light illumination.  Each stimulus condition was tested for 
two sequential sessions:  in a randomly determined order for each animal, 0.0 mg/kg was 
administered immediately prior to one session, whereas 0.32 mg/kg PRAM was administered 
immediately before the other session.  After all four stimulus conditions were tested once, this 
process was repeated, and a second set of sessions was conducted with the order of stimulus 
conditions and order of pretreatments re-determined randomly for each animal. 
 
Data analysis:  The following endpoints of PR performance were measured:  active responses, 
break point, number of ratios completed, total session length (min), and inactive responses.  The 
three sessions conducted with each pretreatment dose, as well as the final three remifentanil self-
administration training sessions, were averaged for analysis.  As a preliminary test to check for 
effects of pretreatment dose order, the number of ratios completed in extinction was analyzed 
using a two-way ANOVA with the within-subjects factor of pretreatment dose and the between-
subjects factor of dose order (ascending vs. descending).  Not finding significant effects of dose 
order, the data were combined between orders for all subsequent analyses.  To determine 
whether PRAM altered extinction responding, each endpoint was analyzed using repeated-
measures ANOVA with the within-subjects factor of pretreatment dose.  Following a significant 
omnibus effect, each dose of PRAM was compared to vehicle (0.0 mg/kg) using post hoc 
Bonferroni tests.  To determine if extinction responding differed from self-administration 
responding, each pretreatment condition was compared to the final self-administration training 
sessions using Bonferroni-corrected paired t-tests. 
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To characterize the effects of PRAM on the intrasession allocation of responding, the 
active responses made in extinction were reanalyzed.  Because the total session length varied 
across sessions, each session was divided into 5 blocks (BLOCK1-5), each encompassing a 
sequential 20% of the total session length.  The rate of responding (responses/min) in each block 
was calculated.  As above, the three sessions conducted with each pretreatment dose were 
averaged for analysis.  The average rate of responding in each block was analyzed using two-
way ANOVA with the within-subjects factors of block and dose.  Following a significant block 
X dose interaction, post hoc Bonferroni tests were used to compare each dose of PRAM to 
vehicle (0.0 mg/kg) in each block. 
To assess the influence of stimulus manipulation on the response-increasing effects of 
PRAM, the two determinations of each pretreatment condition under each stimulus condition 
were averaged.  Animals’ active responses and inactive responses were analyzed separately 
using two-way ANOVA with the within-subjects factors of pretreatment (0.0 mg/kg vs. 0.32 
mg/kg PRAM) and stimulus condition (context, DS only, CS only, DS+CS).  Following a 
significant pretreatment X stimulus condition interaction, post hoc Bonferroni tests were used to 
compare 0.0 mg/kg and 0.32 mg/kg PRAM under each stimulus condition. 
Analyses were performed using Prism 5.0 (GraphPad Software, La Jolla, CA) or SPSS 
Statistics 20.0 (IBM, Armonk, NY).  Differences were considered significant when p < .05, two-
tailed. 
 
Experiments 2 and 3:  New-response acquisition with a remifentanil-paired stimulus 
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Apparatus:  Experimental sessions were conducted in two experimental chambers (ENV-008, 
Med Associates) contained inside light- and sound-attenuating cubicles.  Each experimental 
chamber was located in a separate room of the laboratory.  The right wall of each experimental 
chamber contained a white incandescent houselight (ENV-215M, Med Associates) and a sound 
generator and speaker (ENV-230 and ENV-224AM, Med Associates).  Two nose-poke 
manipulanda with built-in LED stimulus lights (ENV-114BM, Med Associates) could also be 
inserted into the right wall.  When present, the nose-pokes were located 2.5 cm above the grid 
floor.  The right nose-poke was located 4 cm from the front wall of the experimental chamber, 
whereas the left nose-poke was located 4 cm from the rear wall.  The houselight was centered 
horizontally between the nose-pokes and located 9 cm above the grid floor.  The speaker was 
located above the right nose-poke, 7.5 cm above the grid floor.  Blank aluminum panels were 
inserted when the nose-pokes were removed, but all other elements of the experimental chamber 
remained in place. 
IV drug injections were delivered by motorized syringe drivers (PHM-107, Med 
Associates) through Tygon tubing (S-54-HL, Norton Performance Plastics) connected to a fluid 
swivel (375/22PS, Instech Laboratories or QCS-D, Strategic Applications Inc.) and spring tether, 
which were mounted to a counterbalanced arm.  The syringe drivers were located outside of the 
light- and sound-attenuating cubicles. 
 
Pavlovian conditioning:  After recovery from catheterization surgery, rats received either 
“paired” or “random” Pavlovian conditioning (PAV) for five consecutive sessions.  During all 
PAV sessions, the nose-pokes were removed from the experimental chambers, and all animals 
received response-independent IV injections of remifentanil (3.2 µg/kg delivered in a volume of 
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100 µl/kg) and response-independent deliveries of a light-noise compound stimulus.  The dose of 
remifentanil was chosen based on previous work in the laboratory on remifentanil self-
administration (Cooper et al. 2008).  The light-noise stimulus consisted of houselight 
illumination and white noise (80±5 db as measured at the center of the chamber).  Injections and 
stimuli lasted 2.0±0.5 s, depending on the weight of the individual animal.  In the paired PAV 
groups, a single variable time (VT) 3 min schedule controlled both remifentanil injection and 
stimulus delivery, and injections and stimuli always co-occurred.  In the random PAV control 
groups, remifentanil injection and stimulus delivery were each controlled by independent VT3 
min schedules.  Injections and stimuli were not explicitly unpaired.  For both paired PAV and 
random PAV, inter-injection/inter-stimulus intervals ranged from 0.0 to 6.0 min.  The 3 min 
average inter-injection interval was chosen based on the half-life of remifentanil (Crespo et al. 
2005) to allow for extensive drug metabolism between injections.  Each PAV session lasted until 
20 injections and 20 stimuli were delivered, approximately 60 min. 
 
Instrumental acquisition:  Instrumental acquisition (ACQ) test sessions began the day after the 
conclusion of PAV.  In all ACQ sessions, the two nose-pokes were present in the chamber, and 
animals could respond in the active nose-poke, which produced the light-noise stimulus alone, or 
the inactive nose-poke, which had no scheduled consequences.  Illumination of the stimulus 
lights inside both nose-pokes signaled the start of each ACQ session, and both nose-pokes 
remained illuminated for the duration of the session.  In each group, the side of the active nose-
poke (left vs. right) was counterbalanced across animals.  Responses in the active nose-poke 
produced the light-noise stimulus under a modified random ratio (RR) 2 schedule of 
reinforcement:  the first response in the active nose-poke in each session produced the stimulus 
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with a probability of 1.0, whereas each subsequent response in the session produced the stimulus 
with a probability of 0.5.  No remifentanil injections were given at any point during ACQ.  
Animals were attached to the tether, but saline replaced remifentanil on the syringe driver, and 
the driver never operated.  Responses in the inactive nose-poke were recorded but had no 
scheduled consequences.  Active and inactive responses made during stimulus presentation itself 
were not recorded.  In each experiment, pretreatment group assignments were made randomly 
before the start of ACQ.  The number and duration of ACQ sessions varied between 
experiments, as described below. 
In Experiment 2, each group was tested in 14 ACQ sessions (ACQ1-14).  ACQ1 lasted 
for 60 min, and no pretreatment injection was given to any group before ACQ1.  ACQ1 provided 
a “baseline” measurement of responding with the stimulus to check that the groups did not differ 
significantly before the start of PRAM administration.  From ACQ2-14, the session length was 
increased to 240 min, and a pretreatment injection was administered 10 min before each session.  
After paired PAV, PRAM (0.1 mg/kg, 0.32 mg/kg, or 1.0 mg/kg) or vehicle (0.0 mg/kg) was 
administered to separate groups of animals on ACQ2-8 and ACQ10-14.  A control group was 
pretreated with 0.32 mg/kg PRAM after random PAV.  On ACQ 9, all groups were pretreated 
with vehicle to examine possible carry-over or history effects from prior PRAM exposure.  All 
animals were returned to their homecages for the 10 min between injection and the start of the 
session. 
In Experiment 3, each group was tested in 8 ACQ sessions (ACQ1-8).  All ACQ sessions 
lasted 60 min.  As in Experiment 2, no pretreatment injection was given before ACQ1.  From 
ACQ2-8, animals were injected with either vehicle or 0.32 mg/kg PRAM either 10 min or 190 
min before each session, giving four different pretreatment conditions:  10 min vehicle (n = 4), 
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190 min vehicle (n = 4), 10 min PRAM (n = 6), and 190 min PRAM (n = 8).  As in Experiment 
2, animals were returned to their homecages for the interval between injection and the start of the 
session. 
 
Data analysis:  In Experiment 2, ACQ responding was analyzed in four phases, corresponding 
to when the animals did or did not receive PRAM:  (1) ACQ1, when no pretreatment injection 
was given; (2) ACQ2-8, when PRAM was given before each session; (3) ACQ 9, when all 
groups received vehicle pretreatment; and (4) ACQ10-14, when PRAM was again given before 
each session.  For ACQ1 and ACQ9, the mean active and inactive nose-pokes made by each 
group were analyzed using two-way ANOVA with the within-subjects factor of manipulandum 
(active vs. inactive) and the between-subjects factor of group (vehicle, 0.1 mg/kg PRAM, 0.32 
mg/kg PRAM, 1.0 mg/kg PRAM).  For ACQ1, group assignments represent the animals’ 
pretreatment fate; for ACQ9, group assignments represent the animals’ pretreatment history.  For 
ACQ2-8 and ACQ10-14, the mean active and inactive responses made by each group in each 
session were analyzed using three-way ANOVA with the within-subjects factors of 
manipulandum and session and the between-subjects factor of group.  If significant effects of 
manipulandum and group were found, responding was averaged across sessions to perform two 
sets of pairwise comparisons.  To determine if stimulus presentation reinforced the active 
response, paired t-tests were used to compare the active and inactive nose-pokes of each group.  
To determine if PRAM increased responding, unpaired t-tests were used to compare the active 
and inactive responses of each PRAM-treated group to the active and inactive responses, 
respectively, of the vehicle-treated group.  To characterize the effects of PRAM on the 
intrasession allocation of responding, the active responses made by the vehicle and 0.32 mg/kg 
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PRAM groups during ACQ2-8 were re-analyzed.  The rate of responding (responses/min) in 
each of the four hours (HOUR1-4) of each of these sessions was calculated.  The mean rates in 
each hour of each session were analyzed using three-way ANOVA with the within-subjects 
factors of session and hour and the between-subjects factor of group.  Following significant 
effects of hour and group, the data were averaged across sessions for pairwise comparison 
(unpaired t-tests) of the vehicle and 0.32 mg/kg PRAM groups at each hour.  The Holm-
Bonferonni method was used to correct for multiple pairwise comparisons. 
 In Experiment 3, as a preliminary analysis, the responses of the vehicle-treated animals 
were evaluated using three-way ANOVA with the within-subjects factors of session (ACQ1-8) 
and manipulandum and the between-subjects factor of pretreatment interval (10 min vs. 190 
min).  Because the effects of pretreatment interval were not significant, the two groups were 
combined into a single vehicle control condition for all subsequent analyses.  As in Experiment 
2, responding in ACQ1 and ACQ2-8 were analyzed separately.  For ACQ1, the mean active and 
inactive nose-pokes made by each group were analyzed using two-way ANOVA with the within-
subjects factor of manipulandum and the between-subjects factor of group (vehicle, 10 min 
PRAM, 190 min PRAM).  For ACQ2-8, the mean active and inactive responses made by each 
group in each session were analyzed using three-way ANOVA with the within-subjects factors 
of manipulandum and session and the between-subjects factor of group.  Following significant 
effects involving manipulandum and group, responding was averaged across sessions, and two 
sets of pairwise comparisons were made.  To determine if stimulus presentation reinforced the 
active response, paired t-tests were used to compare the active vs. inactive responses of each 
group.  To determine if PRAM increased responding, unpaired t-tests were used to compare the 
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active and inactive responses of each PRAM-treated group to the active and inactive responses, 
respectively, of the vehicle-treated group. 
 All analyses were performed using Prism 5.0 (GraphPad Software, La Jolla, CA) or SPSS 





Experiment 1:  Resistance-to-extinction of remifentanil self-administration responding 
   
Based on the number of ratios completed, the effects of PRAM on extinction responding 
[main effect of pretreatment dose:  F(4,24) = 12.61, p < .001] did not differ when the doses were 
given in ascending vs. descending order [main effect of dose order:  F(1,6) = 0.93, p = .37; 
pretreatment dose X dose order:  F(4,24) = 1.95, p = .13].  For all subsequent analyses, therefore, 
the data were combined across dose orders.  Figure 3.1 uses the combined data to present the PR 
responding of rats when stably self-administering remifentanil and when tested with PRAM in 
extinction.  Rats’ extinction responding was affected by the PRAM pretreatment dose, with 
significant changes in active responses [Figure 3.1a; F(4,28) = 8.61, p < .001], break point 
[Figure 3.1b; F(4,28) = 8.92, p < .001], the number of ratios completed [Figure 3.1c; F(4,28) = 
11.11, p < .001], and session length [Figure 3.1d; F(4,28) = 11.66, p < .001].  Compared to 
vehicle, 0.32 mg/kg PRAM significantly increased each of these endpoints (3.77 < t(28) < 5.29, 
all p’s < .01), whereas the effects of the other PRAM doses were not significantly different from 
vehicle (0.19 < t(28) < 2.25, all p’s > .05).  Compared to remifentanil self-administration, 
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extinction significantly reduced responding when animals were pretreated with vehicle or the 
smaller doses of PRAM:  active responses [0.0-0.032 mg/kg PRAM:  5.09 < t(7) < 6.99, all p’s < 
.05], break point [0.0-0.1 mg/kg PRAM:  3.95 < t(7) < 7.07, all p’s < .05], and the number of 
ratios completed [0.0-0.1 mg/kg PRAM:  5.04 < t(7) < 9.23, all p’s < .05].  For each of these 
endpoints, when animals were pretreated with higher PRAM doses, extinction responding was 
not significantly different from remifentanil self-administration [0.054 < t(7) < 3.87, all p’s > 
.05].  Session length did not differ between self-administration and extinction [0.21 < t(7) < 3.92, 
all p’s > .05], except for a significant increase in session length with 0.32 mg/kg PRAM 
pretreatment [t(7) = 4.59, p = .022].  Inactive responding was infrequent throughout (mean < 3 in 
all conditions) and did not change with PRAM preatement dose [Figure 3.1e; F(4,28) = 1.20, p = 
.31] or between self-administration and extinction [0.30 < t(7) < 0.95, all p’s > .05]. 
To characterize the effects of PRAM on the intrasession allocation of responding, each 
extinction session was divided into 5 blocks, each encompassing a sequential 20% of the total 
session length.  The rate of active responding in each block is presented in Figure 3.2.  As noted 
above, responding was significantly affected by PRAM pretreatment [main effect of dose:  
F(4,35) = 6.88, p < .001].  The rate of active responding changed significantly over the course of 
the session [main effect of block:  F(4,140) = 7.17, p < .001], and the effect of PRAM 
pretreatment depended on the portion of the session [pretreatment X block:  F(16,140) = 15.32, p 
< .001].  Numerically, when pretreated with vehicle, 0.032 mg/kg PRAM, or 0.1 mg/kg PRAM, 
animals responded most rapidly in BLOCK1, with decreases across the subsequent blocks.  A 
different pattern was observed in animals treated with 0.32 mg/kg or 1.0 mg/kg PRAM:  the 
lowest rate of responding occurred in BLOCK1, with increases across the subsequent blocks.  By 
pairwise comparison to vehicle, PRAM significantly decreased response rate in BLOCK1:  0.1 
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mg/kg [t(140) = 4.28, p < .001], 0.32 mg/kg [t(140) = 5.44, p < .001], and 1.0 mg/kg [t(140) = 
5.64, p < .001].  Only 0.32 mg/kg PRAM changed responding later in the session:  compared to 
vehicle, rates were increased in BLOCK3 [t(140) = 5.55, p < .001], BLOCK4 [t(140) = 5.93, p < 
.001], and BLOCK5 [t(140) = 4.71, p < .001].  All other comparisons to vehicle were not 
significant [0.055 < t(140) < 2.77, all p’s > .05]. 
Figure 3.3 presents the effects of PRAM on animals’ active responding when responding 
either did or did not produce the remifentanil-associated stimuli.  Responding differed 
significantly when the stimuli present in the session were changed [main effect of stimulus 
condition:  F(3,21) = 6.76, p = .002].  Responding also differed when animals were administered 
PRAM vs. vehicle [main effect of pretreatment:  F(1,7) = 6.58, p = .037]; however, the effects of 
pretreatment differed depending on the stimuli present in the session [pretreatment X stimulus 
condition:  F(3,21) = 5.12, p = .008].  By pairwise comparison to vehicle, 0.32 mg/kg PRAM 
increased responding only in the CS alone condition [difference:  438.25; 95% confidence 
interval: 45.47, 831.02].  Inactive responding (data not shown) did not differ by stimulus 
condition or pretreatment [main effects and interaction:  0.91 < F < 1.05, all p’s > .10]. 
 
Experiment 2:  New-response acquisition with remifentanil-paired stimuli 
 
Figure 3.4 presents the active and inactive nose-poke responses of animals treated with 
PRAM after paired PAV.  Figures 3.4a-3.4d present the responses of the four groups in each of 
the 14 ACQ sessions.  Responding in each of the four phases of ACQ is summarized in Figures 
3.4e-3.4h. 
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In ACQ1 (Figure 3.4e), animals responded differently in the active vs. inactive nose-
pokes [main effect of manipulandum:  F(1,28) = 5.73, p = .023], but responding did not differ 
among the groups [main effect of group:  F(3,28) = 0.14, p = .93; group X manipulandum:  
F(3,28) = 0.42, p = .73].  Collapsing across groups, animals made significantly more active 
responses than inactive responses [t(31) = 2.46, p = .019]. 
In ACQ2-8, animals continued to respond differently in the active vs. inactive nose-pokes 
[main effect of manipulandum:  F(1,28) = 44.79, p < .001].  Neither the main effect of session 
[F(6,168) = 0.37, p = .89] nor the session X manipulandum interaction [F(6,168) = 1.63, p = .14] 
was significant.  Averaged across sessions (Figure 3.4f), animals pretreated with vehicle [t(7) = 
3.55, p = .027], 0.1 mg/kg PRAM [t(7) = 3.17, p = .031], and 0.32 mg/kg PRAM [t(7) = 5.77, p 
= .002] made significantly more active responses than inactive responses.  Numerically, animals 
pretreated with 1.0 mg/kg PRAM made more active responses than inactive responses, but the 
difference was not statistically significant [t(7) = 1.90, p = .098].  PRAM pretreatment dose 
significantly affected responding [main effect of group:  F(3,28) = 11.43, p < .001; group X 
session:  F(18,168) = 2.25, p = .004], and the effects of PRAM differed for active vs. inactive 
responding [group X manipulandum:  F(3,28) = 14.75, p < .001; group X session X 
manipulandum:  F(18,168) = 2.83, p < .001].  By pairwise comparison, 0.32 mg/kg PRAM 
significantly increased active responding compared to vehicle [t(14) = 4.97, p = .0012], whereas 
neither 0.1 mg/kg PRAM [t(14) = 0.23, p = .81] nor 1.0 mg/kg PRAM [t(14) = 1.21, p = .48] 
changed active responding.  No dose of PRAM significantly changed inactive responding 
compared to vehicle [0.007 < t(14) < 0.58, all p’s > .10]. 
 In ACQ9 (Figure 3.4g), when all groups received a vehicle pretreatment, animals 
responded differently in the active vs. inactive nose-pokes [main effect of manipulandum:  
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F(1,28) = 23.49, p < .001], but responding did not differ among the groups [main effect of group:  
F(3,28) = 1.79, p = .17; group X manipulandum:  F(3,28) = 0.91, p = .44].  Collapsed across 
groups, animals made more active responses than inactive responses [t(31) = 4.86, p < .001].  
Numerically, animals that had been pretreated with 0.32 mg/kg PRAM made the most active 
responses in ACQ9, but their responding was not significantly different from that of the animals 
that had been pretreated with vehicle [t(14) = 1.66, p = .11]. 
 During ACQ10-14, animals continued to respond differently in the active vs. inactive 
nose-pokes [main effect of manipulandum:  F(1,28) = 32.45, p < .001], whereas responding did 
not differ significantly across sessions [main effect of session and all interactions:  0.50 < F < 
1.15, p > .10].  Collapsed across sessions (Figure 3.4h), animals in all groups made significantly 
more active responses than inactive responses [vehicle:  t(7) = 4.24, p = .011; 0.1 mg/kg PRAM: 
t(7) = 4.32, p = .014; 0.32 mg/kg PRAM:  t(7) = 3.69, p = .007; 1.0 mg/kg PRAM:  t(7) = 3.93, p 
= .011].  PRAM pretreatment significantly affected responding [main effect of group:  F(3,28) = 
6.91, p < .001], and the effects of PRAM differed for active vs. inactive responding [group X 
manipulandum:  F(3,28) = 7.87, p < .001].  Animals treated with 0.32 mg/kg PRAM [t(14) = 
3.33, p = .024] or 1.0 mg/kg PRAM [t(14) = 3.49, p = .021], but not 0.1 mg/kg PRAM [t(14) = 
2.26, p = .16], made significantly more active responses than vehicle-treated animals.  PRAM 
pretreatment did not alter inactive responding compared to vehicle [0.18 < t(14) < 1.26, all p’s > 
.10]. 
Figure 3.5 presents the active and inactive nose-poke responses of the control group that 
was treated with 0.32 mg/kg PRAM after random PAV.  Responding in this group did not differ 
by manipulandum or session in any phase of ACQ [ANOVA main effects and interactions:  0.65 
< F < 4.79, all p’s > .05; pairwise comparisons:  0.32 < t(7) < 0.75, all p’s > .05]. 
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Figure 3.6 presents the rate of active responding in each hour of ACQ2-8 of the groups 
pretreated with vehicle or 0.32 mg/kg PRAM.  These two groups were chosen because only 0.32 
mg/kg significantly increased the overall quantity of active responding during this first phase of 
PRAM administration.  The rate of active responding in ACQ1 is also presented in Figure 3.6 for 
reference.  In ACQ2-8, the rate of responding differed across the hours of the session [main 
effect of hour:  F(3,42) = 8.94, p < .001; hour X session:  F(18,252) = 1.72, p = .036] and by 
pretreatment [main effect of group:  F(1,14) = 24.30, p < .001; group X session:  F(6,84) = 3.52, 
p = .004].  However, the effect of PRAM pretreatment depended on the hour [group X hour:  
F(3,42) = 13.08, p < .001].  The main effect of session was not significant [F(6,84) = 1.14, p = 
.34], and the pretreatment X hour interaction did not depend on the session [session X 
pretreatment X hour:  F(18,252) = 0.88, p = .60]; therefore, responding was averaged across 
sessions for pairwise comparison of the groups in each hour.  PRAM significantly increased 
responding in HOUR3 [t(14) = 6.06, p < .001] and HOUR4 [t(14) = 4.06, p = .003], but not in 
HOUR1 [t(14) = 1.35, p = .19] or HOUR2 [t(14) = 2.19, p = .091]. 
 
Experiment 3:  Comparison of PRAM pretreatment intervals in new-response acquisition 
 
In the vehicle-treated animals, the pretreatment interval (10 min vs. 190 min) did not 
affect responding [all main effects and interactions:  0.009 < F < 1.57, all p’s > .10].  Therefore, 
these data were combined to form a single vehicle control group for all subsequent analyses.  
Figure 3.7 presents the active (Figure 3.7a) and inactive (Figure 3.7b) nose-poke responses of the 
vehicle-treated animals and animals treated with 0.32 mg/kg PRAM either 10 min or 190 min 
before the start of the session.  In ACQ1 (Figure 3.7c), before the start of pretreatments, 
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responding did not differ among the groups [main effect of group:  F(2,19) = 0.38, p = .69; group 
X manipulandum:  F(2,19) = 0.06, p = .94].  The main effect of manipulandum was not 
significant [F(1,19) = 4.08, p = .057]; however, combined across groups, animals made 
significantly more active responses than inactive responses by pairwise comparison [t(21) = 2.09, 
p = .048].  In ACQ2-8, when pretreatments were given, the animals responded differently in the 
active vs. inactive nose-pokes [main effect of manipulandum:  F(1,19) = 19.92, p < .001; session 
X manipulandum:  F(6,114) = 0.44, p = .84; group X manipulandum:  F(2,19) = 1.06, p = .36].  
Averaged across sessions (Figure 3.7d), the animals in each group made significantly more 
active responses than inactive responses in ACQ2-8 [vehicle:  t(7) = 2.94, p = .043; 10 min 
PRAM:  t(5) = 4.12, p = .027; 190 min PRAM:  t(7) = 2.37, p = .049].  Responding in ACQ2-8 
also differed by pretreatment condition [main effect of group:  F(2,19) = 3.63, p = .046; session 
X group:  F(12,114) = 2.86, p = .002; session X group X manipulandum:  F(12,114) = 2.20, p = 
.016].  Numerically, both of the PRAM-treated groups responded less than the vehicle-treated 
group.  Collapsed across sessions, however, the mean active responses of the PRAM-treated 
animals did not differ from the mean active responses of the vehicle-treated animals, and the 
mean inactive responses of the PRAM-treated animals did not differ from the mean inactive 




Drug-associated environmental stimuli are thought to contribute significantly to human 
drug abuse and dependence (e.g., Di Chiara 1999; Everitt et al. 2008; Koob and Le Moal 2001; 
Robinson and Berridge 2008).  The conditioned reinforcing effects of drug-paired stimuli, 
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specifically, may be particularly important for (1) preserving drug-seeking behaviors over 
extended delays to drug delivery (i.e., in extended chains of responses that ultimately lead to 
drug or under extinction conditions) and (2) maintaining the flexibility and diversity of drug-
seeking responses by influencing behavior in a consequence-dependent manner (i.e., as 
contrasted with stimulus-response “habit” mechanisms) and by training new types of responses 
that had not necessarily led previously to drug delivery (reviewed by Milton and Everitt 2010).  
The present studies assessed the effects of the D3-preferring agonist, PRAM, on responding 
maintained by stimuli associated with the potent, short-acting µ-opioid agoinst, remifentanil.  
These stimuli were studied in two different behavioral preparations:  Experiment 1 examined the 
resistance to extinction of remifentanil self-administration, a situation in which responding may 
be influenced by the discriminative and/or conditioned reinforcing effects of the stimuli, whereas 
Experiments 2 and 3 focused specifically on the conditioned reinforcing effects of the stimuli in 
a behaviorally stringent new-response acquisition procedure.  Previous studies of the effects of 
selective dopaminergic agonists on rats’ acquisition of responding with conditioned 
reinforcement have focused on stimuli that were paired with non-drug primary reinforcers.  
Systemic administration of several selective D2-like, but not D1-like, agonists has been shown to 
enhance rats’ new-response acquisition with food-paired stimuli (Beninger and Ranaldi 1992; 
Beninger and Rolfe 1995; Sutton et al. 2001), whereas both the D2-like agonist, quinpirole, and 
the D1-like partial agonist, SKF 38393, enhanced acquisition with water-paired stimuli when 
injected directly into the nucleus accumbens (Wolterink et al. 1993).  The ability of selective, 
direct dopamine receptor agonists to enhance the acquisition of a new response with drug-
conditioned reinforcement has not, to my knowledge, been previously reported. 
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In Experiment 1, pretreatment with PRAM dose-dependently increased responding in 
extinction after remifentanil self-administration training.  These results are consistent with 
previous reports of the response-enhancing effects of the D3/D2 agonist, bromocriptine (Wise et 
al. 1990), and the D3-preferring agonist, quinpirole (De Vries at al. 2002), in rats trained to self-
administer heroin, confirming the importance of D2-like receptor activity generally in opioid-
trained animals.  The present study expands on these previous results in several noteable ways. 
First, in complement to the FR1 training procedures used previously, the use of a PR 
schedule for training and testing in the present study provides an alternative assessment of the 
motivational effects of the drug-associated stimuli.  In the work of Wise and colleagues (1990) 
and De Vries and colleagues (2002) animals made 30-50 responses per session when stimulated 
by the D2-like agonist.  Presently, rats made more than 600 total responses and more than 100 
responses with a single delivery of the stimulus (i.e., break point > 100) when treated with 
PRAM.  Interpretation of PR breakpoints as a pure index of motivation remains controversial 
(Bradshaw and Killeen 2012), but it is clear from the present results that, under the influence of 
PRAM, rats will respond with the stimuli alone as much as or more than they responded with 
self-administered remifentanil during the training phase. 
Second, the present study systematically assessed the interaction of PRAM pretreatment 
with the different types of exteroceptive stimuli that were programmed during the session.  When 
the remifentanil-associated DS and/or remifentanil injection-paired CS were or were not 
presented, PRAM pretreatment increased responding only when the injection-paired CS were 
presented.  These results are consistent with a mechanism involving the conditioned reinforcing 
effects of the remifentanil-paired stimuli.  For example, if generalization decrements alone were 
responsible for changes in extinction responding, the most responding should have been 
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observed in the DS+CS condition because the stimuli present in this condition were most similar 
to the stimuli that were present during self-administration training (Wike 1966; Williams 1994).  
However, because the same response produced the CS and remifentanil during self-
administration training, these results can still not determine conclusively whether the injection-
paired stimuli were functioning as conditioned reinforcers on their own or as discriminative 
stimuli for the primary reinforcement contingency between responding and remifentanil. 
In addition to this exteroceptive discriminative stimulus function, the rats’ extinction 
responding may also have been influenced by the interoceptive discriminative stimulus functions 
of the training and testing drugs.  The interoceptive stimulus produced by the self-administered 
drug during training can provide a signal that responding will be reinforced:  drug in the body 
indicates that drug is available.  If the interoceptive stimulus properties of the pretreatment test 
drug resemble those of the self-administration training drug, animals may respond as though the 
manipuladum were still active (i.e., producing drug injections), increasing rates of responding 
(Collins et al. 2012; Stewart and de Wit 1987).  This interoceptive similarity may be especially 
important when testing dopaminergic agonists in cocaine-trained animals.  Both D2-like and D1-
like agonists can substitute partially or fully for cocaine in cocaine-saline drug discrimination 
studies in rats (reviewed by Callahan et al. 1997; see also Caine et al. 2000; Chausmer and Katz, 
2002).  When co-administered with the training drug, D2-like ligands can alter the discriminative 
stimulus effects of µ-opioid agonists in rats, although these effects are often observed only under 
conditions of significant rate suppression (Colpaert et al. 1977; Cook and Beardsley 2004a, 
2004b; Corrigall and Coen 1990; McCarten and Lal 1979).  In substitution tests, a variety of D3-
preferring agonists have failed to substitute for heroin in rats trained to discriminate heroin from 
water (Cook and Beardsley 2004b), and morphine did not substitute for the D3-preferring 
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agonist, quinpirole, in rats trained to discriminate quinpirole from saline (Baladi et al. 2010).  
This bidirectional lack of substitution suggests that the interoceptive stimulus properties of µ-
opioid agonists and D2-like dopamine agonists are significantly dissimilar, and so changes in 
extinction responding after opioid self-administration may be less likely to be caused by the 
animals’ difficulty discriminating the activity of the manipulanda.  Nonetheless, even if the 
content of the interoceptive stimulus is different, as revealed in drug discrimination experiments, 
any drugged state may increase responding by being more like the interoceptive state 
experienced during self-administration training compared to drug-free extinction.  The training 
and test drugs may also share internal effects that are not detected by or relevant to drug 
discrimination assays (Stewart and de Wit 1987). 
The new-response acquisition procedures used presently minimize the influence of both 
exteroceptive and interoceptive discriminative stimuli:  because the animals never self-
administered remifentanil, the light-tone stimulus could not have been established as a 
discriminative stimulus for an association between the nose-pokes and remifentanil, and the 
interoceptive stimulus properties of remifentnail could, likewise, not serve as a discriminative 
stimulus indicating the activity of the nose-pokes.  In Experiment 2, animals pretreated with 
vehicle acquired responding with the remifentanil-paired stimulus, as indicated by their 
significant preference for the active nose-poke, which produced the stimulus alone, over the 
inactive nose-poke, which had no scheduled consequences, during both ACQ2-8 and ACQ10-14.  
Compared to vehicle, PRAM pretreatment significantly increased active responding without 
changing inactive responding.  In the first period of PRAM pretreatment (ACQ2-8, Figure 3.4f), 
PRAM pretreatment produced a biphasic dose-effect function, with only 0.32 mg/kg PRAM 
significantly increasing active responding.  In the second period of PRAM pretreatment 
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(ACQ10-14, Figure 3.4h), animals treated with either 0.32 mg/kg PRAM or 1.0 mg/kg PRAM 
made significantly more active responses than vehicle-treated animals.  Such biphasic dose-
response curves have been previously observed with amphetamine-enhanced acquisition of food-
associated responding (e.g., Mazurski and Beninger 1986).  In contrast to these effects with the 
remifentanil-paired stimulus, systematic changes in active responding were not observed when 
the active nose-poke produced the stimulus after the stimulus had been randomly presented with 
remifentanil during PAV.  After random PAV, animals did not differentiate between the nose-
pokes in any phase of ACQ.  PRAM’s behavioral selectivity based on the Pavlovian contingency 
between the stimulus and remifentanil is consistent with the effects of pipradrol (Robbins 1976) 
and amphetamine (Taylor and Robbins 1984) on the acquisition of responding with stimuli that 
either were or were not consistently paired with water.  As required for a change in conditioned 
reinforcement, therefore, the difference in responding between the active and inactive nose-
pokes depends on the difference between paired and random PAV. 
These results provide direct evidence that D2-like activation enhances responding with 
drug-conditioned reinforcement specifically, apart from the other associative and nonassociative 
behavioral processes that can change rates of responding and that could, likewise, be influenced 
by dopaminergic manipulations.  Even so, responding with conditioned reinforcement has a 
complex associative basis, depending by definition on both Pavlovian and instrumental learning 
(Mackintosh 1974; O’Brein and Gardner 2005; Williams 1994).  Therefore, the changes in nose-
poking observed presently could have resulted from PRAM changing (1) the Pavlovian 
associaton between the stimulus and remifentanil, (2) the instrumental contingency between the 
response and the stimulus, and/or (3) discrimination between the active and inactive 
manipulanda (Gerdjikov et al. 2011; Palmatier et al. 2008; cf., Berridge et al. 2009).  For 
	  92	  
example, the present results cannot separate the ability of PRAM to increase the relative 
reinforcing effectiveness of the stimulus in the instrumental contingency from the ability of 
PRAM to prevent the extinction of the Pavlovian stimulus-remifentanil association that would 
otherwise have occurred as the stimulus was presented by itself during ACQ.  It is important to 
note that limitations of this type are not more or less of an issue with any particular method of 
studying conditioned reinforcement, but they are in the nature of conditioned reinforcement as a 
stimulus function.  Additional studies with dedicated experimental preparations designed to 
study instrumental vs. Pavlovian learning (e.g., reinforcer devaluation, Pavlovian-to-instrumental 
transfer) may provide complementary insight into the ability of PRAM to alter individual 
learning processes, as opposed to its ability to alter one specific stimulus function vs. another, 
which was the focus of the present experiments on conditioned reinforcement. 
In both Experiment 1 and Experiment 2, the effects of PRAM varied significantly over 
the course of the session, with increases in responding observed only in the final 50-60% of the 
session.  This pattern of performance may be mediated by extended exposure to PRAM, 
extended exposure to the task, or extended exposure to the task under the influence of PRAM.  
The results of Experiment 3 emphasize the importance to new-response acquisition of exposure 
to the task under the influence of PRAM.  Compared to vehicle-treated animals, animals given 
0.32 mg/kg PRAM 190 min before 60 min sessions did not increase their responding, as animals 
given PRAM 10 min before 240 min sessions did.  Crucially, in these latter animals, increases 
were observed specifically in the last 60 min of the 240 min session.  Thus, if 190 min of 
exposure to PRAM itself were sufficient to increase responding, regardless of whether that 
exposure occurred in the home cage or experimental chamber, then differences between the 
vehicle and 190 min PRAM groups should have been observed in Experiment 3.  Instead, daily 
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exposure to PRAM, administered either 10 min or 190 min before 60 min test sessions, did not 
significantly increase responding.  These results suggest that rats must perform the task for an 
extended period under the influence of PRAM for PRAM to increase responding, although the 
importance of extended exposure to the operant context itself, independent of actual task 
performance, cannot be resolved from the present results. 
Systemic PRAM administration can significantly alter rats’ locomotor activity in open-
field tests:  either increases or decreases in locomotion can be observed depending on the dose 
(Maj et al. 1997) and time from PRAM administration (Chang et al. 2011; Lagos et al. 1998).  
For example, Lagos and colleagues (1998) measured the effects of 0.5 mg/kg PRAM in a 30 min 
session beginning either 5 min or 125 min after drug administration.  Compared to saline, 
activity was reduced by PRAM after a 5 min pretreatment but increased by PRAM after a 125 
min pretreatment.  Similarly, measuring locomotor activity for 90 min immediately after PRAM 
injection, Chang and colleagues (2011) found that 0.3 mg/kg PRAM significantly suppressed 
activity in the first 30 min of the session and significantly increased activity in the final 40 min 
of the session.  This pattern of initial decreases in behavior followed by subsequent increases in 
behavior parallel the intrasession changes in response rate observed in the present experiments 
(Figure 3.2, Figure 3.6).  It is, however, unlikely that the increases in nose-poking are the result 
only of general locomotor activation by PRAM.  In Experiment 1, PRAM increased responding 
only when the CS were presented.  If PRAM were simply eliciting nose-poking, responding 
should not have been significantly modulated by the presence/absence of the CS.  Likewise, in 
Experiment 2, PRAM increased responding only in the active nose-poke, with responding in the 
inactive nose-poke never differing significantly from vehicle pretreatment, and the difference 
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between active and inactive nose-poking was observed only when remifentnail and the stimulus 
had been consistently paired during PAV. 
The ability of PRAM, specifically, to increase responding with conditioned reinforcement 
may be especially noteworthy considering PRAM’s widespread clinical use.  Approved for 
human use internationally, PRAM has become the most widely prescribed direct dopamine 
agonist treatment for Parkinson’s disease (Antonini et al. 2010).  PRAM has also been approved 
by regulators in both the United States and Europe to treat restless legs syndrome (Brindani et al. 
2009) and is commonly used “off label” to treat fibromyalgia (Roskell et al. 2011).  In all three 
of these patient populations, PRAM administration is associated with a set of behavioral side 
effects known collectively as impulse control disorders (ICD) (e.g., Cornelius et al. 2010; 
Holman 2009; Pourcher et al. 2010; Weintraub et al., 2010).  ICD are observed at similar rates in 
Parkinson’s disease and restless legs syndrome patients, with ~15% of those receiving PRAM 
showing one of more ICD (Cornelius et al. 2010; Pourcher et al. 2010; Weintraub et al. 2010).  
Common ICD involve excessive or compulsive gambling, eating, shopping, sexual behavior, 
hobby activities, and punding.  Whereas ICD may be influenced by changes in the processing of 
primary reinforcers, many of these behaviors occur in stimulus-dense environments and may be 
influenced, at least in part, by increased control over behavior by conditioned reinforcement 
(e.g., the lights and sounds of slot machine gambling and money itself as a conditioned reinforcer 
of human behavior).  Whereas a number of ICD are unrelated to drugs of abuse (e.g., compulsive 
shopping for clothing items), recent evidence suggests that PRAM treatment can also induce 
increased drug use (Bienfait et al. 2010).  The case reported by Bienfait and colleagues (2010) 
concerns PRAM-induced changes in cigarette smoking, and the effects of PRAM on this 
particular behavior may be especially relevant, given accumulating evidence for the importance 
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of nicotine-associated stimuli for both tobacco smoking in humans and nicotine self-
administration in laboratory animals (Chaudhri et al. 2006; Le Foll and Goldberg 2005).  
Moreover, ICD are agonist-induced, as either discontinuation of PRAM or dose reduction 
resolves the behavior, and reintroduction of agonist treatment is associated with ICD return (e.g., 
Bienfait et al. 2010).  A similar pattern was observed in the present study in the animals treated 
with 0.32 mg/kg PRAM.  When the vehicle pretreatment probe session (ACQ9) was inserted into 
the course of PRAM treatment, the responses of animals that had been receiving PRAM were not 
different from animals that had never received PRAM; however, when PRAM pretreatments 
were resumed, animals’ responding was again increased. 
The similarity of the ICD induced in humans treated for Parkinson’s disease vs. restless 
leg syndrome and fibromyalgia suggests that large-scale dopaminergic depletion is not necessary 
for PRAM to produce these behaviors.  Nonetheless, future studies should investigate the ability 
of PRAM to increase responding with conditioned reinforcement in animals with dopaminergic 
lesions to model the interaction of changes experienced by human Parkinson’s disease patients 
undergoing agonist therapy.  Subsequent experiments should also focus on the neuroanatomical 
locus of PRAM’s effects.  Previous studies have specifically implicated D2-like receptors in the 
nucleus accumbens in the enhanced acquisition responding with water-conditioned 
reinforcement (Wolterink et al. 1993), and D3 receptors in the amygdala may be particularly 
important for responding with drug-associated stimuli under second-order schedules of cocaine-
self administration (Di Ciano 2008).  To the extent that D2-like receptor activity appears to be 
important for responding with stimuli paired with both drug and non-drug primary reinforcers, it 
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Figure 3.1.  Progressive ratio responding of rats when self-administering remifentanil or treated 





























































































































































































Figure 3.1.  Effects of pretreatment with pramipexole (PRAM) prior to sessions in which rats’ 
responding was reinforced under a progressive ratio schedule by presentation of stimuli 
previously associated with self-administered remifentanil.  The remifentanil self-administration 
(SA) point represents the mean±SEM of the final 3 self-administration training sessions.  All 
pretreatment points represent the mean±SEM of the 3 extinction test sessions conducted with 
each pretreatment dose.  a:  Active (nose-poke) responses resulted in the presentation of stimulus 
light illumination previously paired with remifentanil injection.  b:  Break point was defined as 
the value of the final ratio completed in the session.  c:  For remifentanil SA, the number of 
ratios completed corresponds to the number of remifentanil injections earned.  For pretreatment 
sessions, the number of ratios completed corresponds to the number of stimulus presentations 
earned.  d:  Sessions lasted 240 min or until a ratio was not completed in 45 min, whichever 
occurred first.  e:  Inactive (lever) responses were counted but had no programmed consequences 
in any session.  ***, p < .001.  Significant difference in effect of the pretreatment dose vs. 
vehicle (0.0 mg/kg) determined by one-way repeated measures ANOVA with post hoc 
Bonferroni tests.  #, p < .05; ##, p < .01; ###, p < .001.  Significant difference from remifentanil 









Figure 3.2.  Intrasession allocation of active responding in extinction under the progressive ratio 
schedule 


































Figure 3.2.  Intrasession allocation of active responding in extinction under the progressive ratio 
schedule.  Each block represents 20% of the total session length, which varied across sessions.  
Each bar displays the mean±SEM number of responses made per minute in each block.  ***, p < 
.001.  Significant difference within each block compared to vehicle (0.0 mg/kg) as determined by 














Figure 3.3.  Effects of pramipexole when active responding did or did not produce the 




































Figure 3.3.  Effects of PRAM on active responding when responding did or did not produce the 
illumination stimuli previously paired with remifentanil availability and/or remifentanil injection.  
Illumination of the nose-poke aperture served as the discriminative stimulus (DS) indicating 
remifentanil availability.  Illumination of LED the stimulus lights above the nose-poke aperture 
and the houselight served as injection-paired conditioned stimuli (CS).  In the context condition, 
neither the DS nor the CS was presented.  Under all stimulus conditions, the PR schedule was in 
effect for the active response, and inactive responses (data not shown) were counted but had no 
scheduled consequences.  Each bar represents the mean±SEM.  *, p < .05.  Significant difference 
between 0.0 mg/kg PRAM and 0.32 mg/kg PRAM determined by two-way repeated measures 
ANOVA with post hoc Bonferroni tests. 
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Figure 3.4.  Effects of PRAM pretreatment on the acquisition of a novel nose-poke response that 
produced a stimulus previously paired with response-independent IV remifentanil injection 
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Figure 3.4.  Effects of PRAM pretreatment on the acquisition of a novel nose-poke response that 
produced a stimulus previously paired with response-independent IV remifentanil injection.  
Responses in the active nose-poke produced the stimulus alone under the modified RR2 
schedule.  Responses in the inactive nose-poke had no scheduled consequences.  ACQ1 lasted 60 
min, whereas ACQ2-14 lasted 240 min.  a-d:  Session-by-session record of responding by 
separate groups of animals treated with vehicle (0.0 mg/kg PRAM), 0.1 mg/kg PRAM, 0.32 
mg/kg PRAM, or 1.0 mg/kg PRAM, respectively.  e:  Responding in ACQ1, when no 
pretreatment was given.  f:  Mean responding in ACQ2-8, when a pretreatment injection of 
vehicle or PRAM was given before each session.  g:  Responding in ACQ9, when all groups 
received a vehicle pretreatment.  h:  Mean responding in ACQ10-14, when pretreatments of 
vehicle or PRAM were resumed.  All data are presented as the mean±SEM.  *, p < .05; **, p < 
.01; ***, p < .001.  Significant difference between the active and inactive nose-pokes either 
within each group (for ACQ2-8 and ACQ10-14) or combined across groups (for ACQ1 and 
ACQ9) as determined by paired t-test with the Holm-Bonferroni correction.  #, p < .05; ##, p < 
.01; ###, p < .001.  Significant difference in responding on the same manipulandum compared to 
the vehicle treatment as determined by unpaired t-test with the Holm-Bonferroni correction.  
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Figure 3.5.  Nose-poke responses made by rats treated with PRAM after random PAV, when the 
remifentanil and stimulus were paired only by chance   
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Figure 3.5.  Nose-poke responses made by rats treated with PRAM after random PAV, when the 
remifentanil and stimulus were paired only by chance.  PRAM pretreatments were given during 
ACQ2-8 and ACQ10-14, with a vehicle pretreatment given on ACQ9.  Each point represents the 
mean±SEM.  Rats did not acquire nosepoking:  active vs. inactive responses were not 
significantly different in any phase of ACQ, as assessed by one-way ANOVA (ACQ2-8, 







Figure 3.6.  Intrasession allocation of active responding during ACQ2-8 by animals treated with 
either vehicle (0.0 mg/kg) or 0.32 mg/kg PRAM 


















































































Figure 3.6.  Intrasession allocation of active responding during ACQ2-8 by animals treated with 
either vehicle (0.0 mg/kg) or 0.32 mg/kg PRAM.  Rates in ACQ1 are presented for reference.  a: 
Rate in each hour of each ACQ session by animals treated with vehicle.  b) Rate in each hour of 
each ACQ session by animals treated with 0.32 mg/kg PRAM.  c) Rate in each hour averaged 
across ACQ2-8.  All data are presented as the mean±SEM.  **, p < .01; ***, p < .001.  



















Figure 3.7.  Effects of different PRAM pretreatment intervals (10 min vs. 190 min) on the 
acquisition of nose-poking with the remifentanil-paired stimulus 
 


















































































































Figure 3.7.  Effects of different PRAM pretreatment intervals (10 min vs. 190 min) on the 
acquisition of nose-poking with the remifentanil-paired stimulus.  Responses in the active nose-
poke produced the stimulus alone under the modified RR2 schedule.  Responses in the inactive 
nose-poke had no scheduled consequences.  All ACQ sessions lasted 60 min.  Pretreatments of 
vehicle or PRAM were given either 10 min or 190 min before ACQ2-8.  The responses of the 10 
min vehicle and 190 min vehicle groups were collapsed to form the single vehicle group 
presented.  a:  Session-by-session record of active responding by the three groups.  b:  Session-
by-session record of inactive responding by the three groups.  c:  Responding in ACQ1, when no 
pretreatment injection was given.  d:  Mean responding in ACQ2-8, when a pretreatment 
injection was given before each session.  All data are presented as the mean±SEM.  *, p < .05.  
Significant difference between the active and inactive responses, as determined by paired t-test 















Effects of Pramipexole on New-Response Acquisition with Remifentanil-Conditioned 




Following the localization of dopamine D3 receptor protein and/or mRNA in brain 
structures and systems associated in laboratory animals with the reinforcing effects of drugs of 
abuse and responding with drug-associated stimuli (e.g., the mesolimbic dopaminergic system, 
extended amygdala, corticostriatal loops), D3-preferring antagonists have received considerable 
attention as potential pharmacotherapies for human drug abuse and dependence (Garcia-Ladona 
and Cox 2003; Heidbreder 2013; Heidbreder and Newman 2010; Le Foll et al. 2005; Shafer and 
Levant 1998; Sokoloff et al. 2006).  In rats, much of this work has focused on the ability of D3-
preferring compounds (both agonists and antagonists) to alter responding with cocaine-
associated stimuli in reinstatement procedures or under second-order schedules of cocaine self-
administration.  Administered systemically, a variety of D3-preferring agonists can increase 
(Cervo et al. 2003; Collins and Woods 2009; Collins et al. 2012; De Vries et al. 1999, 2002; Dias 
et al. 2004; Edwards et al. 2007; Fuchs et al. 2002; Koeltzow and Vezina 2005; Self et al. 1996) 
and D3-preferring antagonists can decrease (Cervo et al. 2007; Gál and Gyertyán 2006; Gilbert 
et al. 2005) cocaine-appropriate responding in extinction after cocaine self-administration 
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training.  These changes are observed when rats respond in the presence of cocaine-associated 
contextual and discriminative stimuli, and/or their responding on the cocaine-appropriate 
manipulandum produces exteroceptive stimuli (e.g., cue lights, tones) previously paired with 
cocaine injection, but not cocaine itself.  D3-preferring antagonists can also attenuate the ability 
of cocaine itself (Peng et al. 2009; Vorel et al. 2002; Xi et al. 2006) or a D3-preferring agonist 
(Collins et al. 2012) to increase extinction responding under these conditions, whereas D3-
preferring agonists can enhance cocaine’s response-increasing effects (Fuchs et al. 2002; Self et 
al. 1996).  Finally, D3-preferring antagonist administration can reduce rats’ cocaine self-
administration under second-order schedules of reinforcement before any cocaine has actually 
been delivered, i.e., in the first phase of the session when responding has produced only the 
cocaine-associated stimuli (Di Ciano et al. 2003; see also Pilla et al. 1999). 
Compared to this body of work with cocaine, relatively few studies have examined the 
effects of D3-preferring or D3/D2 ligands on responding with stimuli paired with other drugs of 
abuse, particularly opioid-paired stimuli (Beninger and Banasikowski 2008; Heidbreder 2013; 
Heidbreder and Newman 2010).  Wise and colleagues (1990) first reported that response-
independent IV injection of the D3/D2 agonist, bromocriptine, could increase rats’ drug-
appropriate responding in extinction after either cocaine or heroin self-administration.   
Subsequently, De Vries and colleagues (2002) reported that SC injection the D3-preferring 
agonist, quinpirole, could increase heroin-appropriate responding in extinction after heroin self-
administration (see also De Vries et al. 1999).  Among antagonists, the D3/D2 antagonist, 
raclopride, was shown to attenuate (numerically) the response-increasing effects of 
experimenter-administered heroin in extinction after heroin self-administration (Shaham and 
Stewart 1996).	  	  These results implicate D2-like receptor activity in opioid-trained responding, 
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but both the associative learning mechanisms and D2-like receptor subtype(s) involved in these 
effects remain unclear. 
First, considering associative mechanisms, several authors have suggested that D3-
preferring ligands can alter the conditioned reinforcing effects of drug-paired stimuli (Cervo et 
al. 2003, 2007; Collins and Woods 2009; Collins et al. 2012; Di Ciano et al. 2003; Gál and 
Gyertyán 2006; Le Foll et al. 2005; Pilla et al. 1999).  If the exteroceptive stimuli that are paired 
with drug injection during self-administration training become conditioned reinforcers as a result 
of this pairing, then responding in the absence of the drug could be maintained by these 
conditioned reinforcers.  In turn, increases or decreases in responding when D3-preferring 
agonists or antagonists are given could be due to increases or decreases, respectively, in the 
effectiveness of these conditioned reinforcers.  However, changes in the extinction of an 
established (self-administration) response or in responding under second-order schedules of 
reinforcement can be influenced by a number of behavioral mechanisms other than conditioned 
reinforcement, including the primary reinforcing effects of the training drug and the 
discriminative stimulus functions of the training drug, testing drug, and stimuli (Collins et al. 
2012; Kelleher and Gollub 1962; Mackintosh 1974; Wike 1966; Williams 1994).  Measuring the 
ability of animals to acquire a new response that produces a drug-paired stimulus (i.e., a response 
that does not and did not also produce the drug itself) can provide a more valid assessment of the 
conditioned reinforcing effects of that stimulus (Mackintosh 1974; Williams 1994).  Systemic 
administration of several D2-like agonists, including 7-OH-DPAT, bromocriptine, and 
quinpirole, has been shown to enhance new-response acquisition with food-paired stimuli 
(Beninger and Ranaldi 1992; Sutton et al. 2001).  However, additional work is needed to 
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determine the effects of D3-preferring ligands on new-response acquisition with drug-paired 
stimuli.	  
Second, considering receptor subtypes, it is unclear whether the changes in responding 
reported previously depend on D3 activity and/or D2 activity.  In particular, the use of 
bromocriptine (Beninger and Ranaldi 1992; Sutton et al. 2001; Wise et al. 1990) and quinpirole 
(Beninger and Ranaldi 1992; De Vries et al. 2002) in previous studies of both heroin-trained 
responding and new-response acquisition with food-paired stimuli is noteworthy.  Whereas 
quinpirole is D3-preferring in vitro and in vivo (Collins et al. 2005, 2007; Freedman et al. 1994; 
Millan et al. 2002; Sautel et al. 1995), bromocriptine has been shown to have either 
approximately equal affinity for D2 and D3 receptors or a modest preference for D2 receptors 
(Coldwell et al. 1999; Freedman et al. 1994; Millan et al. 2002; Sautel et al. 1995; Seeman et al. 
2005).  These results suggest that strong D3 preference is not necessary for a D2-like agonist to 
enhance responding; however, bromocriptine’s effects as a dopaminergic agonist are difficult to 
interpret because of its high affinity for and efficacy at non-dopaminergic sites (e.g., serotonin 
receptors, Millan et al. 2002; Newman-Tancredi et al. 2002; see also Filip et al. 2010).  
Therefore, the specific importance of D3 receptor activity in responding with opioid-paired 
stimuli remains to be determined. 
To focus specifically on opioid-associated conditioned reinforcement, the present study 
characterized the effects of the D3-preferring agonist, pramipexole (PRAM), on rats’ acquisition 
of a new response with a remifentanil-paired stimulus.  PRAM is D3-preferring both in vitro and 
in vivo, but there is considerable variability in the degree of D3 vs. D2 selectivity reported 
among in vitro studies, from a low of 2-fold selective (Seeman et al. 2005) to a high of 488-fold 
selective (Gerlach et al. 2003).  These values also differ from the 32-fold in vivo D3 vs. D2 
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selectivity calculated by Collins and colleagues (2007) by comparing the smallest doses of 
PRAM capable of eliciting a D3-mediated response (yawning) or a D2-mediated response 
(hypothermia) in rats.  Therefore, in Experiment 1, pretreatments of the D3-preferring antagonist, 
SB-277011A, or the D2-preferring antagonist, L-741,626, were used to clarify the necessity of 
D3 or D2 activation to the response-enhancing effects of PRAM.  These antagonists were 
classified as D3- or D2-preferring based on previous in vivo work in rats (Collins et al. 2007).  
After finding that SB-277011A did not alter the effects of PRAM on new-response acquisition, 
Experiment 2 was conducted to verify the ability of SB-277011A to block two D3-mediated 
responses elicited by PRAM:  yawning and penile erection (PE) in male rats (Collins et al. 2005, 
2007, 2009).  These elicited responses are not necessarily related to the effects of PRAM on 
conditioned reinforcement; rather, alterations in yawning and PE would indicate that SB-
277011A can block behavioral effects of PRAM in rats that have previously been shown to 






Animals:  Male Sprague-Dawley rats weighing at least 250 g were obtained from Harlan 
(Indianapolis, IN) to serve as subjects in both experiments.  In Experiment 1, all experimental 
groups contained 8 rats.  In Experiment 2, the experimental group contained 6 rats.  Animals 
were housed in a climate controlled facility under a 12 h light-dark cycle (lights on at 7:00 am).  
All animals were allowed to acclimate to the facility for at least 7 days before the start of any 
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experimental procedures.  Experimental sessions were conducted 5-7 days/week (except where 
noted in Experiment 2) during the light phase of the cycle.  All animals had unrestricted access to 
standard pellet chow and tap water in the home cage for the duration of their experiment.  All 
studies were performed in accordance with the Guide for the Care and Use of Laboratory 
Animals (Institute of Laboratory Animal Research 1996), as adopted and promulgated by the 
National Institutes of Health, and all experimental procedures were approved by the University 
of Michigan Committee on the Use and Care of Animals. 
 
Drugs:  Remifentanil was obtained from the hospital pharmacy of the University of Michigan 
Health System (Ultiva brand, GlaxoSmithKline, Uxbridge, UK).  Pramipexole was obtained 
from APAC Pharmaceutical (Columbia, MD).  SB-277011A was synthesized by the laboratory 
of Dr. Shaomeng Wang (University of Michigan, Ann Arbor, MI).  L-741,626 was obtained 
from Tocris Biosciences (Bristol, UK).  Remifentanil and pramipexole were dissolved in sterile 
physiological saline.  SB-277011A was dissolved in a 20% (w/v) solution of β-cyclodextrin and 
sterile water.  L-741,626 was dissolved in a 5% (v/v) solution of ethanol and sterile water.  
Remifentail injections were delivered IV in a volume of 100 µl/kg.  Pramipexole and L-741,626 
were injected SC in a volume of 1.0 ml/kg.  Due to solubility limitations, SB-277011A was 
injected SC in volumes of 1.0-3.2 ml/kg. 
 
Experiment 1:  D3 vs. D2 receptor involvement in the enhancement of new-response 
acquisition with remifentanil-conditioned reinforcement 
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Surgery:  After acclimating to the facility, each animal received a chronic, indwelling venous 
catheter to allow for IV drug administration.  Catheters were custom made from polyurethane 
tubing (MRE 040, Braintree Scientific, Braintree, MA) and Tygon tubing (S-54-HL, Norton 
Performance Plastics, Akron, OH).  Catheterization surgery was performed under 
ketamine/xylazine (90:10 mg/kg, IP) anesthesia.  The catheter was inserted into the left femoral 
vein and routed subcutaneously to the area between the scapulae for externalization.  At the 
scapulae, the catheter was attached to 22 ga stainless steel tubing which was passed through and 
secured to a Dacron mesh back-plate (DC95BS, Instech Laboratories, Plymouth Meeting, PA).  
Rats were allowed at least 5 days to recover from surgery before starting experimental sessions.  
Catheters were flushed with 0.25 ml of heparinized saline (50 U/ml) each day during recovery, 
as well as before and after experimental sessions to ensure patency. 
 
Apparatus:  Experimental sessions were conducted in two experimental chambers (ENV-008, 
Med Associates, St. Albans, VT) located inside light- and sound-attenuating cubicles.  Each 
experimental chamber was located in a separate room of the laboratory.  The right wall of each 
experimental chamber contained a white incandescent houselight (ENV-215M, Med Associates) 
and a sound generator and speaker (ENV-230 and ENV-224AM, Med Associates).  Two nose-
poke manipulanda with built-in LED stimulus lights (ENV-114BM, Med Associates) could also 
be inserted into the right wall.  When present, the nose-pokes were located 2.5 cm above the grid 
floor and 4 cm from the front wall (right nose-poke) or 4 cm from the rear wall (left nose-poke).  
The houselight was located 9 cm above the grid floor, centered between the two nose-pokes.  
The speaker was located above the right nose-poke, 7.5 cm above the grid floor.  Blank 
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aluminum panels were inserted when the nose-pokes were removed; all of the other elements of 
the experimental chamber remained in place. 
Drug solutions were delivered by a motorized syringe driver (PHM-107, Med Associates) 
through Tygon tubing (S-54-HL, Norton Performance Plastics) connected to a fluid swivel 
(375/22PS, Instech Laboratories) and spring tether, which were mounted to a counterbalanced 
arm.  The syringe drivers were located outside of the light- and sound-attenuating cubicles. 
 
Pavlovian conditioning:  After recovery from catheterization surgery, all rats received 5 
consecutive sessions of Pavlovian conditioning (PAV).  During each PAV session, the nose-
pokes were removed from the experimental chambers, and animals received 20 response-
independent IV injections of 3.2 µg/kg/injection remifentanil.  A light-noise compound stimulus 
consisting of houselight illumination and white noise (80±5 db as measured at the center of the 
chamber) co-occurred with each remifentanil injection.  Injections and stimuli lasted 2.0±0.5 s, 
depending on the weight of the individual animal.  Injections and stimuli were controlled by a 
variable time (VT) 3 min schedule (range of intervals:  0.0-6.0 min).  The dose of remifentanil 
was chosen based on previous work in the laboratory on remifentanil self-administration (Cooper 
et al. 2008), and the 3 min average interval was chosen based on the half-life of remifentanil 
(Crespo et al. 2005) to allow for extensive drug metabolism between injections.  PAV sessions 
ended after 20 injections and stimuli were delivered, approximately 60 min. 
 
Instrumental acquisition:  Instrumental acquisition (ACQ) sessions began the day after the 
final PAV session.  During ACQ sessions, the two nose-pokes were present in the chamber.  
Illumination of the stimulus lights inside both nose-pokes signaled the start of each ACQ session, 
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and both nose-pokes remained illuminated for the duration of the session.  Responses in the 
active nose-poke produced the light-noise stimulus alone under a modified random ratio (RR) 2 
schedule of reinforcement.  The first response in the active nose-poke in each session produced 
the stimulus with a probability of 1.0, and each subsequent response in the session produced the 
stimulus with a probability of 0.5.  No remifentanil injections were given at any point:  animals 
were attached to the tether, but saline replaced remifentanil on the syringe driver, and the driver 
did not operate.  Responses in the inactive nose-poke were recorded but had no scheduled 
consequences.  Active and inactive responses made during stimulus presentation itself were not 
recorded.  In each group, the side of the active nose-poke (left vs. right) was counterbalanced 
across animals. 
Ten ACQ sessions (ACQ1-10) were conducted as follows.  ACQ1 lasted for 60 min, and 
no pretreatment injection was given.  ACQ2-10 lasted for 240 min.  An injection of 0.32 mg/kg 
PRAM was given to all animals 10 min before ACQ2-6.  ACQ7-10 were the antagonist test 
sessions, and all animals received two pretreatment injections before each of these sessions.  The 
first pretreatment injection was given 40 min before the start of the session and contained SB-
277011A, L-741,626, or their vehicles.  The second pretreatment injection was given 10 min 
before the start of the session and contained 0.32 mg/kg PRAM or its vehicle.  Two groups of 
animals were tested with L-741,626:  a high-dose group (High L) received vehicle, 0.32 mg/kg, 
and 3.2 mg/kg, whereas a low-dose group (Low L) received vehicle, 0.1 mg/kg, and 1.0 mg/kg.  
One group of animals received SB-277011A (SB):  vehicle, 5.6 mg/kg, and 56.0 mg/kg.  Each 
antagonist dose was tested for a single session.  In each group, antagonist doses were given in 
either ascending or descending order before 0.32 mg/kg PRAM.  An antagonist vehicle + PRAM 
vehicle condition was tested first or last (i.e., on ACQ7 or ACQ10) in each group.  This latter 
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condition was included to check that 0.32 mg/kg PRAM increased responding over vehicle 
pretreatment (i.e., that PRAM had a response-enhancing in each group).  Antagonist pretreatment 
doses and times were based on previous work in the laboratory (Collins et al. 2007, 2012).  
Group assignments were made randomly before the start of ACQ. 
 
Data Analysis:  For ACQ1, the mean active and inactive nose-pokes made by each group were 
analyzed using two-way ANOVA with the within-subjects factor of manipulandum (active vs. 
inactive) and the between-subjects factor of group (SB, Low L, High L).  Following a 
nonsignificant group X manipulandum interaction, responding was collapsed across groups, and 
a paired t-test was used to compare active vs. inactive responding.  To check that PRAM did not 
have a different effect in the three groups before the start of the antagonist test sessions, the mean 
active and inactive nose-pokes made in each session from ACQ2-6 were analyzed using three-
way ANOVA with the within-subjects factors of manipulandum and session and the between-
subjects factor of group.  Following a lack of significant effects involving group, responding was 
collapsed across groups for pairwise comparison.  Paired t-tests were used to compare the active 
and inactive responses made in each session to each other and to compare the responses made in 
each subsequent session to the responses made in ACQ2.  The Holm-Bonferroni method was 
used to correct for multiple comparisons.  In the antagonist test sessions, the mean active and 
inactive nose-pokes of each group were analyzed using two-way ANOVA with the within-
subjects factors of manipulandum and pretreatment condition.  Based on a previous study in the 
laboratory of D3- vs. D2-preferring antagonists (Collins et al. 2012), it was hypothesized a priori 
that both SB-277011A and L-741,626 would attenuate the effects of PRAM, and so planned 
comparisons were used to determine if active or inactive responding in the other pretreatment 
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conditions differed from the vehicle antagonist + 0.32 mg/kg PRAM condition.  To determine if 
antagonist pretreatments altered responding before the stimulus was delivered, the latency to the 
first active response in each antagonist test session was calculated in minutes.  If an animal made 
no (0) active responses in a session, the latency was recorded as 240 min.  Prior to analysis, the 
latencies were log-transformed to reduce the heterogeneity of variance.  For each group, the 
transformed latencies were analyzed using one-way ANOVA with the within-subjects factor of 
pretreatment condition.  If a significant effect of pretreatment was found, post hoc Dunnett’s 
tests were used to compare the vehicle antagonist + 0.32 mg/kg PRAM condition to each of the 
other conditions.  Analyses were performed using Prism 5.0 (GraphPad Software, La Jolla, CA) 
or SPSS Statistics 20.0 (IBM, Armonk, NY).  Differences were considered significant when p < 
.05, two-tailed. 
 
Experiment 2:  Antagonism of D3-mediated elicited behaviors by SB-277011A 
 
Apparatus:  PRAM-induced yawning and PE were measured in two transparent plastic 
observation chambers (48 x 23 x 20 cm).  The observation chambers resembled the animals’ 
home cages, except there was no food, water, or bedding in the observation chambers.  Angled 
mirrors were placed behind the observation chambers to facilitate viewing the animal regardless 
of its location in the chamber. 
 
Behavioral observation:  One group of six rats was observed in two sessions to measure 
yawning behavior and PE elicited by PRAM.  Two rats were observed at a time, one per 
chamber.  In each session, yawns and PE were recorded by an experienced observer who was 
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blind to the antagonist treatment condition.  Yawning was defined as a prolonged (~1 s), wide 
opening of the mouth followed by a rapid closure, whereas PE was defined as an emerging, 
engorged penis, typically followed by an upright posture and genital grooming (Collins et al., 
2009). 
Animals were allowed to acclimate to the observation chamber for 30 min at the start of 
the session.  After the acclimation period, animals were injected with 56.0 mg/kg SB-277011A 
or its vehicle.  Half of the animals were first injected with SB-277011A, whereas the other half 
were first injected with vehicle, and the pretreatments were counterbalanced across the two 
sessions.  30 min after antagonist injection, animals were injected with 0.1 mg/kg PRAM and 
observed for 1 h beginning immediately after PRAM injection.  The second observation session 
was conducted 3 days after the first to allow for drug washout.  The dose of 0.1 mg/kg PRAM 
was selected based on previous dose-effect studies of PRAM-induced yawning (Collins et al. 
2005, 2007). 
 
Data analysis:  To analyze the effects of SB-277011A on yawning, the mean number of yawns 
made in each observation session was compared using a paired t-test.  To analyze the effects of 
SB-277011A on PE, each observation session was divided into 15 min blocks, and PE incidence 
was calculated as the percentage of blocks that contained at least one PE.  Mean PE incidence in 
each observation session was compared using a paired t-test.  Analyses were performed using 
Prism 5.0 (GraphPad Software, La Jolla, CA), and differences were considered significant when 





Experiment 1:  D3 vs. D2 receptor involvement in the enhancement of new-response 
acquisition with remifentanil-conditioned reinforcement 
 
Figure 4.1 presents the effects of pretreatment with SB-277011A or L-741,626 on the 
response-enhancing effects of 0.32 mg/kg PRAM.  Figure 4.1a presents the nose-poke responses 
of the three antagonist pretreatment groups (SB, Low L, High L) before the start of antagonist 
administration:  in ACQ1 when no pretreatment was given and ACQ2-6 when all groups were 
treated with 0.32 mg/kg PRAM alone.  In ACQ1, animals responded differently in the active vs. 
inactive nose-pokes [main effect of manipulandum:  F(1,21) = 5.22, p = .032].  Overall 
responding varied among the groups [main effect of group:  F(2,21) = 5.36, p = .013], but the 
difference between the nose-pokes did not depend on the group [group X manipulandum:  
F(2,21) = 0.65, p = .53].  Collapsed across groups, animals made more active responses than 
inactive responses [t(23) = 2.32, p = .029].  In ACQ2-6, animals responded differently in the 
active vs. inactive nose-pokes [main effect of manipulandum:  F(1,21) = 34.10, p < .001] and 
across sessions [main effect of session:  F(4,84) = 5.07, p < .001; session X manipulandum:  
F(4,84) = 6.34, p < .001]; however, responding did not differ by group [main effect of group and 
all interactions involving group:  0.10 < F < 0.75, all p’s > .10].  Collapsing across groups, 
animals made significantly more active responses than inactive responses in each session from 
ACQ2-ACQ6 [2.99 < t(23) < 6.52, all p’s < .05].  Active responding also increased over the 
course of PRAM treatment:  animals made more active responses in ACQ6 than ACQ2 [t(23) = 
4.03, p = .002], whereas inactive responding did not differ in any subsequent session compared 
to ACQ2 [0.74 < t(23) < 1.65, all p’s > .10]. 
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Figure 4.1b presents the responses of animals pretreated with SB-277011A.  Across 
pretreatment conditions, animals made more active responses than inactive responses [main 
effect of manipulandum:  F(1,7) = 32.78, p < .001].  Antagonist pretreatment condition did not 
have a significant effect on responding overall [main effect of pretreatment:  F(3,21) = 0.93, p = 
.44; pretreatment X manipulandum:  F(3,21) = 1.31, p =  .29].  However, by pairwise 
comparison, animals made significantly fewer active responses when pretreated with vehicle SB-
277011A + vehicle PRAM than with vehicle SB-277011A + 0.32 mg/kg PRAM [t(7) = 3.32, p = 
.012].  Inactive responding did not differ among pretreatment conditions [0.52 < t(7) < 1.92, all 
p’s > .05]. 
 Figures 4.1c and 4.1d present the responses of the animals pretreated with L-741,626.  
Animals in the Low L group (Figure 4.1c) made more active responses than inactive responses 
across pretreatment conditions [main effect of manipulandum:  F(1,7) = 16.74, p = .005].  
Antagonist pretreatment condition affected active and inactive responding differently [main 
effect of pretreatment:  F(3,21) = 4.16, p = .018; pretreatment X manipulandum:  F(3,21) = 4.62, 
p = .012].  Pretreatment with 1.0 mg/kg L-741,626 + 0.32 mg/kg PRAM [t(7) = 2.49, p = .041] 
or vehicle L-741,626 + vehicle PRAM [t(7) = 2.57, p = .036] significantly reduced active 
responding compared to vehicle L-741,626 + 0.32 mg/kg PRAM, whereas inactive responding 
did not differ among pretreatment conditions [0.31 < t(7) < 1.16, all p’s > .10].  Animals in the 
High L group (Figure 4.1d) also made more active responses than inactive responses across 
pretreatment conditions [main effect of manipulandum:  F(1,7) = 30.70, p < .001].  Antagonist 
pretreatment condition affected active and inactive responding differently [main effect of 
pretreatment:  F(3,21) = 6.19, p = .004; pretreatment X manipulandum:  F(3,21) = 5.52, p = 
.006].  Pretreatment with 3.2 mg/kg L-741,626 + 0.32 mg/kg PRAM [t(7) = 3.52, p = .009] or 
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vehicle L-741,626 + vehicle PRAM [t(7) = 2.64, p = .033] significantly reduced active 
responding compared to vehicle L-741,626 + 0.32 mg/kg PRAM, whereas inactive responding 
did not differ among pretreatment conditions [0.065 < t(7) < 2.27, all p’s > .05].  
 Figure 4.2 presents the mean latency (log transformed) between the start of each 
antagonist test session and the first active response made.  In the SB group, the latency to initiate 
responding varied across pretreatment conditions [F(3,21) = 3.49, p = .033]; however, by 
pairwise comparison, no other pretreatment condition was different from vehicle SB-277011A + 
0.32 mg/kg PRAM [0.70 < q < 2.27, all p’s > .05].  In both the Low L group [F(3,21) = 1.96, p = 
.15] and High L group [F(3,21) = 2.33, p = .10], pretreatment condition did not affect the latency 
to initiate responding. 
 
Experiment 2:  Antagonism of D3-mediated elicited behaviors by SB-277011A 
 
Figure 4.3 presents the effects of SB-277011A on PRAM-induced yawning and PE.  
Compared to vehicle, pretreatment with 56.0 mg/kg SB277011A significantly reduced both the 
number of yawns made [t(5) = 5.02, p = .004] and the incidence of PE [t(5) = 3.50, p = .017] 




 The dopamine D3 receptor has received considerable attention in recent years as a target 
for new medications for human drug abuse and dependence (e.g., Heidbreder 2013; Heidbreder 
and Newman 2010).  In rats, D3-preferring antagonists have been shown to reduce responding in 
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extinction after cocaine self-administration training (Cervo et al. 2007; Gál and Gyertyán 2006; 
Gilbert et al. 2005; Peng et al. 2009; Vorel et al. 2002; Xi et al. 2006) and under second-order 
schedules of cocaine self-administration (Di Ciano et al. 2003; see also Pilla et al. 1999).  These 
effects suggest that D3 activity is important for drug self-administration behaviors, with a 
particular focus on responding with drug-associated stimuli (e.g., Le Foll et al 2005).  However, 
fewer studies have been performed with D2-preferring antagonists, and so it has been difficult to 
compare directly the relative importance of D3 vs. D2 activity or to draw conclusions about the 
necessity and sufficiency of D2 receptor activity for different drug self-administration behaviors.  
Specifically, only one previous study has, to my knowledge, directly compared the effects of a 
D2-preferring antagonist with a D3-preferring antagonist on responding with drug-associated 
stimuli:  Collins and colleagues (2012) compared within-subjects the ability of L-741,626 and 
the D3-preferring antagonist, PG01037, to attenuate the response-enhancing effects of PRAM in 
extinction after cocaine self-administration training.  In this study, 1.0 mg/kg L-741,626 
produced a parallel rightward shift of the PRAM dose-effect function, whereas 32.0 mg/kg 
PG01037 produced a downward shift of the PRAM dose-effect function.  These results suggest 
that D2 receptor activity, as well as D3 receptor activity, may be important for responding with 
drug-associated stimuli. 
The present study used L-741,626 and the D3-preferring antagonist, SB-277011A, to 
clarify the roles of the D2 and D3 receptors in the effects of PRAM on responding with drug-
conditioned reinforcement.  Because several behavioral processes, other than conditioned 
reinforcement, can influence the extinction of a previously trained (self-administration) response 
and the maintenance of responding under second-order schedules (Kelleher and Gollub 1962; 
Mackinstosh 1974; Schindler et al. 2002; Wike 1966; Williams 1994), the present study assessed 
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the effects of PRAM on the acquisition of a new response with a remifentanil-paired stimulus.  
Among laboratory procedures, new-response acquisition provides a comparatively stringent test 
for the conditioned reinforcing effects of a stimulus (Mackintosh 1974; Williams 1994). 
Presently, the remifentanil-paired stimulus served as a conditioned reinforcer, as 
indicated by the significant preference for the active nose-poke over the inactive nose-poke in 
ACQ1 before the start of PRAM treatment.  Between ACQ2-6, when pretreatments of PRAM 
alone were given before each session, active responding increased systematically, whereas 
inactive responding did not differ among sessions.  In the antagonist test sessions, substituting 
vehicle for PRAM significantly reduced active responding selectively (i.e., without changing 
inactive responding), indicating that PRAM treatment significantly enhanced the conditioned 
reinforcing effects of the remifentanil-paired stimulus.  L-741,626 attenuated the effects of 0.32 
mg/kg PRAM, with both 1.0 mg/kg L-741,626 and 3.2 mg/kg L-741,626 significantly decreasing 
active responding selectively compared to vehicle L-741,626 + 0.32 mg/kg PRAM.  In a 
previous study of the effects of L-741,626 on elicited responses in rats, 1.0 mg/kg L-741,626 was 
D2-selective, attenuating the D2-mediated hypothermia, but not the D3-mediated yawning 
behavior, elicited by D2-like agonist administration (Collins et al. 2007).  In the same study, 3.2 
mg/kg L-741,626 was not selective.  This higher dose of L-741,626 affected both behaviors, 
indicating that it exerts a significant blockade at both D2 and D3 receptors.  In contrast, SB-
277011A did not change the effect of PRAM pretreatment on new-response acquisition in the 
present study.  The highest dose of SB-277011A tested presently, 56.0 mg/kg, has been shown to 
be D3-selective in vivo (Collins et al. 2007) and is equal to or larger than doses of SB-277011A 
that have been effective in several other behavioral tasks involving drug self-administration 
and/or responding with drug-paired stimuli (e.g., Cervo et al. 2007; Di Ciano et al. 2003; Higley 
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et al. 2011; Ross et al. 2007; Xi et al. 2005).  However, under circumstances that were designed 
specifically to produce responses previously associated with D3 activity specifically (Collins et 
al. 2005; 2007; 2009), 56.0 mg/kg SB-277011A was active in the present study, significantly 
reducing both the yawning behavior and PE observed after PRAM administration. 
In open-field tests, locomotor effects of PRAM (Chang et al. 2011; Lagos et al. 1998; 
Maj et al. 1997), SB-277011A (Song et al. 2011), and L-741,626 (Chang et al. 2011; Millan et al. 
2000) have been observed, but it is unlikely that the changes in nose-poke responding observed 
presently were caused exclusively by nonspecific locomotor effects of the drugs.  Changes in 
active responding, but not inactive responding, were observed both when PRAM was 
administered alone and in combination with the antagonsits.  This difference between the nose-
pokes may have been due to the difference between the rates of each response prior to the start of 
drug administration (active > inactive); however, there were also no significant differences in 
animals’ latency to initiate active responding when treated with SB-277011A or L-741,626.  In 
each group, giving the antagonist + 0.32 mg/kg PRAM did not increase latencies over the vehicle 
+ 0.32 mg/kg PRAM condition.  Consistent with a reinforcement mechanism, animals began 
responding at the beginning of the session, before the first stimulus presentation, but they did not 
then persist in responding after the stimulus was presented when treated with L-741,626 (or 
when PRAM was omitted and vehicle was given). 
The present results, therefore, indicate that PRAM is not acting through the D3 receptor 
in enhancing new-response acquisition.  Rather, D2 activity may be particularly important for 
responding with (opioid-based) conditioned reinforcement.  Whereas considerable attention has 
focused on the D3 receptor, there are several lines of evidence suggesting that D2 receptor 
activity is also important for drug self-administration and responding with drug-associated 
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stimuli, beyond the work of Collins and colleagues (2012) with L-741,626 reviewed above.  
First, when D3-preferring agonists are used to increase extinction responding after either cocaine 
or heroin self-administration, the effective doses are consistently in the range of doses that 
produce significant D2-mediated elicited effects in rats (Collins et al. 2005, 2007):  PRAM, ≥ 
0.32 mg/kg (Collins et al. 2012); quinpirole, ≥ 0.1 mg/kg (Collins and Woods 2007; De Vries et 
al. 1999, 2002; Koetzlow and Vezina 2005; Self et al. 1996); 7-OH-DPAT, ≥ 1.0 mg/kg (Cervo 
et al. 2003; Fuchs et al. 2002; Self et al., 1996); quinelorane, 0.25 mg/kg (Dias et al. 2004).  At 
lower doses, including those doses that produce D3-mediated elicited effects without producing 
D2-mediated elicited effects, these agonists cause either no change or a significant reduction in 
extinction responding.  Second, D2 receptor knockout mice have been shown to fail to acquire 
both morphine-conditioned place preference (Maldonado et al. 1997; Smith et al. 2002; but see 
Dockstader et al. 2001) and morphine self-administration (Elmer et al. 2002).  Some of these 
deficits may be preferentially expressed with opioids; for example, in these same studies, D2 
knockout mice were shown to acquire responding with water reinforcement (Elmer et al. 2002) 
and to acquire cocaine-conditioned place preference (Smith et al. 2002; see also Bello et al. 
2011).  It has also been reported that D2 knockout mice successfully self-administer cocaine 
(Caine et al. 2002), and D2 knockout mice show a loss of morphine-potentiation, but not 
amphetamine-potentiation, of electrical brain stimulation reward (Elmer et al. 2005). 
The lack of effect of SB-277011A in Experiment 1 may depend on the particular training 
drug (µ-opioid agonist) and/or the particular stimulus function maintaining behavior (conditioned 
reinforcement).  The effects of SB-277011A on the acquisition of responding with cocaine-
paired stimuli has not, to our knowledge, been reported, but SB-277011A has been shown to 
block the conditioned place preference produced by both cocaine (Vorel et al. 2002) and heroin 
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(Ashby et al. 2003).  Therefore, SB-277011A is not categorically inactive with opioid-paired 
stimuli.  However, like resistance-to-extinction and second-order schedule performance, 
conditioned place preference cannot isolate the conditioned reinforcing effects of the drug-paired 
stimuli from other behavioral processes, especially Pavlovian conditioned approach (Bardo and 
Bevins 2000; Tzschentke 2007).  Therefore, additional work is needed to determine whether 
there is a particular role for D2 receptors (or a particular lack of a role for D3 receptors) in drug-
conditioned reinforcement.  It is also important to replicate the present findings with additional 
D3 and D2 preferring antagonists, to check that the present results are not an outcome of the 
particular compounds chosen, before drawing strong inferences about the functions of either 
receptor subtype.  There are several other D3-preferring antagonists that have been evaluated in 
multiple behavioral tasks with drug-associated stimuli (reviewed by Heidbreder and Newman 
2010).  Less in vivo work has been done with D2-preferring antagonists, but several new 
compounds have recently been reported which may prove useful for future studies (Langlois et 
al. 2012; Luedtke et al. 2012).  If their selectivity and lack of agonist activity can be verified in 
vivo, systematic comparison of novel D2-preferring compounds with L-741,626, as well as the 
various D3-preferring antagonists, should provide considerable additional insight into the roles 
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Figure 4.1.  Effects of the D3-preferring antagonist, SB-277011A, or the D2-preferring 





















































































































Figure 4.1.  Effects of the D3-preferring antagonist, SB-277011A, or the D2-preferring 
antagonist, L-741,626, on PRAM-induced increases in responding with the remifentanil-paired 
stimulus.  a:  Acquisition of nose-poke responding with the remifentanil-paired stimulus before 
the start of antagonist administration.  No pretreatment was given on ACQ1, whereas 0.32 mg/kg 
PRAM alone was administered before each session from ACQ2-6.  b:  The D3-preferring 
antagonist, SB-277011A, did not alter the response-enhancing effects of PRAM.  c-d:  A lower 
or higher dose, respectively, of the D2-preferring antagonist, L-741,626, attenuated the ability of 
PRAM to increase responding with the remifentanil-paired stimulus.  All data are presented as 
the mean±SEM.  *, p < .05; **, p < .01; ***, p < .001.  Significant difference after collapsing 
across groups between active and inactive responses, as assessed by paired t-test with the Holm-
Bonferroni correction.  ##, p < .01.  Significant difference from ACQ2 in responding on the 
same manipuladum (active vs. active or inactive vs. inactive), as assessed by paired t-test with 
the Holm-Bonferroni correction.  †, p < .05; ††, p < .01.  Significant difference from the vehicle 
antagonist + 0.32 mg/kg PRAM condition in responding on the same manipulandum (active vs. 








































































































































































Figure 4.2.  Neither SB-277011A nor L-741,626 significantly increased the latency for animals 
to begin responding at the start of the session.  a:  Animals treated with SB-277011A.  b:  
Animals treated with lower doses of L-741,626.  c:  Animals treated with higher doses of L-
741,626.  All data were log-transformed before analysis to correct for extreme heterogeneity of 
variance and are presented as the mean±SEM of the transformed values.  In each group, no 
antagonist dose differed from vehicle + 0.32 mg/kg PRAM when compared pairwise using post 
























































Figure 4.3.  SB-277011A, 56.0 mg/kg, inhibits the yawning and PE elicited by 0.1 mg/kg 
PRAM.  Animals were pretreated with either SB-277011A or its vehicle prior to being 
administered 0.1 mg/kg PRAM.  All animals were exposed to both antagonist conditions in 
counterbalanced order.  Both yawning and PE were recorded from all animals in the same 
observation periods.  All data are presented as the mean±SEM.  * p < .05; ** p < .01.  Significant 












The potential importance of conditioned reinforcement to human and non-human animal 
behavior generally, and to drug self-administration behaviors more specifically, has been long 
recognized (e.g., Everitt et al. 2008; Hull 1943; Koob and Le Moal 2008; Skinner 1953; Wikler 
1971; Williams 1994).  Many of the laboratory methods that have been used to study conditioned 
reinforcement, however, present significant interpretational difficulties:  the behaviors they 
generate may actually be influenced by a combination of conditioned reinforcement and other 
associative and nonassociative behavioral processes, and in some cases, the target stimuli may 
have no conditioned reinforcing effects at all (Cunningham 1993; Kelleher and Gollub 1962; 
Mackintosh 1974; Schindler et al. 2002; Shahan 2010; Wike 1966; Williams 1994).  Therefore, it 
has been difficult to characterize the influence over behavior that drug-paired stimuli can exert 
specifically because of their conditioned reinforcing effects, with a particular lack of work on the 
conditioned reinforcing effects of opioid-paired stimuli (Davis and Smith 1987; Di Ciano and 
Everitt 2004). 
Outside of the laboratory, many behaviors do, at some point, involve contact with a 
primary reinforcer, even if this contact follows only after a complicated chain of responses, a 
considerable temporal delay from a given response, and/or various types of experiences with 
environmental stimuli.  To model these complex interactions, it is often most fitting in laboratory 
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procedures to study behavior as it is influenced by multiple mechanisms simultaneously or in 
sequence (e.g., by the combined effects of primary and conditioned reinforcement contingencies 
acting together).  Nonetheless, it is also important to characterize the separate contributions made 
by individual learning mechanisms or stimulus functions.  There are, in particular, many 
different associations that could possibly be made when a laboratory animal or human learns to 
self-administer a drug and engage in various kinds of drug-seeking and drug-taking behaviors, 
and it is important to determine which associations actually are made in different circumstances 
(cf., Hogarth and Duka 2006; Milton and Everitt 2010).  If precisely characterized, these 
mechanisms can be more effectively targeted by behavioral and/or pharmacological interventions 
designed to reduce self-administration and related maladaptive behaviors while minimizing 
changes in other, more adaptive forms of learning or memories (reviewed by Milton and Everitt 
2010; Myers and Carlezon 2010; Taylor et al. 2009).  Even considering only Pavlovian drug-
conditioned stimuli, it may be possible to differentiate, both behaviorally and neurobiologically, 
several different ways that responding can be changed by stimulus presentation:  Pavlovian 
conditioned approach, Pavlovian-to-instrumental transfer, and conditioned reinforcement (Milton 
and Everitt 2010).  It is possible, therefore, that different kinds of environmental or 
pharmacological interventions may be more or less effective at reducing a target behavior based 
on the mechanism(s) generating the behavior in the first place.  The present study focused on 
several different environmental and pharmacological determinants of performance with drug-
associated conditioned reinforcement.  
 Rats acquired a novel nose-poke response that produced a light-noise compound stimulus 
that had been paired with the potent, short-acting µ-opioid agonist, remifentanil.  Control 
procedures were designed to verify that performance met the criteria of Mackintosh (1974) for a 
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sufficient demonstration of conditioned reinforcement.  First, to prevent the association of 
responding with remifentanil as a primary reinforcer, Pavlovian conditioning procedures alone 
(i.e., only response-independent events) were used to establish the drug-stimulus pairing, and 
animals had no operant training history before the start of nose-poke acquisition.  Second, to 
establish that acquisition depended on, or was sensitive to, the Pavlovian contingency between 
the stimulus and remifentanil, animals exposed to stimulus-remifentanil pairings were compared 
to animals given remifentanil injections and stimulus presentations without consistent pairing.  
Third, to establish that acquisition depended on the instrumental contingency between a 
particular response and the stimulus, animals were allowed to choose between an active nose-
poke manipulandum, which produced the stimulus, and an inactive nose-poke manipulandum, 
which had no scheduled consequences.  Significantly greater active responding was found with 
the remifentanil-paired stimulus, but not the randomly presented control stimulus.  Therefore, the 
remifentanil-paired stimulus was, indeed, acting as a conditioned reinforcer.  Whereas previous 
studies have produced responding with nicotine-paired stimuli (Palmatier et al. 2007, 2008) and 
cocaine-paired stimuli (Di Ciano and Everitt 2004; Panlilio et al. 2007) that meets the criteria of 
Mackintosh (1974), the present studies are, to my knowledge, the first demonstration of the 




Most broadly, the same questions can be raised about responding with conditioned 
reinforcement as with primary reinforcement:  any operation known to alter the acquisition of 
responding with primary reinforcement may potentially also alter the acquisition of responding 
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with conditioned reinforcement (e.g., see Campbell and Carroll 2000 for a number of variables 
that can influence the acquisition of drug self-administration).  The present discussion will focus 
on issues related to (1) potentially unique features of responding with conditioned reinforcement, 
(2) the effects of the dopaminergic manipulations pursued, and (3) evidence that the behavior of 
human drug users is acutally reinforced by drug-paired stimuli. 
Responding with conditioned reinforcement necessarily has a complex associative basis.  
The present experiments were designed to generate responding that depended on the conditioned 
reinforcing effects of the remifentanil-paired stimulus as distinguished from other stimulus 
functions.  Even if, under ideal circumstances, the conditioned reinforcing effects of a stimulus 
can be studied in genuine isolation, this single stimulus function still results from multiple 
associative processes (Berridge et al. 2009; Mackintosh 1974; O’Brien and Gardner 2005; cf., 
Schuster 1969).  Responding with conditioned reinforcement necessarily depends on not only the 
Pavlovian contingency between the stimulus and a primary reinforcer, but also the instrumental 
contingency between the response and the stimulus (Mackintosh 1974).  This dual dependency 
constrains attempts to interpret the effects of environmental or pharmacological manipulations 
on responding with conditioned reinforcement.  When responding with conditioned 
reinforcement is increased or decreased, these behavioral changes may depend on changes in 
Pavlovian and/or instrumental learning (Gerdjikov et al. 2011; Palmatier et al. 2008).  In the 
present experiments, for example, pramipexole pretreatment may have increased the reinforcing 
effectiveness (or value) of the stimulus as an outcome in the instrumental contingency or reduced 
the extinction of the Pavlovian drug-stimulus association.  Functionally, this distinction may be 
irrelevant, as relatively greater reinforcer effectiveness results from an increase or the lack of a 
	  164	  
decrease.  However, changes in acquisition responding alone cannot be used to identify the 
source of the change (cf., Downs and Woods 1975, p 426).   
Separate behavioral procedures designed to assess specifically the effects of Pavlovian 
learning (e.g., Pavlovian-to-instrumental transfer) or instrumental learning (e.g., reinforcer 
devaluation) may be adaptable to test the effects of pramipexole (and other manipulations) on 
responding with opioid-paired stimuli in a way that would allow for inferences about specific 
associative structures.  For example, Pavlovian-to-instrumental transfer effects have recently 
been demonstrated with cocaine-paired stimuli (LeBlanc et al. 2012).  Because the stimulus is 
presented response-independently during both the training and test phases of the experiment, 
Pavlovian-to-instrumental transfer may provide an index of the motivational effects of the 
stimulus that does not depend on instrumental learning about the stimulus.  Dopamine receptor 
antagonists can attenuate the ability of food-paired stimuli to produce Pavlovian-to-instrumental 
transfer (Smith et al. 2000), but to my knowledge, it remains to be determined if selective 
dopamine receptor agonists or antagonists can modify Pavlovian-to-instrumental transfer with 
drug-paired stimuli. 
New-response acquisition may be influenced by other behavioral processes, including 
discrimination between the active and inactive response manipulanda and attention to the stimuli.  
In human opioid users, opioid-paired stimuli have been shown to have significant effects on 
attention-related neuropsychological tasks, such as the Stroop task and dot-probe task (e.g., 
Garland et al. 2012; Lubman et al. 2000; Marissen et al. 2006; Waters et al. 2012).  Generally, 
these studies show that human opioid users attend more intensely to opioid-associated stimuli 
than other stimuli.  Nonetheless, manipulations or interventions that change the extent to which 
the stimuli are attended during the Pavlovian conditioning phase or instrumental acquisition 
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phase could change responding with conditioned reinforcement.  Forgetting, a modification of 
the drug-stimulus contingency or response-stimulus contingency that occurs without 
programmed training, may also alter responding with conditioned reinforcement, although 
experiments designed to assess this possibility in rats have not shown strong forgetting effects 
(Di Ciano and Everitt 2004; but see Samaha et al. 2011 for results compatible with either 
extinction or forgetting). 
Finally, it is important to consider the use of Pavlovian conditioning procedures to pair 
remifentanil injection and the light-noise stimulus.  In designing the present new-response 
acquisition experiments, it was a priority that the animals have as restricted an operant training 
history as possible, i.e., to prevent the animals from having experimental experience with any 
particular response manipulandum that was or was not programmed to have a particular 
consequence.  Restricting the animals’ history in this way provides an assessment of their ability 
to make a new response in the most comprehensive or stringent sense of new.  One potential 
disadvantage of this approach, however, is that human drug users often experience their drug-
stimulus pairings in the context of drug self-administration.  Most human drug users do not get 
all of their experience with either drugs or stimuli through response-independent events, as the 
rats in the present new-response acquisition experiments did, and so these Pavlovian procedures 
potentially lack (at least) face validity with human drug use.  There may be important behavioral 
and neurobiological differences in animals exposed to response-dependent vs. response-
independent opioid injections.  In rats, for example, response-dependent vs. response-
independent heroin administration can produce different behavioral effects (Lecca et al. 2007) 
and different effects on dopamine release in the nucleus accumbens (Hemby et al. 1995; Lecca et 
al. 2007). 
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However, other-administered drug may play an important role in at least some cases of 
human drug abuse and dependence, with drug administered by a physician to a patient (Musto 
1985; Walker 1978, Case #2) or, among “street” users, by a more experienced/skilled drug user 
to a less experienced/skilled drug user (Crofts et al. 1996; Day et al. 2005; Faupel 1991; 
Kermode et al. 2007; Levine 1974; McBride et al. 2001).  For example, in a recent study of 
opioid users, 88% of participants were injected by another person in their first experience with 
opioid injection (Barry et al. 2012), and similar, high rates of initial injection by another person 
(73-94% of participants) were found in several earlier studies of individuals whose first injection 
experience involved opioids or psychomotor stimulants (Crofts et al. 1996; Doherty et al. 2000; 
Roy et al. 2002).  In certain cases or certain subpopulations of drug users, injection by another 
may persist well beyond the first experience with injection (Doherty et al. 2000; Faupel 1991; 
Levine 1974, Case #1; Walker 1978, Case #2).  This is not to discount the importance of self-
administration, but it is noteworthy that many human drug users may actually have histories that 
include both self-administered and other-administered drug.  Therefore, thorough 
characterization of the motivational effects of a drug in laboratory animals should ultimately 
encompass the consequences of both response-dependent and response-independent drug 
delivery. 
 
Are human drug self-administration behaviors influenced by conditioned reinforcement? 
 
 The roles proposed for drug-associtated conditioned reinforcers in human drug abuse and 
dependence (e.g., as reviewed by Milton and Everitt 2010) are quite similar to the roles long 
proposed for conditioned reinforcers in human and non-human animal behavior generally:  
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maintaining responding in the absence of the primary reinforcer until the primary reinforcer is 
ultimately delivered (e.g., Hull 1943; Skinner 1953).  It is also thought that conditioned 
reinforcement is responsible for “flexible drug-seeking” (Milton and Everitt 2010, Figure 4).  
The drug-seeking behavior maintained by conditioned reinforcement is considered flexible 
because it is sensitive to its consequences, and this flexible drug-seeking can be contrasted with 
behaviors that are elicited by antecedent stimuli without regard to the events that follow, as with 
stimulus-response or “habit” learning mechanisms.  Broadly, patterns of behavior consistent with 
these two functions have been observed in human drug users, but the evidence for specific 
instances of conditioned reinforcement (i.e., changes in the rate of particular behaviors that lead 
to the delivery of particular stimuli) in human opioid use is presently limited. 
Ethnographic accounts or case histories of human opioid users emphasize the long, 
complex sequences of behavior in which these individuals will engage to obtain (1) money to 
buy drugs, (2) drugs themselves, and (3) a safe location in which the drugs can be consumed 
(e.g., Biernacki 1979; Dickson-Gómez et al. 2004; Faupel 1991; Fernandez 1998, Chapter 4; 
Fields and Walters 1985; Lalander 2003).  These behaviors can last for hours or (sometimes) 
days before the drugs are obtained and consumed (Faupel 1991; Lex 1990).  Upon securing the 
necessary elements, drug users will often prepare their drugs for consumption using complex 
“rituals” or “ceremonies.”  Particular sensory stimuli are often given special emphasis or 
importance during drug preparation, including the sound of aluminum foil being handled for 
users who smoke heroin (Lalander 2003) and the sight of blood in the syringe prior to injection 
for IV drug users (McBride et al. 2001).  These long sequences of pre-consumption behavior 
may be supported significantly by the conditioned reinforcing effects of drug-associated stimuli. 
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In the laboratory, several studies have examined opioid self-administration in humans 
under second-order schedules of reinforcement, which can also require long periods of 
responding before drug is obtained (Lamb et al. 1991; Mello et al. 1981, 1982).  These studies 
indicate that human participants will engage in extended episodes of behavior, including 
responding for long time intervals (90 min of sustained performance; Mello et al. 1981, 1982) or 
with high work requirements (3000 responses, Lamb et al. 1991) for a single opioid injection.  
However, these experiments did not address the specific contributions of drug-associated stimuli 
to responding, as performance with drug-associated stimuli was not compared to performance 
without stimuli or with stimuli that had not been associated with drug.  Such manipulations could 
not establish unambiguously the conditioned reinforcing effects of the stimuli (e.g., Williams 
1994), but they would be an important step in systematically establishing and studying the 
influence exerted (by whatever mechanism or mechanisms) over human behavior by drug-
associated stimuli. 
The ability of conditioned reinforcers to train new responses (including responses that 
have never led to the drug itself) may help to account for the diversity and flexibility of human 
drug-seeking behaviors.  Again, ethnographic accounts emphasize the range of different 
behaviors in which human opioid users will engage to gain drugs and the money to buy drugs.  
To the extent they are able, human opioid users attempt to acquire the most drug with the least 
effort expended, and so they will change behavior as conditions in the drug marketplace change 
(Lex 1990).  Human drug users may engage in a variety of different activities to maximize gains 
and minimize losses of drugs and money (Lalander 2003; Lex 1990).  Sources of income for 
substance users can include formal employment, informal employment (i.e., “under the table” or 
“off the books” employment), criminal activity, government entitlements or benefits, loans, and 
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gifts (Biernacki 1979; Fields and Walters 1985; Zlotnick and Robertson 1996).  Different kinds 
of behavior are necessary to access and maintain these various sources.  There may be some 
degree of behavioral specialization, such that many opioid users have a “main hustle” by which 
they typically raise money for drugs or procure the drugs themselves; however, these invididuals 
will also engage in alternative behaviors based on negative or positive life events (Faupel 1991; 
Fields and Walters 1985; Lex 1990).  Changes in behavior may be prompted by law enforcement 
intervention or other challenges that limit drug availability (Fields and Walters 1985; Lalander 
2003) or because particular opportunities are present (Faupel 1991; Fields and Walters 1985; Lex 
1990).  These opportunities may recur cyclically (e.g., outdoor work that is possible during the 
summer but not winter), or they may be more unpredictable, as an idiosyncratic opportunity is 
identified and exploited (e.g., property that is momentarily unattended, an accidental injury that 
could lead to monetary compensation or access to prescription opioids).  Individuals may also 
create opportunities, for example, by causing a diversion or distraction so that otherwise attended 
property becomes unattended, such that “almost any social setting can have potential for 
hustling” (Lex 1990, p 399).  Even within a particular type of “hustle,” a drug user may occupy 
different roles or participate in different activities at different times (Faupel 1991), and so a 
simple division of behavior into “hustles” may not fully capture its true diversity.  The flexibility 
of behavior described in these qualitative data may or may not map onto a specific difference 
between response-outcome learning and stimulus-response learning as studied in animals, but it 
is clear that human drug users can engage in a number of different behaviors and, at least in 
some ways, alter their responses based on environmental outcomes. 
Altogether, therefore, human opioid users have been observed to, or have reported 
themselves to, seek and take drugs in ways that are consistent with the proposed effects of 
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conditioned reinforcers.  Nonetheless, direct evidence is lacking for specific behaviors that 
change in frequency because of stimulus delivery.  Considering particular behaviors that may 
lead to the delivery of particular drug-associated stimuli, the “needle fixation” reported among 
some injection drug users may be caused, at least in part, by conditioned reinforcement (Levine 
1974; McBride et al. 2001; Pates and Gray 2009; Pates et al. 2001).  Needle fixation describes a 
phenomenon in which injection drug users will repeatedly puncture the skin whether or not drug 
is actually consumed and whether or not the user expects to experience drug effects (Pates et al. 
2001, p 15).  This independence of injection behavior from drug intake suggests that needle use 
has itself become a goal, or that “the means of administration has in itself become rewarding” 
(McBride et al. 2001, p 1050).  Laboratory studies involving persistent self-injection without 
drug administration are rare (see O’Brien et al. 1979 for a study involving repeated saline self-
injection), and as a result, most of the evidence for the existence and features of needle fixation 
comes from case reports and other forms of qualitative research with drug users.  For example, 
some injection drug users report that they feel addicted to the needle itself, as well as to the drug 
(Pates et al. 2001).  Such users report that the prospect of giving up injecting makes it more 
difficult to consider discontinuing drug use, and/or they would not use drug if injecting were 
impossible (McBride et al. 2001).  However, it is difficult to assess the relative importance of the 
injection itself from the drug that typically follows in these cases.  In the course of actually 
taking drug, some injection drug users report feeling strong drug-like effects when preparing the 
drug for consumption and, more specifically, during the injection experience when the skin is 
broken (McBride et al. 2001).  Moreover, some users report greater subjective pleasure during 
the injection than after (i.e., when the drug is actually in the body), and needle fixation has been 
ascribed particularly to individuals who inject drugs and report no experience of drug effects 
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(Levine 1974, Case #1; McBride et al. 2001).  As reported by one individual, drug-like 
subjective effects can begin “as soon as the needle hits your skin even though it can not have 
possibly entered your blood stream or hit your brain, you do feel it and they call that needle 
buzzing” (McBride et al. 2001, p 1052-1053). 
This reported lack of subjective effects does not rule out primary reinforcement by the 
drug, as positive emotional experiences or subjective pleasure is not the same as behavioral 
reinforcement.  Stronger evidence for the reinforcing effects of the injection itself comes from 
reports of individuals who inject themselves with water or break the skin without delivering an 
injection (Levine 1974, Case #2, McBride et al. 2001; Pates and Gray 2009; Pates et al. 2001).  
For example, Levine (1974, Case #2) reports a patient who would inject tap water IM “as often 
as every five minutes” (p 298), and a number of the users surveyed by McBride and colleagues 
(2001) reported either injecting water themselves or (more commonly) knowing other drug users 
who inject water.  In a more recent study that classified drug users as either needle-fixated or not 
needle-fixated, the needle-fixated participants self-reported greater willingness to inject water 
when drug is unavailable and/or a history of having injected water (Pates and Gray 2009).  These 
results are consistent with the injection having become a consequence that that can sustain 
behavior on its own, but additional work is needed to determine whether the injection (or some 
of its components) can be shown to be a reinforcer that is amenable to experimental 
manipulation and analysis, and if so, whether the conditioned reinforcing effects of the drug-
associated injection stimuli can be separated from other behavioral mechanisms (e.g., primary 
reinforcement from the pain of the injection and/or its resolution) that could maintain injection 
behavior in the absence of the drug. 
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Rather than focusing on stimuli that have been paired with drug during human drug 
users’ individual natural histories, a potentially fruitful alternative experimental approach could 
establish the conditioned reinforcing effects of stimuli paired with drug taken in the laboratory.  
For example, Foltin and Haney (2000) paired a novel combination of visual, auditory, and 
olfactory stimuli with smoked cocaine self-administration in a study of human cocaine users.  
After this history, the participants chose to expose themselves to the cocaine-paired stimuli over 
a control set of placebo-paired stimuli at a rate significantly greater than chance.  Thus, 
participants would make a choice behavior that delivered the cocaine-paired stimuli, consistent 
with a conditioned reinforcing effect.  Similar results were found by Mucha and colleagues 
(1998) in a study of tobacco smokers.  Auditory stimuli were first paired with periods of 
smoking or no smoking, and then the participants could activate a switch to hear one of two 
sounds instead of white noise.  Smokers spent more time listening to the sound that was paired 
with cigarette smoking, compared to the sound that was paired with no smoking periods, and this 
effect seemed to depend on the number of smoking-stimulus pairings.  These results are 
promising, but it remains to be determined whether human opioid users would make similar 
choices for an opioid-paired stimulus over other stimuli or otherwise work to produce an opioid-
paired stimulus.  Generally, this approach is noteworthy because the experimenter can ensure 
that all participants have the same history of conditioning with the same stimuli and drug 
exposures and could potentially program unique combinations of stimuli with unique 
combinations of responses to create a human analogue of a new-response acquisition task.  Of 
course, there may also be important ethical limitations to the work that could be done if it 
involves creating new drug-stimulus associations that could later promote drug-seeking or drug-





The present experiments indicate that new-response acquisition procedures can provide 
valid measures of opioid-based conditioned reinforcement in the rat.  These procedures are 
comparatively simple to implement and rapid in generating the behavior of interest, without the 
need for complex schedules of reinforcement or two separate operant acquisition phases, and 
they can produce responding that is persistent enough across acquisition test sessions to be 
practically useful.  Furthermore, the basic behavioral procedures are flexible enough to 
accommodate several different environmental or pharmacological interventions.  In particular, 
the present use of pramipexole provides, to my knowledge, the most direct evidence to date that 
D2-like dopaminergic agonism enhances the conditioned reinforcing effects of a drug-paired 
stimulus.  Furthermore, among the D2-like subtypes, the present antagonist experiments 
highlight the potential importance of the D2 receptor specifically in responding with (drug-
associated) conditioned reinforcement.  These effects may be particularly important given the 
current widespread use of pramipexole and other D2-like agonists in the clinic for treating 
movement disorders and fibromyalgia.  Future studies could easily implement other 
environmental or pharmacological manipulations during the Pavlovian conditioning phase, 
during the instrumental acquisition phase, or in a gap between the two phases of the procedure.  
Considerable work remains to be done to elucidate the environmental and neurobiological 
determinants of drug-based conditioned reinforcement, but new-response acquisition procedures 




Barry D, Syed H, and Smyth BP (2012) The journey into injecting heroin use. Heroin Addict 
Relat Clin Probl 14: 89–100. 
 
Berridge KC, Robinson TE, and Aldridge JW (2009) Dissecting components of reward: ‘liking’, 
‘wanting’, and learning. Curr Opin Pharmacol 9: 65–73. doi: 10.1016/j.coph.2008.12.014 
 
Biernacki P (1979) Junkie work, “hustles” and social status among heroin addicts. J Drug Issues 
9: 535–551. 
 
Campbell UC and Carroll ME (2000) Acquisition of drug self-administration: environmental and 
pharmacological interventions. Exp Clin Psychopharmacol 8: 312–325. doi: 10.I037//1064-
1297.8.3.312 
 
Crofts N, Louie R, Rosenthal D, and Jolley D (1996) The first hit: circumstances surrounding 
initiation into injecting. Addiction 91: 1187–1196. doi: 10.1046/j.1360-0443.1996.918118710.x 
 
Cunningham CL (1993) Pavlovian drug conditioning, in Methods in Behavioral Pharmacology 
(van Haaren F ed) pp 349–381, Elsevier, New York. 
 
	  175	  
Davis WM and Smith SG (1987) Conditioned reinforcement as a measure of the rewarding 
properties of drugs, in Methods of Assessing the Reinforcing Properties of Abused Drugs 
(Bozarth MA ed) pp 199–210, Springer-Verlag, New York. 
 
Day CA, Ross J, Dietze P, and Dolan K (2005) Initiation to heroin injecting among heroin users 
in Sydney, Australia: cross sectional survey. Harm Reduct J 2: 2. doi: 10.1186/1477-7517-2-2 
 
Di Ciano P and Everitt BJ (2004) Conditioned reinforcing properties of stimuli paired with self-
administered cocaine, heroin, or sucrose: implications for the persistence of addictive behaviour. 
Neuropharmacology 47: 202–213. doi: 10.1016/j.neuropharm.2004.06.005 
 
Dickinson A, Smith J, and Mirenowicz J (2000) Dissociation of Pavlovian and instrumental 
incentive learning under dopamine antagonists. Behav Neurosci 114: 468–483. doi: 
I0.1037M735-7044.114.3.46S 
 
Dickson-Gómez J, Weeks MR, Martinez M, and Radda K (2004) Reciprocity and exploitation: 
social dynamics in private drug use sites. J Drug Issues 34: 913–932. doi: 
10.1177/002204260403400410 
 
Doherty MC, Garfein RS, Monterroso E, Latkin C, Vlahov D (2000) Gender differences in the 




Downs DA and Woods JH (1975) Fixed-ratio escape and avoidance-escape from naloxone in 
morphine-dependent monkeys: effects of naloxone dose and morphine pretreatment. J Exp Anal 
Behav 23: 415–427. doi: 10.1901/jeab.1975.23-415 
 
Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, and Robbins TW (2008) Neural 
mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and 
addiction. Philos Trans R Soc Lond B Biol Sci 363: 3125–3135. doi: 10.1098/rstb.2008.0089 
 
Faupel CE (1991) Shooting Dope: Career Patterns of Hard-Core Heroin Users. University of 
Florida Press, Gainesville, Florida. 
 
Fields A and Walters JM (1985) Hustling: supporting a heroin habit, in Life With Heroin: Voices 
from the Inner City (Hanson B, Beschner G, Walters JM, and Bovelle E eds) pp 49–73, 
Lexington Books, Lexington, Massachusetts. 
 
Fernandez H (1998) Heroin. Hazelden, Center City, Minnesota. 
 
Foltin RW and Haney M (2000) Conditioned effects of environmental stimuli paired with 




Garland EL, Froeliger BE, Passik SD, and Howard MO (2012) Attentional bias for prescription 
opioid cues among opioid dependent chronic pain patients. J Behav Med. doi: 10.1007/s10865-
012-9455-8 
 
Gerdjikov TV, Baker TW, and Beninger RJ (2011) Amphetamine-induced enhancement of 
responding for conditioned reward in rats: interactions with repeated testing. 
Psychopharmacology (Berl) 214: 891–899. doi: 10.1007/s00213-010-2099-x 
 
Hemby SE, Martin TJ, Co C, Dworkin SI, and Smith JE (1995) The effects of intravenous heroin 
administration on extracellular nucleus accumbens dopamine concentrations as determined by in 
vivo microdialysis. J Pharmacol Exp Ther 273: 591–598. 
 
Hogarth L and Duka T (2006) Human nicotine conditioning requires explicit contingency 
knowledge: is addictive behavior cognitively mediated? Psychopharmacology (Berl) 184: 553–
566. doi: 10.1007/s00213-005-0150-0 
 
Hull CL (1943) Principles of Behavior: An Introduction to Behavior Theory. Appleton-Century-
Crofts, New York. 
 
Kelleher RT and Gollub LR (1962) A review of positive conditioned reinforcement. J Exp Anal 
Behav 5: 543–597. doi: 10.1901/jeab.1962.5-s543 
 
	  178	  
Kermode M, Longleng V, Singh BC, Hocking J, Langkham B, and Crofts N (2007) My frist 
time: initiation into injecting drug use in Manipur and Nagaland, north-east India. Harm Reduct J 
4: 19. doi: 10.1186/1477-7517-4-19 
 
Koob GF and Le Moal M (2001) Drug addiction, dysregulation of reward and allostasis. 
Neuropsychopharmacology 24: 97–129. doi: 10.1016/S0893-133X(00)00195-0 
 
Lalander P (2003) Hooked on Heroin: Drugs and Drifters in a Globalized World. Berg, New 
York. 
 
Lamb RJ, Preston KL, Schindler CW, Meisch RA, Davis F, Katz JL, Henningfield JE, and 
Goldberg SR (1991) The reinforcing and subjective effects of morphine in post-addicts: a dose-
response study. J Pharmacol Exp Ther 259: 1165–1173. 
 
LeBlanc KH, Ostlund SB, and Maidment NT (2012) Pavlovian-to-instrumental transfer in 
cocaine seeking rats. Behav Neurosci 126: 681–689. doi: 10.1037/a0029534 
 
Lecca D, Valentini V, Cacciapaglia F, Acquas E, and Di Chiara G (2007) Reciprocal effects of 
response contingent and noncontingent intravenous heroin on in vivo nucleus accumbens shell 
versus core dopamine in the rat: a repeated sampling microdialysis study. Psychopharmacology 
(Berl) 194: 103–116. doi: 10.1007/s00213-007-0815-y 
 
	  179	  
Levine DG (1974) “Needle freaks”: compulsive self-injection by drug users. Am J Psychiatry. 
131: 297–300. 
 
Lex BW (1990) Narcotic addicts’ hustling strategies: creation and manipulation of ambiguity. J 
Contemp Ethnogr 18: 388–415. doi: 10.1177/089124190018004002 
 
Lubman DI, Peters LA, Mogg K, Bradley BP, and Deakin JFW (2000) Attentional bias for drug 
cues in opiate dependence. Psychol Med 30: 169–175. 10.1017/S0033291799001269 
 
Mackintosh NJ (1974) The Psychology of Animal Learning. Academic Press, New York. 
 
Marissen MA, Franken IH, Waters AJ, Blanken P, van den Brink W, and Hendriks VM (2006) 
Attentional bias predicts heroin relapse following treatment. Addiction 101: 1306–1312. doi: 
10.1111/j.1360-0443.2006.01498.x 
 
McBride AJ, Pates RM, Arnold K, and Ball N (2001) Needle fixation, the drug user’s 
perspective: a qualitative study. Addiction 96: 1049–1058. doi: 10.1046/j.1360-
0443.2001.967104914.x 
 
Mello NK, Mendelson JH, Kuehnle JC, and Sellers MS (1981) Operant analysis of human heroin 
self-administration and the effects of naltrexone. J Pharmacol Exp Ther 216: 45–54. 
 
	  180	  
Mello NK, Mendelson JH, and Kuehnle JC (1982) Buprenorphine effects on human heroin self-
administration: an operant analysis. J Pharmacol Exp Ther 223: 30–39. 
 
Milton AL and Everitt BJ (2010) The psychological and neurochemical mechanisms of drug 
memory reconsolidation: implications for the treatment of addiction. Eur J Neurosci 31: 2308–
2319. doi: 10.1111/j.1460-9568.2010.07249.x 
 
Mucha RF, Pauli P, and Angrilli A (1998) Conditioned responses elicited by experimentally 
produced cues for smoking. Can J Physiol Pharmacol 76: 259–268. doi: 10.1139/y98-022 
 
Musto DF (1985) Iatrogenic addiction: the problem, its definition and history. Bull N Y Acad 
Med 61: 694–705. 
 
Myers KM and Carlezon Jr WA (2010) Extinction of drug- and withdrawal-paired cues in animal 
models: relevance to the treatment of addiction. Neurosci Biobehav Rev 35: 285–302. doi: 
10.1016/j.neubiorev.2010.01.011 
 
O’Brien CP, Greenstein R, Ternes J, McLellan AT, and Grabowski J (1979) Unreinforced self-
injections: effects on rituals and outcome in heroin addicts. NIDA Res Monogr 27: 275–281. 
 
O’Brien CP and Gardner EL (2005) Critical assessment of how to study addiction and its 




Palmatier MI, Liu X, Matteson GL, Donny EC, Caggiula AR, and Sved AF (2007) Conditioned 
reinforcement in rats established with self-administered nicotine and enhanced by noncontingent 
nicotine. Psychopharmacology (Berl) 195: 235–243. doi: 10.1007/s00213-007-0897-6 
 
Palmatier MI, Coddington SB, Liu X, Donny EC, Caggiula AR, and Sved AF (2008) The 
motivation to obtain nicotine-conditioned reinforcers depends on nicotine dose. 
Neuropharmacology 55: 1425–1430. doi: 10.1016/j.neuropharm.2008.09.002 
 
Panlilio LV, Thorndike EB, and Schindler CW (2007) Blocking of conditioning to a cocaine-
paired stimulus: testing the hypothesis that cocaine perpetually produces a signal of larger-than-
expected reward. Pharmacol Biochem Behav 86: 774–777. doi: 10.1016/j.pbb.2007.03.005 
 
Pates RM, McBride AJ, Ball N, and Arnold K (2001) Towards an holistic understanding of 
injecting drug use: an overview of needle fixation. Addict Res Theory 9: 3–17. 
 
Pates RM and Gray N (2009) The development of a psychological theory of needle fixation. J 
Subst Use 14: 312–324. doi: 10.3109/14659890903235876 
 
Roy E, Haley N, Leclerc P, Cédras L, and Boivin J-F (2002) Drug injection among street youth: 
the first time. Addiction 97: 1003–1009. doi: 10.1046/j.1360-0443.2002.00161.x 
 
	  182	  
Samaha A-N, Minogianis E-A, and Nachar W (2011) Cues paired with either rapid or slower 
self-administered cocaine injections acquire similar conditioned rewarding properties. PLoS One 
6: e26481. doi: 10.1371/journal.pone.0026481 
 
Schindler CW, Panlilio LV, and Goldberg SR (2002) Second-order schedules of drug self-
administration in animals. Psychopharmacology (Berl) 163: 327–344. doi: 10.1007/s00213-002-
1157-4 
 
Schuster RH (1969) A functional analysis of conditioned reinforcement, in Conditioned 
Reinforcement (Hendry DP ed) pp 192–234, Dorsey Press, Homewood, IL. 
 
Shahan TA (2010) Conditioned reinforcement and response strength. J Exp Anal Behav 93: 269–
289. doi: 10.1901/jeab.2010.93-269 
 
Skinner BF (1953) Science and Human Behavior. Macmillan, New York. 
 
Taylor JR, Olausson P, Quinn JJ, Torregrossa MM (2009) Targeting extinction and 
reconsolidation mechanisms to combat the impact of drug cues on addiction.  
Neuropharmacology 56: 186–195. doi: 10.1016/j.neuropharm.20 08.07.027 
 




Waters AJ, Marhe R, and Franken IHA (2012) Attentional bias to drug cues is elevated before 
and during temptations to use heroin and cocaine. Psychopharmacology (Berl) 219: 909–921. 
doi: 10.1007/s00213-011-2424-z 
 
Wike EL (1966) Secondary Reinforcement: Selected Experiments. Harper & Row, New York. 
 
Wikler A, Pescor FT, Miller D, and Norrell H (1971) Persistent potency of a secondary 
(conditioned) reinforcer following withdrawal of morphine from physically dependent rats. 
Psychopharmacologia 20: 103–117. doi: 10.1007/BF00404365 
 
Williams BA (1994) Conditioned reinforcement: experimental and theoretical issues. Behav Anal 
17: 261–285. 
 
Zlotnick C and Robertson MJ (1996) Sources of income among homeless adults with major 
mental disorders or substance use disorders. Psychiatr Serv 47: 147–151. 
